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Summary 
 
Vitiligo is an acquired idiopathic hypomelanotic skin disorder characterised by depigmented 
macules due to loss of cutaneous melanocytes. Evidence suggests that autoimmunity plays a 
role in the pathogenesis of the disease, since antibodies and T cells against melanocytes can 
be detected in vitiligo patients. A major goal in vitiligo research is to identify the targets of 
the immune response in patients, as this will contribute to defining the pathomechanisms of 
the disease. A better understanding of vitiligo pathogenesis is required in order to allow the 
development of better diagnostic, prognostic and therapeutic measures.   
Previously, the enzyme tyrosine hydroxylase (TH) was identified as a putative B cell 
autoantigen in vitiligo using phage-display technology. The aims of the present study were to 
confirm TH as an antibody target in vitiligo, to investigate the prevalence of TH antibodies 
and to characterise several properties of TH antibodies. 
Firstly, a radioimmunoassay (RIA) with [
35
S]-labelled TH was used to identify TH 
antibodies in sera from patients with either non-segmental vitiligo (n=79), segmental vitiligo 
(n=8) or other autoimmune diseases without concomitant vitiligo (n=91). Sera from healthy 
individuals (n=28) were also tested. The results indicated that segmental vitiligo patients, 
healthy subjects and patients with other autoimmune diseases without concomitant vitiligo 
were all negative for TH antibody reactivity. Of 79 non-segmental vitiligo patients, 18 (23%) 
were positive for TH antibodies. A significant increase in the prevalence of TH antibodies 
was evident in the non-segmental vitiligo patient group when compared with healthy 
participants (P = 0.003). TH antibody prevalence was also significantly elevated in the group 
of patients with active vitiligo compared to the group with stable disease (P = 0.009): TH 
antibodies were detected in 18/64 (28%) of patients with active disease, but not in any of the 
20 patients with stable vitiligo. 
Secondly, the binding sites of TH antibodies were investigated. Initially, the binding 
domains for TH antibodies on the protein were identified using [
35
S]-labelled TH protein 
fragments in RIAs. Further localisation of TH binding sites (epitopes) was carried out in 
antibody absorption experiments using synthetic TH peptides and non-radiolabelled in vitro 
expressed TH protein fragments. In addition, antibody binding to the identified TH epitopes 
was confirmed in TH peptide enzyme-linked immunosorbent assays (ELISA). The results 
indicated that epitopes for vitiligo patient TH antibodies were located at the N-terminus of 
 ii 
 
TH between amino acids 1 and 14 (epitope 1-14) and between amino acids 61 and 80 
(epitope 61-80). Of 18 vitiligo patients, 17 (94%) had antibodies against epitope 1-14, and 11 
(61%) displayed immunoreactivity against epitope 61-80. Antibody binding to both epitopes 
was demonstrated in 10/18 (56%) of vitiligo patients. 
Finally, TH peptide (amino acids 1-14 and 61-80) ELISAs were used to determine the 
subclass and avidity of TH antibodies. The results showed that antibodies against TH epitope 
1-14 were exclusively of the IgG1 subclass. Antibody responses against TH epitope 61-80 
were also predominantly of the IgG1 subclass with a minority of subclass IgG3. TH antibody 
binding was also assessed at increasing NaCl concentrations as a measure of antibody 
avidity. The results suggested that vitiligo patient TH antibodies were of variable avidity 
towards their antigenic TH peptide target.  
Overall, the work in this thesis confirmed TH as an autoantigen in vitiligo, described 
the prevalence of TH antibodies in a vitiligo patient cohort, and characterised several 
properties of TH antibodies including epitopes, subclasses and avidities. 
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1. General Introduction 
 
1.1 The Skin  
The following sections will describe the structure and functions of the skin, with particular 
emphasis on melanocytes (pigment cells) and melanin (pigment) biosynthesis 
(melanogenesis). Such information will provide a background to vitiligo, a depigmenting skin 
disease which is the focus of this project. 
 
1.1.1 Skin structure and functions 
The skin is a complex organ which constitutes approximately one-twelfth of the body mass 
(Millington and Wilkinson 1983) and provides an efficient barrier against physical assault, 
chemical hazards and pathogens present in the external environment (Proksch et al. 2008; 
Jensen and Proksch 2009). It also functions to prevent fluid loss and to regulate body 
temperature (Proksch et al. 2008). Of course, the many functions of the skin are dependent 
upon its structure and its various cellular components, and these are described below. 
 In section, human skin is divided into two main compartments, an outer cellular 
avascular layer, the epidermis, which is derived from the embryonic ectodermal cells, and the 
dermis, a heavily vascularised connective tissue layer derived from the embryonic mesoderm 
(Figure 1.1) (Murphy 2005). The epidermis is mainly composed of keratinocytes which form 
more than 90% of the cellular component. The primary function of keratinocytes is in the 
formation of layers of keratin which protect the skin and the underlying tissue from 
environmental damage such as heat and water loss. These layers are formed through a 
process called keratinisation in which keratinocytes produce increasing amounts of keratin 
and eventually undergo programmed cell death. From the inside to the outside of the 
epidermis, keratinocytes are arranged into the basal cell layer (stratum basalis), the prickle 
cell layer (stratum spinosum), the granular cell layer (stratum granulosum), the transitional 
cell layer (stratum lucidum) and the dead horny squamous cell layer (stratum corneum) 
(Figure 1.1). The innermost basal cell layer consists of a single layer of columnar cells that 
are attached by hemidesmosomes to the basement membrane which forms a junction between 
the epidermis and dermis. The basal keratinocytes proliferate and differentiate as they move 
towards the outer layers. Overlying the basal cell layer is the prickle cell layer which is 
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composed of 5-10 layers of flattened keratinocytes. The prickle-like appearance of the 
keratinocytes within this layer is attributed to the protruding desmosomes which are filled 
with keratin filaments. The granular cell layer is composed of flattened keratinocytes, which 
are so-called because of the presence of basophilic keratohyaline granules in their cytoplasm. 
Following full keratinisation and dissolution and loss of their cellular contents, keratinocytes 
of the granular cell layer form the outermost squamous cell layer and are constantly shed off 
and replaced by new cells. 
 Keratinocytes also play a role in modulating skin immunity (Bos and Kapsenberg 
1993; Nestle et al. 2009). In addition to antimicrobial peptides, they are able to produce an 
array of cytokines, including interleukin (IL)-1β, IL-1α, IL-4 IL-6, and IL-8, tumor necrosis 
factor-α (TNF-α), interferon (IFN)-γ and IFN-β (Bos and Kapsenberg 1993; Feldmeyer et al. 
2007; Nestle et al. 2009), and so hold and recruit immune cells into the epidermis. Regulating 
other skin-resident cells by producing growth factors, including basic fibroblast growth factor 
(bFGF) (Halaban et al. 1988), endothelin-1 (ET-1), stem cell factor (SCF) and transforming 
growth factor-β (TGF-β) (Imokawa and Moretti 2010), is a further function of epidermal 
keratinocytes. Finally, keratinocytes contribute to protecting the body from ultraviolet (UV) 
radiation by taking up melanosomes, vesicles containing melanin, from epidermal 
melanocytes, and then storing the photoprotective pigment (Scott et al. 2002; Watabe et al. 
2008). 
Other cellular components of the epidermal layer include Langerhans cells, Merkel 
cells and melanocytes. Langerhans cells are specialised dendritic cells which reside in the 
suprabasal layer and have an antigen presentation capacity through binding, processing and 
then presenting antigens to effector T cells (Friedmann 1981; Maurer and Stingl 2001; 
Hunger et al. 2004). Merkel cells are scattered throughout the epidermis and are found 
closely associated with small nerve fibres (Boulais and Misery 2007). Although their function 
is still unclear, there is evidence that they are associated with touch responses (Maricich et al. 
2009). Melanocytes are responsible for the synthesis of melanin pigment (Boissy and 
Nordlund 1995a; Sulaimon and Kitchell 2003), and are detailed in Section 1.1.2. 
 The dermis is the layer of the skin found between the epidermis and subcutaneous 
tissues, and is composed of the papillary (stratum papillare) and the reticular (stratum 
reticulare) dermis (Murphy 2005). Its main roles are to regulate temperature and to supply the 
epidermis with nutrient-saturated blood. The dermis is mostly made of collagen and elastic 
fibers which are made by fibroblasts and which lend elasticity and support to the skin. The 
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dermis is the seat of hair follicles, nerve endings, and pressure receptors. Furthermore, the 
dermis defends the body against infectious invaders that can pass through the thin epidermis. 
The papillary dermis is the main agent in dermis function. It is from here that the dermis 
supplies nutrients to select layers of the epidermis and regulates temperature. Both of these 
functions are accomplished with a thin but extensive vascular system. The reticular layer is 
much denser than the papillary dermis. It strengthens the skin, providing structure and 
elasticity, and supports other skin components such as hair follicles, sweat glands, and 
sebaceous glands. 
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Figure 1.1: A schematic representation of the ultra-structure of the skin. 
 
Drawn with information from (Alberts et al. 1989). 
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1.1.2 Melanocytes 
Melanocytes (Figure 1.2) are melanin-producing cells that are found in the skin epidermis, 
uvea of the eye, inner ear and leptomeninges (Boissy and Nordlund 1995a; Sulaimon and 
Kitchell 2003), and are responsible for the colour of the hair and skin. They differentiate from 
melanoblasts (melanocyte precursors) which are derived from the neural crest of the 
embryonic ectoderm (Boyd 1960). Studies of the early human embryo show that 
undifferentiated melanoblasts migrate into the developing epidermis at approximately the 
seventh week of gestation, and subsequently reside in the basal epidermal layer (Holbrook et 
al. 1989; Suder and Bruzewicz 2004). Differentiated melanocytes are found in the epidermis 
by the eighth week and show early melanin synthesis and contain melanin by the tenth week 
(Sagebiel and Odland 1970). Several genes influence the differentiation of the melanocyte 
(Vance and Goding 2004) including paired box-3 (PAX3) (Watanabe et al. 1998; Galibert et 
al. 1999; Chen et al. 2010; Wang et al. 2010), stem cell factor gene (Lahav et al. 1994; Luo 
et al. 1995), c-kit proto-oncogene (Lahav et al. 1994; Luo et al. 1995), microphthalmia-
associated transcription factor (MITF) (Watanabe et al. 1998; Kawasaki et al. 2008; Chen et 
al. 2010; Vachtenheim and Borovansky 2010), and transcription factor SOX10 (Cook et al. 
2005; Chen et al. 2010). Melanocyte differentiation is also influenced by the melanocortin 
hormones and bFGF (Hirobe 1995).  
The population density of melanocytes in the basal cell layer varies in different areas 
of the skin. The highest melanocyte population density has been noted on the face at a 
concentration of 2000 cells/mm
2
 and the lowest on the trunk at an approximate concentration 
of 800 cells/mm
2
 (Staricco and Pinkus 1957; Fitzpatrick and Szabo 1959). There are no 
significant differences in skin melanocyte concentration between Caucasian and African 
American skin (Quevedo et al. 1965). Differences in the rate of melanin synthesis (Iwata et 
al. 1990), the type of pigment produced (Quevedo et al. 1974), and the way it is distributed 
within keratinocytes (Szabo et al. 1988), account for the different skin colours between ethnic 
groups.  
The main function of melanocytes is in the synthesis of melanin which occurs in 
membrane-bound organelles called melanosomes (Setaluri 2003; Barral and Seabra 2004; 
Raposo and Marks 2007; Simon et al. 2008). Each melanocyte in the epidermis is surrounded 
by approximately thirty-six keratinocytes forming the epidermal melanin unit (Fitzpatrick et 
al. 1967), where melanosomes are transported to surrounding keratinocytes via the dendritic 
tips of melanocytes (Scott et al. 2002; Watabe et al. 2008). However, the precise mechanism 
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by which this occurs is not fully understood (Van den Bossche et al. 2006). Melanosomes 
form a cap in the cytoplasm distal to the nuclei where they protect the skin from incident UV 
radiation by absorbing UV photons and reactive oxygen species thereby minimising UV 
radiation-induced DNA damage and guarding against skin cancer development (Gasparro 
2000; Kadekaro et al. 2003; Abdel-Malek et al. 2010).  
In addition, melanocytes behave as accessory cells in the skin immune response (Das 
et al. 2001). They are capable of producing cytokines, which then mature antigen presenting 
cells, such as Langerhans cells, and also recruit immune cells into the skin (Zachariae et al. 
1991; Swope et al. 1994). Furthermore, melanocytes can act as antigen presenting cells by 
expressing on their surface intercellular adhesion molecule-1 (ICAM-1) and major 
histocompatibility complex (MHC) class I and II molecules (Krasagakis et al. 1991; Le Poole 
et al. 1993b; Smit et al. 1993; Das et al. 2001).  
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Figure 1.2: Melanocytes growing in culture. 
 
The cells are shown at X200 magnification. The photograph was kindly provided by Miss Charikila 
Balafa and Prof. Sheila MacNeil, University of Sheffield, Sheffield, UK. 
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1.1.3 Melanin biosynthesis 
The pathways in which melanin is produced are summarised in Figure 1.3, and the most 
important melanogenic enzymes and proteins with their known functions are given in Table 
1.1. The first and rate-limiting step is the conversion of L-tyrosine to L-dopaquinone 
catalysed by tyrosinase (Kwon et al. 1987; Cooksey et al. 1997; Riley 1999; Oetting 2000; 
Simon et al. 2008; Ito and Wakamatsu 2011; Kondo and Hearing 2011). For eumelanin 
synthesis, L-dopaquinone is then cyclised to cyclodopa, which subsequently forms 
dopachrome with the release of 3,4-dihydroxyphenylalanine (L-dopa) (Tsukamoto et al. 
1992; Lopez et al. 2008). Dopachrome tautomerase (DCT) (formerly tyrosinase-related 
protein-2/TRP-2) then rapidly catalyses the conversion of dopachrome to 5,6-dihydroxy-
indole-2-carboxylic acid (DHICA) (Tsukamoto et al. 1992), which is then converted to 
indole-5,6-quinone-2-carboxylic acid by tyrosinase (Aroca et al. 1990). The exact role of 
tyrosinase-related protein-1 (TYRP1) (formerly TRP-1) in melanogenesis in human 
melanocytes is not certain (Ito and Wakamatsu 2011; Kondo and Hearing 2011) (. In the 
absence of DCT, dopachrome can undergo spontaneous decarboxylation to 5,6-dihydroxy-
indole (DHI), which is then converted to indole-5,6-quinone by the action of tyrosinase 
(Korner and Pawelek 1982). In pheomelanin synthesis, L-dopaquinone reacts with thiol 
compounds such as cysteine or glutathione to form cysteinyldopa and subsequently the 
red/yellow pigment pheomelanin (Ito and Wakamatsu 2011; Kondo and Hearing 2011). The 
PMEL protein (formerly Pmel17/gp100) is now regarded as the main component of the 
melanosomal matrix and previously proposed enzymatic functions (Boissy and Nordlund 
1995a) have not been proven.  
 
1.1.4 Regulation of melanogenesis 
Melanogenesis is regulated by several factors (Yamaguchi and Hearing 2009; Vachtenheim 
and Borovansky 2010). Particularly, UV radiation has a direct effect on melanogenesis, 
stimulating pigment synthesis and melanosome transfer to keratinocytes (Friedmann and 
Gilchrest 1987; Scott et al. 2002). Of particular importance in the control of melanogenesis 
are the melanotrophic peptides α-melanocyte-stimulating hormone (α-MSH) and 
adrenocorticotrophic hormone (ACTH) which derive from a common precursor 
propiomelanocortin (POMC), synthesised in both the pituitary gland and locally in the skin, 
and which competitively bind to melanocortin 1 receptor (MC1R) on the melanocyte 
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(Ortonne et al 2000). Cell-signalling pathways, including the cyclic adenosine 
monophosphate (cAMP)-dependent protein kinase pathway and the mitogen-activated protein 
(MAP) kinase pathway, are activated in response to α-MSH binding to MC1R and, 
ultimately, these up-regulate melanogenesis (Ortonne et al. 2000; Park et al. 1999; Park et al. 
2009). 
In addition, several cytokines and growth factors, including TNF-α, ET-1, SCF, bFGF 
and granulocyte-macrophage colony-stimulating factor (GM-CSF), are known to modulate 
melanogenesis (Funasaka et al. 1998; Yamaguchi et al. 2009). For example, ET-1 produced 
from keratinocytes activates melanocyte proliferation, tyrosinase, stimulates TYRP1 
expression and enhances the sensitivity of the MC1R to α-MSH (Imokawa et al. 1992; Yohn 
et al. 1993; Hara et al. 1995; Funasaka et al. 1998; Tada et al. 1998). With regard to genetic 
control, MITF plays an important role in regulating the expression of genes that encode 
proteins involved in melanogenesis and melanosome biosynthesis (Vachtenheim and 
Borovansky 2010).  
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Figure 1.3 A diagrammatic overview of the melanogenesis pathway in human 
melanocytes.  
 
CD, cysteinyl-dopaquinone; DHICA, 5,6-dihydroxy-indole-2-carboxylic acid; DHI, 5,6-dihydroxy-
indole; DQ, dopaquinone; SCD, S-cysteinyldopa. Drawn with information from (Boissy and Nordlund 
1995a; Marles et al. 2003; Sulaimon and Kitchell 2003; Park et al. 2009; Ito and Wakamatsu 2011; 
Kondo and Hearing 2011).  
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Table 1.1: Important melanogenic proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Protein 
 
Size 
(kDa) 
 
 
Function 
 
 
References 
Tyrosinase 70 Catalyses the first step in melanin 
synthesis, the conversion of L-
tyrosine to dopaquinone. 
(Kwon et al. 1987; 
Oetting 2000; Ito and 
Wakamatsu 2011; 
Kondo and Hearing 
2011) 
Tyrosinase-related 
protein-1 (TYRP1)  
 
60 Function unclear in human 
pigmentation. 
(Kobayashi et al. 
1994; Orlow et al. 
1994; Sturm et al. 
1995; Setaluri 2003; 
Ito and Wakamatsu 
2011; Kondo and 
Hearing 2011) 
Dopachrome 
tautomerase (DCT) 
59 Catalyses the tautomerisation of 
dopachrome to 5,6-dihydroxy-
indole-2-carboxylic acid (DHICA). 
(Aroca et al. 1990; 
Jackson et al. 1992; 
Kroumpouzos et al. 
1994; Sturm et 
al.1995; Ito and 
Wakamatsu 2011; 
Kondo and Hearing 
2011) 
PMEL  73 Melanosomal protein that forms 
the fibrillar matrix of the 
melanosome upon which 
eumelanin is deposited.  
(Johnson and Jackson 
1992; Kushimoto et 
al. 2001; Theos et al. 
2006; Valencia et al. 
2007; Harper et al. 
2008; Ito and 
Wakamatsu 2011; 
Kondo and Hearing 
2011) 
Melanoma antigen 
recognised by T cells 
1 (MART-1). Also 
called MelanA 
13 A structural melanosomal protein 
that complexes with PMEL 
enhancing its trafficking to the 
melanosome.  
(Hoashi et al. 2005) 
P-protein  90 Function unclear, but one theory is 
that it maintains melanosomal pH. 
(Rinchik et al. 1993; 
Puri et al. 2000; 
Toyofuku et al. 2002) 
Lysosome-
associated 
membrane protein-1 
90-
120 
Protection of the melanosomal 
membrane. 
(Das et al. 2001) 
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1.2. Vitiligo: Clinical Features and Treatments 
The next sections will describe the skin depigmenting disease vitiligo, including its 
epidemiology, clinical features and treatments.  
 
1.2.1 Definition 
Vitiligo is a common acquired chronic hypomelanotic skin disease characterised by the 
development of progressive depigmented macules (flat patches or lesions) resulting from the 
destruction or non-functioning of melanocytes (pigment cells) in the epidermis (Rezaei et al. 
2007; Taïeb and Picardo 2007). 
 
1.2.2 Epidemiology 
Across the world, vitiligo is a common skin disease. Studies have showed a point prevalence 
of between 1-2% (Mehta et al. 1973; Howitz et al. 1977; Majumder et al. 1993; Boisseau-
Garsaud et al. 2000a). However, a higher frequency of the disease has been reported in some 
areas of the world, especially India where the prevalence is up to 8.8% (Sehgal and 
Srivastava 2007). This elevated frequency may be attributable to a high rate of reporting of 
the disease, perhaps related to the apparent colour difference between affected and normal 
skin. The social implications of having vitiligo may also lead to the patient seeking an early 
consultation (Sehgal and Srivastava 2007). In addition, there may be occupational factors: 
vitiligo in rural areas could be related to the printing, carpet-making and dyeing industries 
(Sehgal and Srivastava 2007). 
 All ages, races and both sexes are equally affected by vitiligo, although females seek 
early consultation due to the greater psychological impact of the disease on them (Hann and 
Lee 1996; Le Poole and Boissy 1997; Cho et al. 2000; Zaima and Koga 2002; Behl et al. 
2003; Handa and Dogra 2003). The disease has been reported to start at the age of 20 years in 
approximately half of all cases, and before the age of 30 years in about 70-80% of patients 
(Engel 2001; Jaigirdar et al. 2002; Behl et al. 2003; Herane 2003). Vitiligo is rarely present at 
birth and, if depigmentation is evident at this stage, consideration must be given to other 
possible diagnoses such as piebaldism.  
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1.2.3 Clinical patterns  
Typical vitiligo lesions consist of milky white macules that vary in diameter from a few 
millimetres to several centimetres. The border of the lesion is well demarcated and the 
affected skin is otherwise normal with respect to the texture. Lesions may be single or 
multiple (Mosher et al. 1999). At present, there is no uniform clinical classification of vitiligo 
but, according to the Vitiligo European Task Force (VETF), the disease is best classified 
initially into either segmental vitiligo or non-segmental vitiligo, which is also referred to as 
generalised, types (Taïeb and Picardo 2007). However, both types may co-exist in some 
patients who are then said to have so-called mixed vitiligo (Gauthier et al. 2003b; Mulekar et 
al. 2006; Taïeb and Picardo 2010a).  
 Segmental vitiligo is found in 5–28% of all patients with vitiligo (Huggins et al. 
2005). The lesions are unilateral and to a varying extent dermatomal or blaschkoid in 
distribution (Figure 1.4a). They may appear as limited small patches without an obvious 
distribution pattern, in which case they are  referred to as focal vitiligo (Taïeb and Picardo 
2010a). The most common sites for segmental vitiligo are the trigeminal area (50%), and the 
neck and trunk. Patients do not tend to have a family history and segmental vitiligo is rarely 
associated with other autoimmune diseases. 
 Non-segmental vitiligo is the most common clinical type of vitiligo. It is characterised 
by a wide distribution of the lesions, which are often symmetrical (Figure 1.4b). The extensor 
surfaces of the elbow, knee, and metatarsal/metacarpal interphalangeal joints are often 
involved. Other regions affected are the umbilicus, anterior tibia, axilla and the malleoli. Peri-
orificial involvement may also be present where the peri-orbital area, the ear, the mucous 
membranes of the lips and the genitals are affected. Some authors recognise vitiligo that 
appears in a predominantly peri-orificial distribution in association with involvement of the 
distal digits, as a subgroup of non-segmental vitiligo described as ‘acro-facial’ (Passeron and 
Ortonne 2010). Patients with generalised vitiligo often have a family history of the disease 
and of other autoimmune diseases such as type 1 diabetes mellitus, pernicious anaemia, 
autoimmune thyroid disease and Addison’s disease and these are detailed in Section 1.2.5. 
 Non-segmental vitiligo may progress over time and proceed to involve more than 
90% of the skin surface area, in which case it is known as ‘vitiligo universalis’, which can be 
associated with multiple endocrinopathies (Taïeb and Picardo 2010a). Rarely, the lesions of 
vitiligo have a slightly elevated inflammatory margin and are associated with itching. This is  
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(b) 
 
 
Figure 1.4: Clinical patterns of vitiligo. 
 
(a) Segmental vitiligo affecting one side of the neck. The photograph was kindly provided by Prof. 
Tony Weetman, Department of Human Metabolism, University of Sheffield, Sheffield, UK. (b) 
Symmetrical vitiligo on the dorsal aspects of the hands. The photograph was kindly provided by Prof. 
David Gawkrodger, Department of Dermatology, Royal Hallamshire Hospital, Sheffield, UK. 
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known as inflammatory vitiligo (Buckley and Lobitz 1953; Watzig 1974; Ortonne et al. 1979; 
Ishii and Hamada 1981; Arata and Abe-Matsuura 1994; Lee et al. 2000). 
In addition to the disease categories described by the distribution of vitiligous skin, a 
three-grade pathological staging system corresponding to depletion of the melanocytes has 
been proposed (Gauthier 1994). In this classification scheme, grade I vitiligo exhibits only a 
partial depletion in epidermal melanocytes and results in the possibility of repigmentation, 
without a follicular pattern, after phototherapy treatment. Grade II vitiligo has complete 
depletion of the epidermal melanocytes and corresponds to a follicular pattern of 
repigmentation, in which melanocytes have migrated from the follicular reservoir to replace 
the absent epidermal melanocytes, after phototherapy treatment. Grade III vitiligo is 
characterised by a total depletion of both epidermal and follicular melanocytes and patients at 
this stage do not respond to medical therapy. More recently, a vitiligo disease activity 
(VIDA) score has been proposed which measures disease activity in relation to time, as 
assessed by the patient (Njoo et al. 1999). 
 
1.2.4 Psychological effects 
In comparison with some diseases, vitiligo might be considered a minor disorder. However, 
the psychological effects of vitiligo are frequently considerable (Kent & Al’Abadie 1996). 
This is particularly the case in people with racially darkly pigmented skin where the 
appearance of the pale patches is very prominent. Individuals with vitiligo may experience 
feelings of stress, embarrassment or self-consciousness when in social contact with strangers. 
A perception of discrimination and of low self-esteem are common, especially in patients 
with white patches in the cosmetically sensitive areas of the hands and face (Ginsburg 1996; 
Ongenae et al. 2005; Ongenae et al. 2006; Schmid-Ott et al. 2007; Dolatshahi et al. 2008; 
Choi et al. 2010).  
 In areas such as India, patients with vitiligo are subjected to isolation from society, 
antagonism or insult (Parsad et al. 2003). They may also undertake diet restriction and 
avoidance of some food such as fish and milk because of local beliefs concerning the 
aetiology of the disease (Parsad et al. 2003). Furthermore, the psychosocial burden of vitiligo 
is greater in females as they may face many social difficulties such as finding a marriage 
partner (Parsad et al. 2003). However, vitiligo can also affect the marital status and sexual 
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health in men due to embarrassment and low self-esteem (Porter et al. 1990; Dolatshahi et al. 
2008). 
 Appropriate psychological intervention and assessment of quality of life in vitiligo 
patients can influence positively the outcome of treatment, as well as improve the patient’s 
self-esteem and confidence (Papadopoulos et al. 1999; Parsad et al. 2003; Picardi et al. 
2003). 
 
1.2.5 Associated disorders 
Vitiligo is frequently associated with other autoimmune disorders (Table 1.2), particularly 
autoimmune thyroid disease (Ochi and DeGroot 1969; Boelaert et al. 2010), autoimmune 
polyendocrine syndromes (Neufeld et al. 1981; Ahonen et al. 1990), pernicious anaemia 
(Dawber 1969), Addison’s disease (Dunlop 1963; Zelissen et al. 1995), and alopecia areata 
(Sharma et al. 1996a; Ahmed et al. 2007). Furthermore, patients with vitiligo are more likely 
to suffer from autoimmune conditions than those in the general population (Cunliffe et al. 
1968; Turnbridge et al. 1977; Liu et al. 2005; Birlea et al. 2008). In a survey of more than 
2,600 unselected Caucasian vitiligo patients, elevated frequencies of autoimmune thyroid 
disease, Addison’s disease, systemic lupus erythematosus and pernicious anaemia were 
found, with approximately 30% of patients being affected with at least one additional 
autoimmune disorder (Alkhateeb et al. 2003). Moreover, these same autoimmune diseases 
occurred at an increased frequency in the first-degree relatives of the patients studied 
(Alkhateeb et al. 2003). Similarly, in multiplex non-segmental vitiligo families, higher 
frequencies of psoriasis, rheumatoid arthritis and type 1 diabetes mellitus were noted in 
addition to autoimmune thyroid disease, Addison’s disease, systemic lupus erythematosus 
and pernicious anaemia (Laberge et al. 2005). Such data indicate that individuals can be 
genetically predisposed to a specific group of autoimmune diseases that includes vitiligo. 
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Table 1.2: Autoimmune associations of vitiligo 
 
 
 
Autoimmune disease 
 
 
Percentage of 
patients with 
vitiligo 
 
 
Reference 
Addison’s disease 9.6 (Zelissen et al. 1995) 
Alopecia areata 3.5 
1.8 
(Ahmed et al. 2007) 
(Sharma et al. 1996b) 
Autoimmune polyendocrine 
syndrome type 1 
13 
8 
(Ahonen et al. 1990) 
(Neufeld et al. 1981) 
Autoimmune polyendocrine 
syndrome type 2 
4.5 
5 
(Ahonen et al. 1990) 
(Neufeld et al. 1981) 
Graves’ disease 1.4 
7 
(Boelaert et al. 2010) 
(Ochi and DeGroot 1969) 
Hashimoto’s thyroiditis 2.6 (Boelaert et al. 2010) 
Type 1 diabetes mellitus (juvenile) 1.7 (Macaron et al. 1977) 
Pernicious anaemia 9 (Dawber 1969) 
 
  
19 
 
1.2.6 Histopathology 
The affected skin in vitiligo shows a loss of melanin and an absence of or decreased numbers 
of melanocytes in the epidermis (Tobin et al. 2000). Figures 1.5a and 1.5b demonstrate the 
difference in density of epidermal melanocytes between normal and vitiligo skin. The 
histological findings vary according to the stage of the disease (Aslanian et al. 2010). In the 
early stage, a few mononuclear cells infiltrate the dermo-epidermal junction. Melanocytes, as 
demonstrated using the Fontana Masson (FM) stain or using an appropriate monoclonal 
antibody technique, are still present, but they disappear from vitiligo skin as the disease 
progresses (Ackerman et al. 2000). 
 In established lesions, the affected skin appears normal apart from absence of melanin 
pigment from the basal layer as demonstrated by FM stain (Spielvogel and Kantor 2005). 
Immunohistochemical studies of vitiligo lesion at this stage have shown that melanocytes are 
usually absent from the basal layer, although they may be present in reduced numbers and 
can show degenerative changes (van den Wijngaard et al. 2000): melanocytes at the edges of 
vitiligo macules appear to be larger with longer dendritic processes than normal melanocytes 
(Spielvogel and Kantor 2005). A superficial peri-vascular lymphocytic infiltration may be 
present at this stage (Wolf et al. 2005). The main histological finding in long-standing vitiligo 
lesions is a prominent absence of pigmentation in the epidermis. No inflammatory infiltrate is 
normally seen at this stage of the disease (Aslanian et al. 2010).   
Degenerative changes have been demonstrated in both melanocytes and keratinocytes 
in apparently normal skin adjacent to vitiligo macules. A few mononuclear cells showing 
vacuolar degeneration have been detected in the basal cell layer of clinically normal skin with 
the deposition of extracellular granular substance (Moellmann et al. 1982; Bhawan and 
Bhutani 1983; Anbar et al. 2009). Recently, T lymphocyte infiltration at the dermo-epidermal 
junction with microscopic absence of melanocytes and decreased epidermal pigmentation has 
been described in clinically uninvolved skin (Wankowicz-Kalinska et al. 2003; Pretti 
Aslanian et al. 2007). 
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 (a) 
 
 
 
(b) 
 
 
 
 
Figure 1.5: Histopathological features of vitiligo. 
 
The skin sections were treated with a L-dopa immunohistochemical stain, which detects tyrosinase 
activity and reveals the melanocytes in brown. (a) Melanocytes in a section of normal cutaneous 
epidermis. (b) Melanocytes in a cutaneous epidermal section from a patient with vitiligo showing a 
much reduced melanocyte density. Taken with kind permission from Springer  Science and Business 
Media (Van Godewijckstraat 30, P.O. Box 17, 3300 AA Dordrecht, The Netherlands) from 
(Gawkrodger 1998). 
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1.2.7 Treatment modalities 
The aetiology of vitiligo is unclear at present and hence there are no specifically targeted 
treatments for the disease. In many cases, the use of sunscreens and cosmetic camouflage is 
the most appropriate intervention rather than the application of a medical or surgical therapy 
(Gawkrodger 1998; Kovacs 1998; Gawkrodger et al. 2010; Taïeb and Picardo 2010b). 
Nonetheless, there are several treatments which can induce a degree of repigmentation and 
the best option can be applied following a detailed assessment of the patient’s vitiligo. 
 
1.2.7.1 Patient assessment 
Before commencing treatment, a complete assessment of the patient is performed to exclude 
other conditions that may mimic vitiligo such as pityriasis versicolor, piebaldism and 
idiopathic guttate hypomelanosis (Gawkrodger et al. 2010). An accurate and full examination 
to determine the extent and distribution of depigmented lesions and the clinical type of 
vitiligo is then made before the available treatment options are discussed with the patient. 
Quality of life assessments are also helpful and the provision of psychological support is 
useful for patients who have suffered serious psychological effects or social stigma as a result 
of the disease (Ongenae et al. 2006; Choi et al. 2010; Gawkrodger et al. 2010; Taïeb and 
Picardo 2010b). Thyroid function and a test for the presence of anti-thyroid antibodies, and 
possibly other endocrine organ antibodies, are valuable since vitiligo can be associated with 
autoimmune thyroiditis in at least 5% of cases (Bjoro et al. 2000).  
 
1.2.7.2 Medical treatments 
Several medical approaches have been used to treat vitiligo including UV light, topical 
agents, camouflaging and depigmenting chemicals and, these are discussed in the next 
sections.  
 
1.2.7.2.1 Topical corticosteroids 
At present, the use of topical corticosteroids, which have anti-inflammatory and 
immunosuppressive effects, is considered to be the first-line treatment in children and adults 
with segmental or non-segmental vitiligo of recent onset (Gawkrodger 1998; Cockayne et al. 
2002; Forschner et al. 2007; Gawkrodger et al. 2008; Abu Tahir et al. 2010; Gawkrodger et 
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al. 2010; Hossani-Madani and Halder 2010; Taïeb and Picardo 2010b; Tamesis and Morelli 
2010; Van der Veen et al. 2010; Whitton et al. 2010). Potent (e.g., betamethasone valerate) 
and highly potent (e.g., clobetasol propionate) topical corticosteroids can induce 
repigmentation in vitiligo lesions to a variable degree, but this is only seen in a proportion of 
patients: repigmentation of more than 75% and of 90-100% was achieved in 2/23 and 6/23 
vitiligo patients, respectively, using clobetasol propionate and betamethasone valerate  
(Kandil 1974; Clayton 1977). Furthermore, in combination with UVA, topical fluticasone 
propionate, a potent steroid, was found to be three times more effective in inducing 
repigmentation when compared to each treatment alone (Westerhof et al. 1999), and topical 
hydrocortisone 17-butyrate together with 308-nm excimer laser treatment was shown to be 
synergistically effective in the therapy of recalcitrant vitiligo lesions on the face and neck 
(Sassi et al. 2008). However, despite their efficacy, potent topical corticosteroids can only be 
used once daily for no more than two months, in order to avoid skin atrophy (Van der Veen et 
al. 2010). 
 
1.2.7.2.2 Topical immunomodulators 
Topical immunomodulators such as tacrolimus and pimecrolimus are preferentially used in 
the treatment of vitiligo lesions on the face and neck in adults and children (Grimes et al. 
2002; Lepe et al. 2003; Mayoral et al. 2003; Coskun et al. 2005; Sendur et al. 2006; Boone et 
al. 2007; Seirafi et al. 2007; Hartmann et al. 2008; Radakovic et al. 2009; Stinco et al. 2009; 
Xu et al. 2009; Hossani-Madani and Halder 2010; Lo et al. 2010; Whitton et al. 2010). Also 
referred to as calcineurin inhibitors, these reagents down-regulate the activation and 
maturation of T cells, immune factors which are thought to be involved in vitiligo 
pathogenesis (Homey et al. 1998). In combination with either narrow-band (NB)-UVB 
(Ostovari et al. 2006; Fai et al. 2007; Esfandiarpour et al. 2009; Majid 2010) or with 308-nm 
excimer laser (Kawalek et al. 2004), tacrolimus also has a synergistic effect in inducing 
repigmentation. Topical immunomodulators have a better safety profile than topical steroids 
with respect to skin side-effects, and percutaneous absorption of topical immunomodulators 
is limited so no significant systemic effects have been reported (De and Kanwar 2008). With 
regard to efficacy, topical tacrolimus has been shown to be as effective as clobetasol 
propionate in inducing repigmentation (Lepe et al. 2003), and pimecrolimus was found to be 
more effective than calcipotriol in the treatment of facial lesions (Bilac et al. 2009). Overall, 
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topical immunomodulators are considered a useful alternative to topical steroids in the 
treatment of vitiligo (Van der Veen et al. 2010). However, more studies are required to assess 
their long-term benefits and safety when used as either a monotherapy or in combination 
treatment. 
 
1.2.7.2.3 Topical vitamin D analogues 
The topical vitamin D analogues, calcipotriol and tacalcitol, have been used in vitiligo 
therapy as, they can promote tyrosinase activitiy and so initiate pigment synthesis. 
Repigmentation of vitiligo lesions has been reported in patients treated with topical 
calcipotriol alone (Gargoom et al. 2004), and in combination with either topical 
corticosteroids, NB-UVB, psoralen with UVA (PUVA) (Section 1.2.7.2.5) or 308-nm 
excimer laser (Katayama et al. 2003; Kullavanijaya and Lim 2004; Travis and Silverberg 
2004; Goktas et al. 2006; Kumaran et al. 2006; Leone et al. 2006; Amano et al. 2008; Gamil 
et al. 2010). The benefits of vitamin D analogues in vitiligo treatment are, however, 
controversial, with several studies reporting either topical calcipotriol monotherapy as 
ineffective or that no additional improvement is noted in repigmentation when they are used 
in combination with other therapies (Chiaverini et al. 2002; Ada et al. 2005; Hartmann et al. 
2005; Goldinger et al. 2007; Rodriguez-Martin et al. 2009). 
 
1.2.7.2.4 Antioxidants 
There is convincing evidence for the occurrence of oxidative stress in the epidermal skin of 
vitiligo patients (Schallreuter 1999; Schallreuter et al. 1999). Antioxidants work by reducing 
high levels of H2O2 in epidermal melanocytes and keratinocytes, thus leading to 
repigmentation of vitiligo lesions (Schallreuter et al. 1995; Schallreuter 1999; Schallreuter et 
al. 1999; Schallreuter et al. 2001). Several different reagents have been tested including 
pseudocatalase (Schallreuter et al. 1995) and vitamin E (Akyol et al. 2002). Pseudocatalase in 
a topical cream, and in combination with short-term UVB exposure, resulted in excellent 
repigmentation in 90% of 33 patients, especially on the dorsum of hands and face 
(Schallreuter et al. 1995). However, further studies are required to evaluate the effectiveness 
of pseudocatalase in vitiligo treatment. Another antioxidant, vitamin E, in combination with 
PUVA, induced 75% repigmentation in 60% of vitiligo patients compared with 40% of 
vitiligo patients for PUVA treatment alone (Akyol et al. 2002). In a randomised, double-
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blind, placebo-controlled multicentre trial, an oral antioxidant pool containing alpha-lipoic 
acid and vitamins C and E was found to improve significantly NB-UVB effectiveness with 
excellent repigmentation in 40% of patients compared with placebo-NB-UVB (Dell'Anna et 
al. 2007). In addition, treatment with the antioxidant pool induced a reduction in oxidative 
stress in the epidermis of the vitiligo patients (Dell'Anna et al. 2007).  
 
1.2.7.2.5 Photochemotherapy  
Psoralen is a furocoumarin compound which can stimulate melanocyte proliferation, 
melanosome formation, melanosome transfer to keratinocytes and tyrosinase activation 
(Gupta and Anderson 1987; Averbeck 1989; Abdel-Naser et al. 1997; Canton et al. 2002; Wu 
et al. 2007). Photochemotherapy using orally applied psoralen with UVA (PUVA) is 
considered as second-line therapy in the adult patients with non-segmental vitiligo affecting 
more than 10-20% of the skin (Njoo et al. 1999; Gawkrodger et al. 2008; Falabella and 
Barona 2009; Alomar 2010; Gawkrodger et al. 2010). However, the treatment is not 
recommended for either children under twelve years of age because of retinal toxicity or for 
those with a personal history of malignant skin lesions, photoallergy, impaired liver function, 
pregnancy and cataract (Carrascosa et al. 2005; Alomar 2010). In contrast, topical 
photochemotherapy can be applied to children over two years and to adults with localised 
vitiligo lesions (Alomar 2010).  
 
1.2.7.2.6 Narrow-band-UVB 
As yet, the precise mechanism of action of narrow-band (NB)-UVB in repigmenting vitiligo 
lesions is unknown. However, NB-UVB can activate the release from keratinocytes of ET-1 
and bFGF, which then stimulate melanocyte proliferation (Wu et al. 2004), and can stimulate 
the expression of focal adhesion kinase and matrix metalloproteinases, which may enhance 
melanocyte migration from the outer root sheath of the hair follicle into the epidermis (Wu et 
al. 2004). When used for vitiligo treatment, more than 75% repigmentation has been achieved 
in 67% (Westerhof and Nieuweboer-Krobotova 1997) and 53% (Njoo et al. 1998) of patients. 
Furthermore, stabilisation of the disease was evident in 80% of those patients with active 
disease (Njoo et al. 1998). Since these early studies, many others have confirmed the efficacy 
of NB-UVB for the treatment of vitiligo (Scherschun et al. 2001; Samson Yashar et al. 2003; 
Hamzavi et al. 2004; Anbar et al. 2006; Brazzelli et al. 2007; Nicolaidou et al. 2007; Kumar 
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et al. 2009; Leone and Tanew 2010) . This modality now represents the phototherapy of 
choice for inducing repigmentation in patients with generalised vitiligo where depigmented 
areas affect multiple sites or large areas of the body. It is also useful for halting the 
progression of currently active disease. Comparative studies have also indicated the superior 
efficacy and better safety profile of NB-UVB over PUVA (Westerhof and Nieuweboer-
Krobotova 1997; Bhatnagar et al. 2007b; Bhatnagar et al. 2007a; Yones et al. 2007).  
 
1.2.7.2.7 Laser treatments 
The 308-nm excimer laser is a new therapeutic option for vitiligo which allows the targeted 
phototherapy of depigmented lesions (Passeron and Ortonne 2005; Passeron and Ortonne 
2006; Leone and Tanew 2010). Although the mechanism of action is not yet understood, 
excimer laser treatment is thought to stimulate melanocyte migration and proliferation and to 
act as an immunosuppressant. The efficacy of excimer laser treatment depends on the 
location of the vitiligo lesions, with the best results being reported for the face and neck, and 
on treatment frequency, with weekly applications optimal (Hofer et al. 2005; Shen et al. 
2007). Furthermore, a combination of 308-nm excimer laser with topical tacrolimus induces a 
greater repigmentation response and a shorter duration of treatment compared to excimer 
laser monotherapy (Kawalek et al. 2004; Passeron et al. 2004). Overall, excimer laser has a 
shorter treatment time and fewer adverse side-effects than other phototherapies (Baltas et al. 
2001; Hofer et al. 2005; Le Duff et al. 2010; Leone and Tanew 2010), but relapse of 
repigmentation has been reported to occur in 15% of patients 1-3 years after discontinuation 
of therapy (Passeron and Ortonne 2005). 
 
1.2.7.2.8 Depigmenting treatments 
Depigmentation with topical monobenzyl ether of hydroquinone is considered in patients 
with extensive depigmentation, usually involving more than 90% of the body surface area, or 
with depigmentation in cosmetically significant sites such as the face or hands, or for whom 
other treatments have been ineffective (Mosher et al. 1977). The combination of topical 4-
methoxyphenol and Q-switched ruby laser therapy has also been shown to elicit effective 
depigmentation (Njoo et al. 2000). Cryotherapy and 4-hydroxyanisole may also produce 
depigmentation (Radmanesh 2000; Di Nuzzo and Masotti 2010).  
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1.2.7.2.9 Camouflage 
Camouflaging has only recently been recognised as a medical intervention for treating 
vitiligo (Rajatanavin et al. 2008; Gawkrodger et al. 2010; Tanioka et al. 2010). Self-tanning 
lotions and pigmented creams can be used to disguise depigmented areas and they can be 
relatively simple to apply (Jouary and DePase 2010). In addition, tattoing is an option to 
cover vitiligo lesions, but this technique has not always given satisfactory results (Boissy and 
Nordlund 1995b; De Cuyper 2008; Holla and Parsad 2010; Jouary and DePase 2010; Singh 
and Karki 2010). 
 
1.2.7.3 Surgical treatments 
Surgical treatment is not a first option for vitiligo and is only used in cases which fail to 
respond to medical therapies. This is particularly so for vitiligo lesions on the fingers, hands 
and feet, where there is a low density of hair follicles and, for segmental vitiligo (Holla and 
Parsad 2010; Olsson 2010). Several surgical techniques have been developed and these are 
listed in Table 1.3. Combining these techniques with medical treatments can also be 
beneficial (Sachdev and Krupashankar 2000; Pai et al. 2002; Toriyama et al. 2004). Selection 
criteria for suitable patients include the site, number and extent of the lesions, the texture of 
the recipient skin, the clinical type of vitiligo and disease stability. The outcome of surgical 
treatments is excellent for patients with stable segmental vitiligo, but for those with non-
segmental vitiligo, patients should not have demonstrated the Koebner phenomenon, the 
extension of old lesions or the development of new lesions over the previous year for a 
successful result (Gawkrodger et al. 2008; Holla and Parsad 2010; Olsson 2010).  
 
1.2.7.4 Summary  
In summary, the treatment choice in vitiligo is dependent upon factors which include vitiligo 
type, patient age and location and stability of lesions (Taieb et al 2010b). However, despite 
many treatment modalities, repigmentation in the majority of vitiligo patients is rarely 
complete or long-lasting. A better understanding of the precise pathogenesis of the disease is 
crucial to improving the efficacy of treatment regimens. 
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Table 1.3: Surgical treatments for vitiligo 
 
 
 
Surgical procedure 
 
 
Comments 
 
Reference 
Autologous grafting e.g., 
minigrafts, suction blisters, ultra-
thin grafting 
Cobblestone appearance is 
common at the recipient site. 
Relatively easy and 
inexpensive methods. 
 
(Boersma et al. 1995; Boissy 
and Nordlund 1995b; Kovacs 
1998; Fongers et al. 2009; 
Olsson 2010) 
Transplantation of cultured 
epidermis 
Results of culturing will 
depend on skin type and any 
previous UV therapy. 
Requires culture facilities and 
trained personnel. 
 
(Boissy and Nordlund 1995b; 
Kovacs 1998; Pianigiani et al. 
2005; Czajkowski et al. 2007) 
Cultured melanocytes and 
keratinocytes  
 
Cells are cultured in 
suspension or on defined 
membranes. Requires culture 
facilities and trained 
personnel. 
 
(Mulekar 2004; Pandya et al. 
2005; El-Zawahry et al. 2010) 
Cultured epidermal sheets with 
CO2 laser 
 
Large lesions can be treated. (Toriyama et al. 2004) 
Autologous grafting with erbium 
YAG laser 
 
Larger lesions can be treated. 
No cobblestone appearance. 
(Sachdev and Krupashankar 
2000; Pai et al. 2002) 
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1.3. Vitiligo: Aetiology and Pathogenesis  
The exact aetiology and detailed pathogenesis of vitiligo still remains obscure. There are 
several proposed causes and these are discussed in the following sections. 
 
1.3.1 Physical trauma 
Mechanical trauma or friction injury to the skin, also known as Koebner’s phenomenon, may 
be a triggering and perpetuating factor of melanocyte loss in vitiligo (Gauthier 1996; Taïeb 
2000), as it has been observed that the distribution of depigmented lesions can correlates with 
the site of friction or injury (Gauthier 1996). The reported incidence of Koebner’s 
phenomenon in vitiligo varies from 21-62% of patients (Barona et al. 1995; Hann et al. 1997; 
Mazereeuw-Hautier et al. 2010; van Geel et al. 2011b) and, recently, a new classification has 
been proposed to allow the evaluation of Koebner’s phenomenon in daily practice or in 
experimental studies (van Geel et al. 2011a). 
 To date, the pathophysiology of Koebner’s phenomenon in vitiligo has not been 
clarified, but may involve factors such as oxidative or immunological stresses which 
eventually lead to melanocyte death (van Geel et al. 2011a). Interestingly, detachment of 
surviving melanocytes from the basal layer following traumatic friction in non-lesional skin 
in patients with generalised vitiligo has been demonstrated (Gauthier et al. 2003a). This 
detachment was followed by the trans-epidermal migration of and ultimately the death of 
pigment cells suggesting that physical stress can be responsible for chronic melanocyte loss 
in vitiligo (Gauthier et al. 2003a).  
 
1.3.2 Psychological stress 
There is evidence to indicate that stressful life events can contribute to the onset of vitiligo in 
some patients (Papadopoulos et al. 1998). In contrast, it has been observed that the 
development of vitiligo is not necessarily related to stressful situations but more to the 
inability to cope with uncontrollable events (Picardi et al. 2003). In addition, a lack of social 
support can increase susceptibility to vitiligo (Picardi et al. 2003). With regard to a 
pathological mechanism, it has been suggested that psychological stress and emotional 
trauma may increase the levels of neuropeptide-Y (Al'Abadie et al. 1994b; Tu et al. 2001) 
and neuroendocrine hormones (Al'Abadie et al. 1994a), which could result in melanocyte 
damage leading to the acute onset of depigmentation. 
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1.3.3 Infections 
It has been suggested that infection may be a possible factor leading to pigment cell loss in 
vitiligo (Le Poole et al. 1993a). The destruction of melanocytes has been explained by the 
display of infectious agent particles with major histocompatibility complex (MHC) class I 
molecules on the infected cell surface thereby triggering a secondary immune response (Le 
Poole et al. 1993a). The cytomegalovirus genome has been identified in lesional and non- 
lesional skin biopsies of some patients with vitiligo suggesting that viral infection may play a 
role in disease onset (Grimes et al. 1996). In addition, vitiligo has been reported to be 
associated with other infections including human immunodeficiency virus (Ivker et al. 1994; 
Vin-Christian et al. 2000; Antony and Marsden 2003), chronic mucocutaneous candidiasis 
(Howanitz et al. 1981) and leprosy (Shegan 1971). 
 
1.3.4 Genetic factors 
The following details and discussion refer to non-segmental since there are few studies that 
provide information with regard to the genetics of the segmental form of the disease.  
 
1.3.4.1 Genetic epidemiology of vitiligo 
The majority of cases of vitiligo are sporadic without a family history of the disease. 
Nevertheless, 15-20% of patients report at least one affected first-degree relative (Alkhateeb 
et al. 2003), lending evidence for a genetic role in the aetiology of vitiligo. Furthermore, 
among Caucasians, the risk of vitiligo developing in a patient’s sibling is approximately 6.1% 
(Alkhateeb et al. 2003), an increase of sixteen-fold compared to the general Caucasian 
population where the prevalence of the disease is 0.38% (Howitz et al. 1977). Similarly, an 
increased risk among first-degree relatives is found in Indian-Pakistanis at 6.1% (Alkhateeb 
et al. 2003), in American Hispanic-Latinos at 4.8% (Alkhateeb et al. 2003) and in Han 
Chinese at 2.6% (Sun et al. 2006). A simple Mendelian inheritance pattern is not displayed in 
these familial aggregations of vitiligo cases (Mehta et al. 1973; Carnevale et al. 1980; Hafez 
et al. 1983; Das et al. 1985; Majumder et al. 1988; Bhatia et al. 1992; Majumder et al. 1993; 
Nath et al. 1994; Alkhateeb et al. 2003; Laberge et al. 2005; Sun et al. 2006), suggesting that 
the disease is probably transmitted as a polygenic trait. Indeed, earlier disease onset in 
familial cases (Alkhateeb et al. 2003; Laberge et al. 2005) and reduced risk of vitiligo with 
increasing genetic distance from the patient (Alkhateeb et al. 2003) are indicative of a 
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polygenic disorder. Formal genetic segregation analyses of vitiligo have also suggested that 
multiple loci contribute to vitiligo susceptibility (Majumder et al. 1993; Nath et al. 1994; Sun 
et al. 2006). Seldom have large multi-generation families been reported, where vitiligo 
segregates in an autosomal dominant pattern (Alkhateeb et al. 2005). 
 Approximately 15-25% of vitiligo patients have an additional autoimmune disorder, 
for example, autoimmune thyroid disease and type 1 diabetes mellitus (Alkhateeb et al. 
2003). Moreover, the risk of occurrence of the same autoimmune diseases is elevated in the 
vitiligo patients’ first-degree relatives (Alkhateeb et al. 2003; Laberge et al. 2005). Such 
findings indicate that these vitiligo patients and their close relatives have a susceptibility to 
autoimmune disease, including vitiligo, which is mediated by shared genes, with additional 
genetic loci determining disease specificity (Spritz 2010b). 
 Twin studies have also provided evidence of a genetic component to vitiligo 
aetiology. For vitiligo in monozygotic twins, the concordance is 23% (Alkhateeb et al. 2003), 
a disease risk that is sixty-fold greater than that in the general population (Howitz et al. 1977) 
and four-fold higher than that for a patient’s sibling (Alkhateeb et al. 2003) 
 
1.3.4.2 Identification of genes involved in vitiligo aetiology 
The genetic epidemiological evidence has prompted the search for genes which predispose an 
individual to the development of vitiligo. Investigations have included families with vitiligo 
as well as cohorts of patients without a familial history of the disease (Fain et al. 2003; 
Cantón et al. 2005). Different approaches have been employed to identify genes which confer 
susceptibility to vitiligo. Candidate gene association studies rely upon testing known genes 
and this type of analysis has been extensively used with populations of unrelated vitiligo 
patients (Blomhoff et al. 2005; Cantón et al. 2005). In contrast, genome-wide linkage studies 
scan the whole genome for regions that segregate in a non-random fashion with vitiligo. This 
approach has been used in analysing genetic factors in vitiligo, but is limited to the analysis 
of family-related vitiligo (Fain et al. 2003; Spritz et al. 2004; Chen et al. 2005; Liang et al. 
2007). Genome-wide association studies combine the advantages of candidate gene 
association and genome-wide linkage analyses and this approach has recently been applied to 
the study of vitiligo susceptibility genes (Birlea et al. 2010; Jin et al. 2010a; Quan et al. 
2010). The genes and genetic loci so far identified have been extensively reviewed (Spritz 
31 
 
2006; Spritz 2007; Spritz 2008; Spritz 2010b; Spritz 2011; Spritz 2012), and are summarised 
in the following sections. 
 
1.3.4.3 Human leukocyte antigen alleles of the major histocompatibility complex  
The studies of human leukocyte antigen (HLA) alleles of the MHC in relation to vitiligo 
susceptibility are summarised in Table 1.4. Initial case control studies demonstrated an 
association between predisposition to vitiligo and several different HLA alleles (Metzker et 
al. 1980; Foley et al. 1983; Dunston and Halder 1990; Finco et al. 1991; Poloy et al. 1991; 
Lorini et al. 1992; Orecchia et al. 1992; Venneker et al. 1992; Ando et al. 1993; Schallreuter 
et al. 1993; Venneker et al. 1993; Al-Fouzan et al. 1995; Venkataram et al. 1995; Buc et al. 
1996). Although these studies showed weak and variable associations, a significant 
association of HLA-DR4 and vitiligo was demonstrated in several populations (Foley et al. 
1983; Dunston and Halder 1990; Venneker et al. 1992) and a subsequent meta-analysis of a 
series of case-control studies reported association of vitiligo with HLA-A2 (Liu et al. 2007). 
 More recently, the use of better analytical and statistical methods has revealed 
associations of vitiligo with HLA-DRB1*04, HLA-DRB1*03 and HLA-DRB1*07 alleles in 
Turkish patients (Tastan et al. 2004), with HLA-DRB4*0101 and HLA-DQB1*0303 in 
Dutch patients (Zamani et al. 2001), HLA-A25-Cw*0602-DQA1*0302, HLA-DQA1*0302, 
HLA-DQB1*0303 and HLA-DQB1*0503 in Han Chinese patients (Yang et al. 2005; Xia et 
al. 2006), and A*33:01, B*44:03, and DRB1*07:01 in Idian and Gujarat patients (Singh et al. 
2012). Furthermore, a study of 76 Caucasian multiplex vitiligo families found the HLA-
DRB1A*04-DQB1*0301 haplotype to be associated with a higher risk of developing vitiligo 
and with an earlier onset of the disease (Fain et al. 2006). Finally, of three genome-wide 
association studies undertaken on populations of vitiligo patients (Birlea et al. 2010; Jin et al. 
2010a; Quan et al. 2010), two reported that predisposition of vitiligo was associated with 
HLA class I and II antigens (Jin et al. 2010a; Quan et al. 2010). 
 
1.3.4.4 Other immune-response genes and loci 
Studies of immune-response gene variants in relation to predisposition to vitiligo 
development are summarised in Table 1.5. Several of these genetic associations have been 
verified while others remain to be confirmed. Of particular note, the allelic variation R620W 
of the PTPN22 gene, which encodes lymphoid protein tyrosine phosphatase, a molecule  
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Table 1.4: Association of human leukocyte antigen (HLA) alleles with vitiligo 
susceptibility 
 
 
 
 
Population 
 
 
Associated HLA allele 
 
Reference 
American (Caucasian) DR4 (Foley et al. 1983) 
American (African) DR4, DQw3  (Dunston and Halder 1990) 
American and British 
(European-derived, 
Caucasian)  
DRB1A*04-DQB1*0301 (Fain et al. 2006) 
American and British 
(European-derived, 
Caucasian)  
Class I (specifically A*0201) and 
II antigens 
(Jin et al. 2010a) 
Chinese (Han) DQA1*0302, DQB1*0303, 
DQB1*0503 
(Yang et al. 2005) 
Chinese (Han)  A25-Cw*0602-DQA1*0302 (Xia et al. 2006) 
Chinese (Han and Uygar) Class I and II antigens (Quan et al. 2010) 
Dutch DR4, DR6, Cw6 (Venneker et al. 1992; Venneker et 
al. 1993) 
Dutch DRB4*0101, DQB1*0303 (Zamani et al. 2001) 
German (Northern) A2 (Schallreuter et al. 1993) 
Hungarian DR1, DR3 (Poloy et al. 1991) 
Italian A30, B27, Cw6, DQw3 (Finco et al. 1991) 
Italian (Northern)  A3 (Lorini et al. 1992) 
Italian (Northern) A30, Cw6, DQw3  (Orecchia et al. 1992) 
Japanese A31, Bw46, Cw4 (Ando et al. 1993) 
Kuwaiti B21, Cw6 (Al-Fouzan et al. 1995) 
Moroccan (Jewish) B13 (Metzker et al. 1980) 
Omani Bw6, DR7  (Venkataram et al. 1995) 
Slovak A2, Dw7 (Buc et al. 1996) 
Turkish DRB1*03, DRB1*04, DRB1*07 (Tastan et al. 2004) 
Yemeni Bw35  (Metzker et al. 1980) 
Indian and Gujarat A*33:01, B*44:03, DRB1*07:01  (Singh et al. 2012) 
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involved in T cell signalling, has been shown to confer vitiligo susceptibility in several 
independent reports (Cantón et al. 2005; Laberge et al. 2008a; Laberge et al. 2008b; Jin et al. 
2010a). In addition, allelic variants in the NLRP1 gene (previously NALP1 or SLEV1), 
which encodes a key regulator of the innate immune system, have been reproducibly 
associated with an increased risk of vitiligo in different populations (Nath et al. 2001; Spritz 
et al. 2004; Jin et al. 2007b; Jin et al. 2007c; D'Osualdo and Reed 2012). More recent 
genome-wide association studies have identified and confirmed the association of vitiligo 
with variations in several immune-response genes e.g., CCR6, FOXP1, FOXP3, TSLP and 
XBP1 (Cheong et al. 2009; Ren et al. 2009; Jin et al. 2010a; Jin et al. 2010b; Quan et al. 
2010; Birlea et al. 2011). 
 In contrast, studying variations in the cytotoxic T lymphocyte antigen 4 (CTLA4) 
gene has yielded conflicting results with respect to vitiligo susceptibility (Kemp et al. 1999; 
Blomhoff et al. 2005; Itirli et al. 2005; Laberge et al. 2008a; Birlea et al. 2009; Pehlivan et 
al. 2009; Deeba et al. 2010; Birlea et al. 2011). Presently, allelic differences in CTLA4 
appear to be predominantly associated with vitiligo occurring together with other 
autoimmune diseases (Blomhoff et al. 2005), and it has been suggested, therefore, that the 
association of CTLA4 with vitiligo is probably secondary to its primary association with 
disorders such as autoimmune thyroid disease (Spritz 2010b). Similar conflicts of data have 
arisen with respect to the study of single nucleotide polymorphisms (SNPs) in the 
autoimmune regulator (AIRE) gene. Mutations in the AIRE gene are the cause of 
autoimmune polyendocrine syndrome type 1 (APS1) of which vitiligo is a common clinical 
manifestation (Nagamine et al. 1997). Significant associations between SNPs in AIRE and 
vitiligo susceptibility were found in one (Tazi-Ahnini et al. 2008), but not in a second  
candidate gene association study (Birlea et al. 2011), and not in a report analysing multiplex 
families (Jin et al. 2007a). 
 
1.3.4.5 Non-immune-response genes and loci  
Many studies have been undertaken to find variations in genes that regulate melanocyte 
metabolism, development or proliferation that could be associated with susceptibility to 
vitiligo (Table 1.6). These have included the genes encoding catalase (Casp et al. 2002; 
Gavalas et al. 2006; Park et al. 2006; Shajil et al. 2007; Liu et al. 2010; Birlea et al. 2011), 
catechol-O-methyltransferase (Türsen et al. 2002; Li et al. 2009a; Birlea et al. 2011),   
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Table 1.5: Association of immune-response gene variants with vitiligo susceptibility 
 
 
 
Gene or 
locus 
 
 
Function 
 
Association 
status 
 
Reference 
AIRE 
 
Autoimmune regulator. Transcription factor which 
determines self-tolerance during T cell maturation 
in the thymus. Causes autoimmune polyendocrine 
syndrome type 1. 
Data conflicting (Jin et al. 2007a; Tazi-
Ahnini et al. 2008; Birlea et 
al. 2011) 
AIS2 
 
Autoimmune susceptibility locus 2. Function 
undefined. Associated with autoimmune disease. 
Confirmed (Spritz et al. 2004) 
AIS3 Autoimmune susceptibility locus 3. Function 
undefined. 
Unconfirmed  (Spritz et al. 2004) 
CCR6 
 
Cytokine-chemokine receptor for CCL20. Recruits 
immune cells on binding of ligand. Associated with 
inflammatory bowel disease. 
Confirmed (Jin et al. 2010a; Jin et al. 
2010b; Quan et al. 2010) 
CD4 CD antigen. Regulates cell-mediated immune 
responses. Associated with type 1 diabetes mellitus. 
Data conflicting (Zamani et al. 2010; Birlea 
et al. 2011) 
C1QTNF6 
 
C1q and tumour necrosis factor-related protein- 6. 
Associated with rheumatoid arthritis and type 1 
diabetes mellitus. 
Confirmed (Jin et al. 2010a) 
CTLA4 
 
Cytotoxic T lymphocyte antigen 4. Negatively 
regulates T cell activation. Associated with several 
autoimmune diseases. 
Data conflicting (Kemp et al. 1999; 
Blomhoff et al. 2005; Itirli 
et al. 2005; Laberge et al. 
2008a; Birlea et al. 2009; 
Pehlivan et al. 2009; Deeba 
et al. 2010; Birlea et al. 
2011) 
DDR1 
 
Discoid domain receptor tyrosine kinase 1. 
Regulates leukocyte function and cell adhesion. 
Data conflicting (Kim et al. 2010; Silva de 
Castro et al. 2010; Birlea et 
al. 2011) 
FOXP1 Forkhead box P1. Transcription factor which 
regulates development of immune cells.  
Confirmed (Jin et al. 2010a; Jin et al. 
2010b) 
FOXP3 Forkhead box P3. Transcription factor which 
regulates regulatory T cell development. Causes 
autoimmune IPEX syndrome. 
Confirmed  (Birlea et al. 2011) 
GZMB 
 
Granzyme B. Regulates cell-mediated immune 
responses. 
Confirmed  (Jin et al. 2010a) 
IL10 Interleukin 10. Cytokine which inhibits T cell 
differentiation and proliferation.  
Data conflicting (Abanmi et al. 2008; Birlea 
et al. 2011) 
IL1RN Interleukin (IL)-1 receptor antagonist.  Modulates 
action of IL1. 
Data conflicting (Pehlivan et al. 2009; Birlea 
et al. 2011) 
IL2RA 
 
Interleukin-2 receptor alpha chain. Receptor for 
cytokine IL2 which induces T and B cell 
proliferation. Associated with many autoimmune 
diseases. 
Confirmed  (Jin et al. 2010a) 
LMP2  
 
Low molecular weight polypeptide-2. Functions in 
processing and presentation of antigens to the 
immune system. 
Unconfirmed 
 
(Casp et al. 2003) 
LMP7 (PSMB8) Low molecular weight polypeptide-7. Functions in 
processing and presentation of antigens to the 
immune system. 
Data conflicting (Casp et al. 2003; Birlea et 
al. 2011) 
LPP 
 
LIM domain-containing preferred translocation 
partner in lipoma. Function unknown. Associated 
with celiac disease and rheumatoid arthritis. 
Confirmed 
 
(Jin et al. 2010a) 
MBL2 Mannose-binding lectin 2. Functions in the innate 
immune response.  
Data conflicting (Onay et al. 2007; Dwivedi 
et al. 2009; Birlea et al. 
2011) 
NLRP1 (NALP1; 
SLEV1) 
NACHT leucine-rich-repeat protein 1. Functions in 
the innate immune response. Associated with many 
Confirmed (Nath et al. 2001; Spritz et 
al. 2004; Jin et al. 2007b; 
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 autoimmune diseases. Jin et al. 2007c) 
PTPN22 
 
Lymphoid protein tyrosine phosphatase. Negatively 
regulates T cell activation. Associated with many 
autoimmune diseases. 
Confirmed (Cantón et al. 2005; 
Laberge et al. 2008a; 
Laberge et al. 2008b; Jin et 
al. 2010a) 
TAP1 
 
Transporter associated with antigen processing 
protein-1. Functions in processing and presentation 
of antigens to the immune system. 
Data conflicting (Casp et al. 2003; Birlea et 
al. 2011) 
TGFBR2 Transforming growth factor beta receptor 2. 
Receptor for cytokine TGF which regulates many 
immune responses and can inhibit melanocyte 
activity. 
Data conflicting (Yun et al. 2010; Birlea et 
al. 2011) 
TNF Tumor necrosis factor-alpha. Proinflammatory 
cytokine which can inhibit melanocyte proliferation 
and melanogenesis. 
Data conflicting (Yazici et al. 2006; Namian 
et al. 2009; Birlea et al. 
2011) 
TSLP Thymic stromal lymphopoietin. Cytokine which 
induces naïve CD4+ T cells to produce Th2 
cytokines.  
Confirmed (Cheong et al. 2009; Birlea 
et al. 2011) 
UBASH3A Ubiquitin-associated and SH3 domain-containing A 
gene. Regulates T cell receptor signalling. 
Associated with type 1 diabetes mellitus. 
Confirmed (Jin et al. 2010a) 
XBP1 
 
X-box binding protein 1. Transcription factor 
which regulates MHC class II gene expression. 
Associated with inflammatory bowel disease. 
Confirmed (Ren et al. 2009; Birlea et 
al. 2011) 
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and ET-1 (Kim et al. 2007a; Lan et al. 2009; Birlea et al. 2011). However, in the majority of 
cases, the data are conflicting and will require further analyses to confirm or deny an 
association with vitiligo. 
 Of particular interest is the association determined between vitiligo and a major allelic 
variant of TYR (402Q), the gene which encodes the melanogenic enzyme tyrosinase (Jin et 
al. 2010a). The protein encoded by the minor 402Q variant of TYR is produced in small 
amounts, is thermosensitive, not correctly glycosylated and is retained in the endoplasmic 
reticulum (Tripathi et al. 1991; Toyofuku et al. 2001). Interestingly, the minor TYR allele 
(402Q) is associated with susceptibility to malignant melanoma (Gudbjartsson et al. 2008; 
Bishop et al. 2009). These observations have led to the postulation that the TYR 402Q 
variant is less available to the immune system such that neoplastic melanocytes may escape 
immune surveillance in melanoma patients with this minor allele (Jin et al. 2010a; Spritz 
2010a). Conversely, 402R tyrosinase is perhaps more efficiently presented to the immune 
system resulting in a more effective immune response against pigment cells in melanoma and 
but predisposing to vitiligo (Jin et al. 2010a; Spritz 2010a). 
 
1.3.4.6 Summary 
Overall, there is considerable evidence for the importance of genes in the development of 
vitiligo (Spritz 2006; Spritz 2007; Spritz 2008; Spritz 2010b; Spritz 2011; Spritz 2012). 
Interestingly, the majority of the confirmed vitiligo susceptibility loci encode proteins which 
play a role in the immune response (Tables 1.6 and 1.7), thus strongly supporting an 
autoimmune basis for the disease. However, exactly how the different gene variants function 
to contribute to the vitiligo phenotype has not yet been determined. Of interest also, is that the 
genetic underpinnings of the disease may vary, for example, between patients without a 
family history of vitiligo and those with family-related vitiligo (Ando et al. 1993; Silva de 
Castro et al. 2010). Patients with vitiligo and associated autoimmune disease may also have 
different genetic factors underlying their disease compared with individuals presenting with 
isolated depigmentation (Kemp et al. 1999; Blomhoff et al. 2005). In addition, differences 
have been reported between gene variants in non-segmental and those in segmental vitiligo, 
although few studies have addressed this issue (Yang et al. 2005; Xia et al. 2006; Li et al. 
2008; Liu et al. 2009). Furthermore, different genes may be involved in the pathogenesis of 
vitiligo in different populations (Fain et al. 2003; Spritz et al. 2004; Chen et al. 2005; Liang 
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et al. 2007; Laddha et al. 2008). Finally, the limited concordance in identical twins 
(Alkhateeb et al. 2003) indicates that other factors, probably environmental, are also involved 
in causing the disorder making vitiligo a complex, polygenic, multi-factorial disease. 
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Table 1.6: Association of variants of non-immune-response genes with vitiligo 
susceptibility 
 
 
 
Gene or locus 
 
 
Function 
 
Association 
status 
 
 
Reference 
ACE 
 
Angiotensin-converting enzyme 
inhibitor. Regulates blood pressure and 
inflammation. 
Data conflicting  (Jin et al. 2004a; Akhtar et al. 
2005; Dwivedi et al. 2008; 
Birlea et al. 2011) 
CAT 
 
Catalase. Regulates breakdown of H2O2 
and so protects against oxidative stress. 
Data conflicting (Casp et al. 2002; Gavalas et 
al. 2006; Park et al. 2006; 
Shajil et al. 2007; Liu et al. 
2010; Birlea et al. 2011) 
CLEC11A (SCGF) C-type lectin (Stem cell growth factor). 
Keratinocyte-derived growth factor 
which egulates growth and function of 
melanocytes. 
Data conflicting (Lan et al. 2009; Birlea et al. 
2011) 
COMT 
 
Catechol-O-methyl transferase. Degrades 
toxic o-quinones.  
Data conflicting (Türsen et al. 2002; Li et al. 
2009a; Birlea et al. 2011) 
COX2 (PTGS2) 
 
Cyclooxygenase. Functions in 
melanocyte proliferation and 
melanogenesis. 
Data conflicting (Li et al. 2009b; Birlea et al. 
2011) 
EDN1 Endothelin-1. Keratinocyte-derived 
growth factor which regulates growth and 
function of melanocytes. 
Data conflicting (Kim et al. 2007a; Lan et al. 
2009; Birlea et al. 2011) 
ESR1 
 
Estrogen receptor 1. Transcription factor 
but exact function in melanocytes is 
unknown. 
Data conflicting (Jin et al. 2004b; Birlea et al. 
2011) 
FBXO11 (VIT1) 
 
F-box protein 11. Regulates melanocyte 
proliferation and apoptosis. 
Data conflicting (Le Poole et al. 2001; Birlea et 
al. 2011) 
FGFR1OP 
 
Fibroblast growth factor receptor 1 
oncogene partner. Functions in 
proliferation and differentiation of 
melanocytes.  
Unconfirmed (Quan et al. 2010) 
FOXD3 (AIS1) Forkhead box D3. Transcription factor. 
Regulates melanoblast differentiation and 
development. Found in a single large 
family with autoimmune-associated 
vitiligo. Autosomal dominant. 
Data conflicting (Alkhateeb et al. 2002; Fain et 
al. 2003; Alkhateeb et al. 2005; 
Birlea et al. 2011) 
GSTT1 
 
Glutathione S-transferase theta 1.  
Protects against oxidative stress. 
Data conflicting (Uhm et al. 2007; Liu et al. 
2009; Birlea et al. 2011) 
GSTM1 
 
Glutathione S-transferase mu 1. Protects 
against oxidative stress. 
Data conflicting (Uhm et al. 2007; Liu et al. 
2009; Birlea et al. 2011) 
KITLG (SCF) KIT ligand (Stem cell factor). 
Keratinocyte-derived growth factor 
which regulates growth and function of 
melanocytes. 
Data conflicting (Lan et al. 2009; Birlea et al. 
2011) 
MYG1 (C12orf10) 
 
Melanocyte proliferating gene 1. 
Functions in skin development. 
Data conflicting  (Kingo et al. 2006; Philips et 
al. 2010; Birlea et al. 2011) 
NFE2L2 Nuclear factor-(erythroid-derived 2)-like 
2. Transcription factor which egulates 
Data conflicting (Guan et al. 2008b; Birlea et al. 
2011) 
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expression of detoxifying and antioxidant 
genes. 
PDGFRA Platelet-derived growth factor receptor 
alpha. Receptor for PDGF α which 
functions in the differentiation of 
melanocytes. 
Data conflicting (Xu et al. 2010; Birlea et al. 
2011) 
RERE  
 
Atrophin-like protein 1. Transcriptional 
co-repressor thought to regulate 
apoptosis. 
Confirmed  (Jin et al. 2010a) 
RNASET2 
 
RNase T2. Regulates oxidative stress. Unconfirmed (Quan et al. 2010) 
SMOC2 
 
SPARC-related modular calcium binding 
2. Function unknown. 
Confirmed (Birlea et al. 2010) 
TNFRSF6 (FAS; 
APO1) 
 
Tumor necrosis factor receptor 
superfamily, member 6. Modulates 
apoptosis.  
Data conflicting  (Li et al. 2008; Birlea et al. 
2011) 
TYR 
 
Tyrosinase. Functions in melanin 
biosynthesis. 
Confirmed (Jin et al. 2010a) 
TXNDC5 Thioredoxin domain containing 5. 
Functions in protein folding and 
chaperoning. 
Data conflicting (Jeong et al. 2010; Birlea et al. 
2011) 
UVRAG UV radiation resistance-associated gene. 
Functions in autophagosome formation. 
Data conflicting (Jeong et al. 2010; Birlea et al. 
2011) 
VDR Vitamin D receptor. Data conflicting (Birlea et al. 2006; Birlea et al. 
2011) 
40 
 
1.3.5 Neural factors 
The neural hypothesis of vitiligo pathogenesis is supported by several clinical, histological 
and pathophysiological findings in patients with the disease. 
 
1.3.5.1 Clinical evidence 
Adverse neurochemical-mediated effects on melanocytes could explain the often symmetrical 
distribution of vitiligo lesions or the dermatomal pattern of segmental vitiligo (Lerner 1959). 
It has also been noted that vitiligo spares denervated skin, for example, below the level of 
neurological damage in certain patients with severe spinal cord injury (Lerner 1959).  
Spontaneous repigmentation of lesions occurs occasionally in vitiligo patients whose nervous 
system has been compromised by diabetic neuropathy (Bose 1994). In contrast, vitiligo-like 
hypopigmented macules are sometimes produced in inflammatory diseases affecting the 
peripheral nervous system such as leprosy, and in neurodysplasias such as neurofibromatosis 
and tuberous sclerosis (Boisseau-Garsaud et al. 2000b; Oiso et al. 2007; Nanda 2008). 
Additional indirect evidence is provided by the requirement for innervation for 
repigmentation to occur following skin transplantation (Lerner 1959). While vitiligo patients 
do not complain of sensory abnormalities in lesional skin, autonomic dysfunction has been 
reported, including: increased skin surface temperature and an increased sweating response in 
vitiliginous areas, when compared to normal skin, and an abnormal sympathetic skin 
response quantified by electrical measurement of sympathetic nerve activity (Chanco-Turner 
and Lerner 1965; Dutta and Mandal 1982; Merello et al. 1993). 
 
1.3.5.2 Histological and ultrastructural abnormalities 
Immunohistochemical studies of lesional and peri-lesional vitiligo skin have demonstrated 
abnormalities in the levels of skin neuropeptides. In 5 of 10 patients with symmetrical 
vitiligo, levels of neuropeptide Y (NPY) were found to be elevated in the margins of vitiligo 
lesions and, of these patients, those with active disease also had increased NPY within 
lesional and perilesional skin (Al'Abadie et al. 1994b; Hristakieva et al. 2000; Lazarova et al. 
2000). Elevated NPY plasma levels have also been demonstrated in patients with vitiligo (Tu 
et al. 2001). In addition, the number of nerve fibres immunoreactive to nerve growth factor 
(NGF) and calcitonin gene-related peptide has been shown to be increased in vitiligo lesions 
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compared to the uninvolved and control skin (Liu et al. 1996). Studies of the ultra-structure 
of dermal nerves using electron microscopy have also demonstrated regenerative and 
degenerative changes (Al'Abadie et al. 1994b), as well as direct cell-cell contact with 
melanocytes (Morohashi et al. 1977), in vitiliginous skin.  Furthermore, melanocytes 
originate from the neural crest and, in many cases of vitiligo, perilesional melanocytes appear 
progressively more neural in their behaviour, both in an increasingly dendritic morphology 
and in an ability to synthesise adrenalin (Iyengar and Misra 1987; Iyengar and Misra 1988).  
 
1.3.5.3 Neurotransmitters 
Several studies have reported increased plasma levels of the catecholamine neurotransmitters 
(e.g., adrenalin, noradrenalin) in early and progressive vitiligo (Morrone et al. 1992; Cucchi 
et al. 2000; Cucchi et al. 2003). Furthermore, elevated synthesis of catecholamines by 
epidermal keratinocytes has been reported in vitiligo skin (Schallreuter et al. 1992). High 
levels of catecholamines are directly toxic. Indirectly, increased catecholamines can cause a 
build-up of melanocyte-damaging oxidative stress (Section 1.3.6) by stimulating severe 
vasoconstriction and the generation of oxyradicals from hypoxia (Morrone et al. 1992; 
Gillbro et al. 2004; Namazi 2007). In turn, hypoxia can lead to the development of 
extracellular acidosis, which may contribute to the activation of the adaptive immune 
response against melanocytes (Section 1.3.9.6) (Martinez et al. 2007). 
 
1.3.6 Biochemical factors 
Biochemical and cellular defects have been proposed to contribute to the loss of melanocytes 
in vitiligo. The theory is supported by clinical and experimental observations, as well as the 
applicability of certain treatment regimens and possible genetic susceptibilities. These are 
discussed below. 
 
1.3.6.1 Accumulation of toxic metabolites 
The accumulation of toxic metabolites has been proposed to play a role in vitiligo aetiology. 
Melanocytes and keratinocytes are capable of the de novo synthesis, recycling and regulation 
of 6-tetrahydrobiopterin (6-BH4), and this is illustrated in Figure 1.6 (Schallreuter et al. 
1994a; Schallreuter et al. 1994b). 6-BH4 is required as a cofactor by phenylalanine 
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hydroxylase (PAH) in the synthesis of tyrosine which is needed for melanin and 
catecholamine production (Figure 1.6). Phenylalanine hydroxylase activity has been 
demonstrated to be low in the epidermis of vitiligo patients with the consequent accumulation 
of high levels of toxic 6-BH4 and 7-BH4, which have been suggested to impair melanocyte 
function (Schallreuter et al. 1994a; Schallreuter et al. 1994b; Schallreuter et al. 1998; 
Schallreuter et al.2008b). Indeed, 6-biopterin, a metabolite of 6-BH4, is highly toxic to 
cultured melanocytes (Schallreuter et al. 1994b). However, this pathway needs to verified by 
examining the expression of PAH in melanocytes. 
 Increased levels of toxic catecholamines in vitiligo patients (Morrone et al. 1992; 
Cucchi et al. 2000; Cucchi et al. 2003) have already been discussed (Section 1.3.5.2). In 
addition, the activity of catechol-O-methyl transferase (Table 1.7), the enzyme which 
inactivates catecholamines, is increased in vitiligo skin indicating the presence of higher 
levels of these compounds (Le Poole et al. 1994). Furthermore, elevated activity of 
monoamine oxidase A (Table 1.7) in the epidermis of patients with vitiligo has been related 
to defective catecholamine synthesis (Schallreuter et al. 1996). 
 With respect to melanin biosythesis, a reduced stability of TYRP1 and the subsequent 
production of toxic melanin intermediates, which could contribute to melanocyte damage, has 
also been reported in vitiligo melanocytes (Jimbow et al. 2001). 
 
1.3.6.2 Oxidative stress 
Inappropriate production of reactive oxygen species and a failure to clear these effectively 
from the cell can cause damage to DNA, proteins and cell membranes. Indeed, oxidative 
stress has long been proposed as a mechanism for melanocyte destruction in vitiligo: 
melanocytes from normally pigmented skin of vitiligo patients exhibit a high in vitro 
susceptibilty to chemically applied oxidants (Maresca et al. 1997; Jimbow et al. 2001; Boissy 
and Manga 2004). In addition, the H2O2-scavanging enzyme catalase (Table 1.7) is present at 
decreased levels in vitiligo patient blood and in cultured vitiligo melanocytes (Schallreuter et 
al. 1991; Schallreuter et al. 1999; Schallreuter et al. 2001). This has been attributed to 
variations in the gene encoding catalase which alter the expression of the enzyme (Table 1.7) 
(Shajil et al. 2007; Wood et al. 2008). Other antioxidant enzymes including thioredoxin 
reductase (Table 1.7) (Schallreuter et al. 1987) and xanthine oxidase (Table 1.7) (Shalbaf et 
al. 2008) also have impaired function in vitiligo skin and could contribute to an imbalance of 
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intracellular antioxidants. The effective use of antioxidants in the treatment of vitiligo 
(Schallreuter et al. 1995; Schallreuter 1999; Schallreuter et al. 2001) is detailed in Section 
1.2.7.2.4. Such  
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Figure  1.6: Synthesis, recycling and regulation of 6-tetrahydrobiopterin. 
 
Melanocytes and keratinocytes are capable of the de novo synthesis, recycling and regulation of 6-
tetrahydrobiopterin (6-BH4). 6-BH4 acts as a cofactor for the hydroxylation of phenylalanine to 
tyrosine by phenylalanine hydroxylase. In addition, 6-BH4 is an uncompetitive inhibitor of tyrosinase 
activity and serves as a cofactor for the hydroxylation of tyrosine to 3,4-dihydroxyphenylalanine (L-
dopa) by tyrosine hydroxylase. 6-BH4 is produced from guanosine triphosphate (GTP) by the action of 
GTP-cyclohydrolase I (GTP-CHI). GTP-CHI is regulated by GTP-CHI feedback regulatory protein 
(GFRP), which responds to 6-BH4 levels. 4a-hydroxy-tetrahydrobiopterin (4a-OH-BH4) is formed as 
an intermediate in the 6-BH4 synthesis pathway and is converted to  quinonoid dihydropterin (qBH2) 
by 4a-OH-BH4 dehydratase. By a non-enzymatic process, 7-tetrahydrobiopterin (7-BH4) is produced 
from 4a-OH-BH4. There is a short circuit which produces qBH2 from 6-BH4 and which releases 
hydrogen peroxide (H2O2). Drawn with information from (Schallreuter et al. 2001). 
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Table 1.7: Biochemical pathways implicated in vitiligo aetiology 
 
 
Enzyme or 
cofactor 
Normal 
function 
Experimental 
observations in 
relation to vitiligo 
Proposed 
contribution to 
disease 
aetiology 
 
Reference 
 
Tetrahydrobiopterin 
 
Regulatory role in 
melanogenesis since it 
is a rate-limiting 
cofactor in L-
phenylalanine → L-
tyrosine, and L-
tyrosine→L-dopa 
conversions.1 
 
 
Phenylalanine 
accumulation seen in 
epidermis of vitiligo 
patients.2,3 
 
6-biopterin, metabolite of 
tetrahydrobiopterin, is 
highly toxic to cultured 
melanocytes.1 
 
Defective 
melanogenesis leads 
to toxic metabolites 
which cause the 
melanocytes to self-
destruct.1 
 
1 (Schallreuter et al. 
1994b) 
2 (Schallreuter et al. 
1998) 
3(Schallreuter et al. 
2005) 
 
 
Thioredoxin 
reductase 
 
A free-radical 
scavenging enzyme 
located on melanocyte 
membrane.  Also 
involved in 
conversion L-
tyrosine→L-
phenylalanine. 
Action inhibited by 
calcium. 
 
 
Vitiligo melanocytes4 and 
keratinocytes5 have 
decreased capacity for 
calcium uptake.  
Extracellular Ca2+ is, 
therefore, higher in 
vitiligo skin. 
 
 
Inhibition of 
thioredoxin reductase, 
by ↑ extracellular 
Ca2+, leads to a build-
up in free-radicals 
which may lead to 
melanocyte 
damage.5,6 Inhibition 
may also affect 
melanogenesis 
leading to the build-
up of toxic 
metabolites.7 
 
4 (Schallreuter et al. 
1996) 
5 (Schallreuter and 
Pittelkow 1988) 
6 (Ortonne and Bose 
1993) 
7 (Schallreuter et al. 
1994b) 
 
 
Catalase 
 
H2O2 scavenging 
enzyme (H2O2 → 
H2O + O2).  
↓oxidative stress in 
epidermis after UVB 
irradiation. 
 
Decreased levels of 
catalase recorded in 
vitiligo patient blood and 
in cultured vitiligo 
melanocytes.8 
 
Toxic levels of H2O2 
may accumulate 
destroying the 
melanocyte.8 
 
8 (Schallreuter et al. 
1991) 
 
Catechol-O-methyl 
transferase (COMT) 
 
 
Enzyme which 
inactivates 
catecholamines by 
methylation. 
 
 
Increased COMT in 
lesional vitiligo skin,9 
indicative of high levels 
of catecholamines. 
 
Increased catecholamines 
in vitiligo patient skin.10 
Elevated synthesis of 
catecholamines by 
epidermal keratinocytes in 
vitiligo patients.10 
 
 
Catecholamines are 
directly cytotoxic in 
high levels. 
Indirectly, 
catecholamines can 
cause a build-up of 
oxidative stress as 
follows; abnormal 
release of 
catecholamines may 
cause increased 
vasoconstriction→ 
hypoxia-ischaemia→ 
reoxygenation→ 
increased production 
of oxidative species.11 
 
9 (Le Poole et al. 
1994) 
10 (Schallreuter et al. 
1992) 
11 (Morrone et al. 
1992) 
 
Xanthine oxidase Hydroxylation of 
hypoxanthine to 
xanthine  →  uric acid 
Allantoin present in 
lesional and non-lesional 
epidermis of patients with 
Presence of allantoin 
is a biomarker for 
oxidative stress. 13 
12 (Nishino et al. 
2005) 
13 (Shalbaf et al. 
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in purine degradation 
pathway, the process 
that yields allantoin 
and H2O2.
12 
active vitiligo and absent 
in healthy subjects.13 
2008) 
Monoamine oxidase Catalyses deamination 
of  norepinephrine 
and epinephrine → 
ammonia, 3,4-
dihydroxymandelic 
aldehyde and H2O2.
14 
Monoamine oxidase 
activity significantly 
increased in lesional and 
nonlesional vitiligo skin.15 
Accumulation of high 
amount of H2O2 and 
6-BH 4 in the 
epidermis → toxic 
damage of epidermal 
cells. 14 
14 (Yasuhara et al. 
1993) 
15 (Schallreuter et al. 
1996) 
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therapeutic approaches, which have also been used in combination with immunosuppressive 
reagents (Akyol et al. 2002), also suggest a role for oxidative stress in vitiligo aetiology. 
 More recent studies have shown that the enzyme heme oxygenase-1 protects human 
melanocytes from H2O2-induced oxidative stress (Jian et al. 2011) and UV radiation 
(Elassiuty et al. 2011) via the nuclear factor E2-related factor (NRF2)-antioxidant response 
element pathway. Polymorphisms in the NRF2 gene promoter have been associated with an 
increased risk of developing vitiligo (Guan et al. 2008b; Zhou et al. 2008), and altered 
cellular localisation of NRF2 protein in the lesional skin of vitiligo patients has also been 
reported (Guan et al. 2008a). Furthermore, expression of the antioxidant response genes 
which are controlled by NRF2 is not elevated in lesional vitiligo skin following oxidative 
stress (Natarajan et al. 2010), indicating an impairment of the NRF2- antioxidant response 
element pathway in vitiligo. 
 
1.3.6.3 Chemically-induced vitiligo 
Chemical compounds, which are aliphatic or aromatic derivatives of phenols or catechols, are 
cytotoxic to melanocytes and can cause depigmentation or leukoderma in exposed individuals 
(Bleehen et al. 1968; Lerner 1971; Cummings and Nordlund 1995). Again, this clinical 
observation indicates that toxic biochemicals can induce vitiligo. Experimental studies using 
phenolic derivatives including 4-tertiary butylphenol (4-TBP) have shown that TYRP1 
mediates the cytotoxic effects of such reagents (Manga et al. 2002). 4- tertiary butylphenol 
undergoes enzymatic conversion into semiquinon free radicals and reactive oxygen species 
which damage melanocytes (Shvedova et al. 2000; Boissy and Manga 2004). In addition, 4-
TBP can increase the melanocyte membrane expression of stress protein heat-shock protein 
70 (HSP70) resulting in sensitisation of melanocytes to dendritic cell-mediated cytotoxicity 
(Denman et al. 2008).  
 
1.3.7 Melanocyte growth factors  
Melanogenesis is regulated by several melanogenic cytokines and growth factors such as ET-
1, SCF, bFGF and GM-CSF. These factors are produced by keratinocytes and fibroblasts and 
co-ordinate with their respective receptors on melanocytes to exhibit their effects on melanin 
synthesis (Imokawa and Moretti 2010). 
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An alteration of the expression of keratinocyte melanogenic cytokines has been 
suggested to occur in vitiligo. For example, a decreased level of SCF mRNA and protein has 
been detected in the depigmented skin of vitiligo patients (Moretti et al. 2002a; Moretti et al. 
2002b; Lee et al. 2005; Moretti et al. 2009). In addition, the protein levels of melanogenic 
cytokines GM-CSF and bFGF (Moretti et al. 2002a; Moretti et al. 2002b; Lee et al. 2005), as 
well as  ET-1 transcript levels (Moretti et al. 2009), have been determined to be reduced in 
the depigmented vitiligo epidermis. The exact involvement that these melanogenic cytokine 
alterations play in the development of vitiligo has yet to be ascertained. 
 
1.3.8 Melanocortin hormones 
The melanocortin peptide α-MSH is an important regulatory agent in skin pigmentation, 
inflammatory modulation and response to stress (Slominski et al. 1991; Abdel-Malek et al. 
1995; Luger et al. 2003; Brzoska et al. 2008; Meyer et al. 2009). The hormone binds to 
MC1R on the melanocyte (Ortonne and Ballotti 2000) (Section 1.1.4). 
Few studies have addressed the alterations of α-MSH in vitiligo. Vitiligo patients 
exhibit significantly lower α-MSH levels in their plasma compared with normal individuals 
(Pichler et al. 2006). In addition, the level and expression of α-MSH in the melanocytes of 
lesional and perilesional vitiligo skin are lower than in the melanocytes from normal skin 
(Wakamatsu et al. 1997; Graham et al. 1999). Furthermore, the proportion of α-MSH 
immuno-positive melanocytes is significantly reduced  in the lesional and perilesional skin of 
vitiligo patients compared to controls (Graham et al. 1999). Although not yet verified, low α-
MSH levels could contribute to melanocyte damage in vitiligo through increased oxidative 
stress (Graham et al. 1999). 
 
1.3.9 Autoimmunity 
Several lines of evidence suggest that autoimmunity plays a role in the pathogenesis of 
vitiligo and these are discussed below. 
 
1.3.9.1 Association of vitiligo with autoimmune diseases 
The association of vitiligo with other autoimmune diseases has been discussed earlier in 
Section 1.2.5. 
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1.3.9.2 Association of vitiligo with immune-response gene polymorphisms 
The association of vitiligo with immune-response gene polymorphisms has been discussed 
earlier in Section 1.3.4. 
 
1.3.9.3 Animal models of vitiligo 
The study of animal models has added credence to the theory that immune mechanisms play 
a part in the development of vitiligo. Several spontaneous animal models of vitiligo exist, 
although the exact relevance of such models to the equivalent human disorder remains to be 
established (Boissy and Lamoreux 1988). The well-documented Smyth line (SL) chickens 
express a genetically inherited form of vitiligo-like depigmentaton resulting from the loss of 
melanocytes in feather and ocular tissues (Smyth 1989). In this avian model, vitiligo begins 
with an inherent melanocyte defect that is followed by an autoimmune response involving 
both humoral and cellular reactions that eliminate abnormal pigment cells (Lamont and 
Smyth 1981; Boissy et al. 1984; Boyle et al. 1987; Pardue et al. 1987). An increase in T and 
B cells in the feather pulp and circulating inflammatory leukocytes has been shown in Smyth 
chickens prior to the onset, and during the development of, vitiligo (Erf et al. 1995; Erf and 
Smyth 1996; Shi and Erf 2012). Antibodies to chicken melanocytes have also been detected 
in the sera of 100% of SL chicks but not in the sera of normally pigmented birds (Austin et 
al. 1992). These antibodies were found to be present both before and during the presentation 
of vitiligo (Searle et al. 1993), and the primary target antigen was identified as TYRP1 
(Austin and Boissy 1995). 
More recently, the expression of immune function-related cytokines in growing 
feathers has been investigated throughout SL vitiligo development and progression (Shi and 
Erf 2012). Expression levels of cytokines IFN-γ, IL-10, and IL-21 began to increase near 
visible SL vitiligo onset, reached peak levels during active disease, and decreased to near pre-
vitiligo levels after the complete loss of melanocytes. The results suggest that SL vitiligo 
appears to be a Th1-polarised autoimmune disease, whereby IFN-γ expression is strongly 
associated with parallel increases in IL-10 and IL-21, particularly during early and active 
stages of the disease. 
In other animals with vitiligo including horses, cats and dogs, antibody reactivity 
occurs against a similar pattern of melanocyte antigens to that found in patients with the 
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disease (Naughton et al. 1983a; Naughton et al. 1986a), suggesting that similar 
immunological responses may occur in both animals and humans. 
 
 
1.3.9.4 Melanocyte abnormalities in vitiligo 
Several studies have shown abnormal expression of MHC class II antigen HLA-DR and 
increased expression of ICAM-1 by perilesional melanocytes in vitiligo compared with 
melanocytes from normal skin (Al Badri et al. 1993a; Hedley et al. 1998; van den Wijngaard 
et al. 2000). Since these molecules have important roles in antigen presentation and in the 
activation of helper T cells, their expression by melanocytes could contribute to the anti-
melanocyte cellular immune responses that are seen in vitiligo (Ogg et al. 1998; van den 
Boorn et al. 2009). Both vitiligo and normal melanocytes are also capable of expressing 
MHC class I molecules (Hedley et al. 1998), which could allow interaction with destructive 
cytotoxic T cells. Furthermore, melanocytes have an antigen processing and presenting 
capability which can make them target cells for T cell-mediated cytotoxicity (Le Poole et al. 
1993b). 
In perilesional vitiligo biopsies, melanocytes express macrophage markers CD68 and 
CD36 (van den Wijngaard et al. 2000) and reduced levels of membrane regulators of 
complement activation, including decay acceleration factor and membrane cofactor protein 
(van den Wijngaard et al. 2002), which suggests a vulnerability of these cells to attack by 
macrophages and the complement system, respectively.  
 
1.3.9.5 Immunosuppressive treatments of vitiligo 
Repigmentation in vitiligo patients receiving treatment with immunosuppressive agents 
(Section 1.2.7) indirectly supports the theory that immune-mediated processes are involved in 
vitiligo pathogenesis. For example, topically applied tacrolimus (FK506), a therapeutic agent 
which exerts a potent immunosuppressive effect on T cells by blocking the action of the 
cytokine gene-activating cofactor calcineurin (Homey et al. 1998), has resulted in successful 
repigmentation responses in vitiligo patients (Boone et al. 2007; Hartmann et al. 2008). 
In addition, topical corticosteroids, which have anti-inflammatory and 
immunosuppressive actions, are considered to be an effective first-line treatment in children 
and adults with segmental or non-segmental vitiligo of recent onset (Abu Tahir et al. 2010; 
Gawkrodger et al. 2010), and, indeed, following treatment of vitiligo patients with systemic 
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steroids, a reduction in anti-melanocyte antibody levels and in antibody-mediated anti-
melanocyte cytotoxicity has been demonstrated (Takei et al. 1984; Hann et al. 1993a). 
Finally, PUVA is used as a second-line therapy for vitiligo (Alomar 2010; 
Gawkrodger et al. 2010). Following PUVA treatment, a reduction in the number of 
Langerhans cells and a decrease in the expression of vitiligo-associated melanocyte antigens, 
which could lead to a blocking of antibody-dependent cell-mediated cytotoxicity against 
melanocytes, have been noted in vitiligo patients (Kao and Yu 1992; Viac et al. 1997). In 
addition,
 
ultraviolet radiation can induce the expression of anti-inflammatory cytokines, 
modulate the expression of ICAM-1, and induce apoptosis of skin-infiltrating T lymphocytes 
(Duthie et al. 1999; Krutmann and Morita 1999).  
 
1.3.9.6 Humoral immune responses in vitiligo 
Several studies have reported circulating autoantibodies directed against melanocytes in 
vitiligo patients in addition to other organ-specific autoantibodies. 
 
1.3.9.6.1 Anti-melanocyte antibodies   
Antibodies to melanocytes occur at a significantly increased frequency in the sera of vitiligo 
patients compared with healthy individuals (Naughton et al. 1983a; Naughton et al. 1983b; 
Cui et al. 1992; Cui et al. 1995; Hann et al. 1996a; Hann and Lee 1996; Rocha et al. 2000; 
Farrokhi et al. 2005). As well as circulating antibodies, antibody deposits have been noted in 
the basement membrane zones of depigmented areas in patients with vitiligo (Uda et al. 
1984). However, no B cells or specific antibodies have yet been isolated from vitiligo lesions. 
Interestingly, correlations can also exist between the incidence and level of melanocyte 
antibodies and both the activity and extent of vitiligo (Naughton et al. 1986b; Aronson and 
Hashimoto 1987; Harning et al. 1991; Yu et al. 1993; Kemp et al. 2011b), indicating that 
melanocyte antibodies are possible markers of disease progression. 
Predominantly, melanocyte antibodies have been characterised as immunoglobulin 
(Ig) G (Naughton et al. 1983b; Naughton et al. 1983a; Uda et al. 1984; Cui et al. 1992; Cui et 
al. 1995; Hann et al. 1996a; Hann et al. 1996b; Rocha et al. 2000; Farrokhi et al. 2005) and 
as belonging to subclasses IgG1, IgG2 and IgG3 (Xie et al. 1991), although anti-melanocyte 
IgA antibodies have also been reported (Aronson and Hashimoto 1987). Initial 
immunoprecipitation studies using melanoma cell extracts revealed that antibodies in vitiligo 
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patients were most commonly directed against antigens with molecular weights of 35, 40-45, 
75, 90 and 150 kDa (Cui et al. 1992). Several of the proteins (40-45, 75 and 150 kDa) 
appeared to be common tissue antigens, while others (35 and 90 kDa) were preferentially 
expressed on melanocytes (Cui et al. 1992). In immunoblotting studies with melanocyte 
extracts, antigens of 45, 65, and 110 kDa have been identified (Hann et al. 1996b; Park et al. 
1996), while vitiligo-associated antibodies have been demonstrated to recognise melanoma 
cell proteins of 68, 70, 88, 90, 110 and 165 kDa (Hann et al. 1996a; Rocha et al. 2000). 
The identity of several melanocyte-associated antibody targets has been reported and 
these are summarised in Table 1.8. Included are the melanogenic enzymes tyrosinase (Song 
et al. 1994; Baharav et al. 1996; Kemp et al. 1997a) and DCT (Kemp et al. 1997b; Okamoto 
et al. 1998), and the melanosomal matrix protein PMEL (Kemp et al. 1998b). 
 
1.3.9.6.2 Other antibodies   
Circulating organ-specific autoantibodies (Table 1.9), particularly to the thyroid, adrenal 
glands, gastric parietal cells, and pancreatic islet cells are commonly detected in the sera of 
vitiligo patients (Brostoff 1969; Betterle et al. 1976; Zauli et al. 1986; Mandry et al. 1996). 
Moreover, antinuclear antibody and IgM-rheumatoid factor have been detected at a 
significant frequency in vitiligo patients (Farrokhi et al. 2005). Anti-keratinocyte intracellular 
antibodies that correlate with disease extent and activity have also been detected in vitiligo 
patients (Yu et al. 1993). The technique of peptide phage-display has identified the melanin-
concentrating hormone receptor 1 (MCHR1) as a target of vitiligo patient antibodies (Kemp 
et al. 2002). Recent proteomic analysis has also revealed lamin A is a vitiligo-associated 
antigen (Li et al. 2011). 
 
1.3.9.6.3 Pathogenic mechanisms  
With respect to pathogenic effects, vitiligo-associated antibodies are able to destroy 
melanocytes and melanoma cells in vitro and in vivo by complement-mediated damage and 
antibody-dependent cellular cytotoxicity (ADCC) (Norris et al. 1988; Fishman et al. 1993; 
Gottumukkala et al. 2006). Complement-mediated cytolysis of melanocytes by vitiligo 
patient antibodies appears to be cell selective and more common in individuals with active  
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Table 1.8: Anti-melanocyte antibodies in vitiligo patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Antigen Number of 
patients 
with 
antibodies 
(%) 
Number 
of 
controls 
with 
antibodies 
(%) 
 
Reference 
PMEL 3/53 (5.9) 0/20 (0) (Kemp et al. 1998b) 
SOX10 3/93 (3.2) 0/65 (0) (Hedstrand et al. 2001) 
SOX9 1/93 (1.1) 0/65 (0) (Hedstrand et al. 2001) 
Tyrosinase 16/26 (61) 0/31 (0) (Song et al. 1994) 
Tyrosinase 7/18 (39) 0/12 (0) (Baharav et al. 1996) 
Tyrosinase 5/46 (10.9) 0/20 (0) (Kemp et al. 1997a) 
TYRP1 3/53 (5.9) 0/20 (0) (Kemp et al. 1998c) 
TYRP1 8/84 (9.5) Not 
reported 
(Li et al. 2011) 
DCT 3/53 (5.9) 0/20 (0) (Kemp et al. 1997b) 
DCT 10/15 (67) 0/21 (0) (Okamoto et al. 1998) 
DCT 20/30 (67) 1/35 (2) (Okamoto et al. 1998) 
GTP-binding 
protein Rab38 
8/53 (15) 0/53 (0) (Waterman et al. 2002) 
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Table 1.9: Other antibodies detected in vitiligo patients 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
MCHR1, melanin-concentrating hormone receptor 1.  
Antibody 
reactivity 
Number of 
patients with 
antibodies (%) 
 
Reference 
Gastric parietal cells 11/65 (17) (Zauli et al. 1986) 
Gastric parietal cells 6/20 (30) (Mandry et al. 1996) 
Gastric parietal cells 17/80 (21) (Brostoff 1969) 
Gastric parietal cells 13/96 (13.7) (Betterle et al. 1976) 
Thyroid cytoplasm 22/80 (28) (Brostoff 1969) 
Thyroid peroxidase 10/20 (50) (Mandry et al. 1996) 
Thyroid peroxidase 19/96 (20) (Betterle et al. 1976) 
Thyroglobulin 8/20 (40) (Mandry et al. 1996) 
Thyroglobulin 7/80 (9) (Brostoff 1969) 
Adrenal gland 3/80 (4) (Brostoff 1969) 
Pancreatic islet cells 7/96 (7.2) (Betterle et al. 1976) 
Anti-nuclear antibody 4/55 (7.3) (Farrokhi et al. 2005) 
IgM-rheumatoid factor 6/55(10.8) (Farrokhi et al. 2005) 
Lamin A 24/84 (28.6) (Li et al. 2011) 
MCHR1
1
 9/55 (16.4) (Kemp et al. 2002) 
MCHR1
1
 12/84 (14.3) (Li et al. 2011) 
MCHR1
1
 24/145 (16.55) (Zhou et al. 2011) 
Gamma-enolase 4/53 (8) (Waterman et al. 2002) 
Alpha-enolase 5/53 (9) (Waterman et al. 2002) 
Heat-shock protein 90 7/53 (13) (Waterman et al. 2002) 
Heat-shock protein 70 16/60 (26) (Kim et al. 2011) 
Fibrin beta 16/60 (26) (Kim et al. 2011) 
Osteopontin 5/53 (9) (Waterman et al. 2002) 
Ubiquitin-conjugating 
enzyme 
8/53 (15) (Waterman et al. 2002) 
Translation-initiation 
factor 2 
3/53 (6) (Waterman et al. 2002) 
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disease (Cui et al. 1993).
 
Passive immunisation of nude mice grafted with human skin has 
also indicated that IgG from vitiligo patients can induce melanocyte destruction (Gilhar et al. 
1995). Furthermore, IgG melanocyte antibodies from individuals with vitiligo can induce 
HLA-DR and intercellular adhesion molecule-1 expression on and release of interleukin-8 
from melanocytes (Yohn et al. 1993). Such changes that may enhance the antigen-presenting 
activity of melanocytes allowing antigen-specific immune effector cell attack resulting in 
melanocyte destruction.  
Antibodies against MCHR1 have been shown to block the function of the receptor in 
a heterologous cell line (Gottumukkala et al. 2006). Stimulation of MCHR1 in cultured 
melanocytes with melanin-concentrating hormone (MCH) can down regulate the actions of 
-MSH, including the production of melanin, suggesting that the MCH/MCHR1 signalling 
pathway has a role with the melanocortins in regulating melanocyte function (Hoogduijn et 
al. 2002). Any adverse effects of MCHR1 antibodies upon the functioning of the receptor in 
melanocytes could potentially disrupt normal melanocyte behaviour, a feature that could 
precede the clinical manifestation of vitiligo. However, this has not yet been reported and is 
still the object of study. 
More recent work has found that 69% (9/13) of vitiligo patient sera tested induced 
melanocyte detachment in a reconstructed epidermis model, although this was unrelated to 
either the extent or the activity of the disease (Cario-Andre et al. 2007). Further studies are 
needed to confirm that this serum effect is antibody mediated and, if so, that the antibody 
activity is specific to vitiligo patient sera. 
 
1.3.9.6.4 The origin of anti-melanocyte antibodies in vitiligo 
How anti-melanocyte antibodies arise in vitiligo has not yet been elucidated and several 
mechanisms could account for their presence. Antibodies might result from a genetic 
dysregulation of the immune system at the B or T cell level resulting in a lack of tolerance to 
melanocyte antigens and the subsequent appearance of anti-pigment cell antibodies (Cooke 
and Fehervari 2007; Sercarz and Raja-Gabaglia 2007). Particularly, this may be the case with 
respect to individuals with AIRE gene mutations who develop vitiligo as part of their APS1 
(Nagamine et al. 1997). 
Alternatively, antigens released from melanocytes disrupted by cellular immune 
reactions (Ogg et al. 1998; Lang et al. 2001; Palermo et al. 2001; Kroll et al. 2005) or non-
immune processes (Kroll et al. 2005; Schallreuter et al. 2005; Dell'Anna and Picardo 2006) 
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could initiate humoral immune responses that target melanocytes. Indeed, antibodies against 
DCT have been identified in melanoma patients during immunotherapy with this pigment 
cell-specific antigen (Okamoto et al. 1998), indicating that exposure to melanogenic proteins 
can stimulate B cell reactivity. Interestingly, TYRP1 and PMEL have been found to be 
expressed transiently on the surface of melanocytes and, therefore, are accessible as an 
antibody targets (Takechi et al. 1996; Leonhardt et al. 2011). Other autoantigens, including 
the MCHR1, are cell-surface receptors so are exposed to possible antibody interaction 
without the need for cellular damage (Cui et al. 1992; Park et al. 1996; Kemp et al. 2002; 
Farrokhi et al. 2005; Gottumukkala et al. 2006). Conceivably, a humoral immune response to 
pigment cells could also occur in vitiligo patients if melanocytes expose antigens that are 
similar to either an infecting agent or to other cells that are themselves the primary target of 
antibodies. Indeed, several vitiligo autoantigens appear to be expressed on cells other than 
melanocytes (Cui et al. 1992; Kemp et al. 2002).  
In summary, it has not been determined how melanocyte antibodies arise and this 
process may be patient-specific and/or antigen-dependent. Whether or not melanocytes are 
the targets of a primary or secondary humoral immune response, a major question remains 
concerning the contribution pigment cell antibodies make to the development of 
depigmentation in vitiligo.  
 
1.3.9.7 Cellular immune responses in vitiligo 
Many studies have reported cellular immune responses directed against melanocytes in 
vitiligo patients and these are described in the next sections. 
 
1.3.9.7.1 Macrophages 
Macrophage infiltration has been demonstrated in vitiligo lesions, with increased numbers 
present in perilesional skin (Le Poole et al. 1996; van den Wijngaard et al. 2000). It is 
possible that macrophages are involved in clearing melanocytes that have been induced to 
apoptose by cytotoxic T lymphocytes. Additional evidence for the active involvement of 
macrophages in vitiligo pathogenesis is demonstrated by their expression of immunoglobulin 
receptors: in a mouse model, it has been shown that macrophages, expressing the common 
gamma (γ) chain of the activating Fc receptors, can mediate vitiligo in the presence and 
absence of complement C3 fraction (Trcka et al. 2002). 
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1.3.9.7.2 Dendritic cells  
The density of Langerhans cells in vitiliginous skin has been variously reported as normal, 
increased and decreased compared with pigmented skin from the same patients and from 
control subjects (Riley 1967; Claudy and Rouchouse 1984; Hatchome et al. 1987; Searle et 
al. 1993). The differences in the documented densities of Langerhans cells may be due to the 
type of vitiligo, the sampling techniques used or the site of skin biopsies. An increase in the 
number of Langerhans cells could contribute to the immunological processes that damage 
melanocytes. However, although degenerative changes in Langerhans cells have been 
observed in vitiligo skin lesions, their role in vitiligo still remains unclear. 
More recently, dendritic cell-mediated destruction of melanocytes has been 
demonstrated in vivo and in vitro (Kroll et al. 2005). This process is related to the release of 
HSP70 by stressed melanocytes, which induces an immune response against the cells from 
which it is produced. At the same time there is an increased expression of TNF-related 
apoptosis which induces ligand receptors on stressed melanocytes making them more prone 
to killing by dendritic cells (Kroll et al. 2005; Denman et al. 2008). 
 
1.3.9.7.3 Natural killer cells 
Studies of natural killer (NK) cells in vitiligo are controversial. The mean percentage of 
peripheral NK cells was reported to be significantly higher in vitiligo patients than in healthy 
individuals (Hann et al. 1993b). However, no significant difference (Abdel-Naser et al. 
1992), and a lower NK cell number (Mahmoud et al. 2002) have also been described in 
patients with vitiligo compared to healthy subjects. Abnormalities in NK cells have been 
observed in vitiligo including increased cell activity, elevated activatory receptor and 
decreased inhibitory receptor, all indicating a possible role of NK cells in vitiligo 
pathogenesis (Basak et al. 2008). 
 
1.3.9.7.4 CD4+ helper and CD8+ cytotoxic T lymphocytes 
Autoimmune disorders are often associated with an expansion of peripheral CD4+ helper T 
cells. However, with respect to vitiligo, inconsistent data regarding abnormalities in 
circulating helper T cells have been reported. An increase in the number of activated CD4+ 
helper T cells was detected in patients with stable vitiligo as well as in their first-degree 
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relatives when compared with healthy individuals (Soubiran et al. 1985; D'Amelio et al. 
1990; Abdel-Naser et al. 1992). In contrast, a decrease in the CD4+ helper T cell population 
has also been observed in individuals with vitiligo (Grimes et al. 1986; Halder et al. 1989). 
No simple explanation exists for these differences but they could be attributable to the factors 
such as the population of patients under study, disease characteristics and received 
treatments.  
Circulating melanocyte-specific CD8+ cytotoxic T lymphocytes that target 
melanocyte-specific antigens, including MelanA (MART-1), PMEL and tyrosinase, have been 
detected in vitiligo patients (Ogg et al. 1998; Lang et al. 2001; Le Gal et al. 2001; Palermo et 
al. 2001; Mandelcorn-Monson et al. 2003; Le Poole et al. 2004; Garbelli et al. 2005; Le 
Poole and Luiten 2008; van den Boorn et al. 2009). They were found to express high levels 
of the skin-homing receptor cutaneous lymphocyte-associated antigen and their frequency 
correlated with both the extent and activity of the disease (Lang et al. 2001). In addition, 
melanocyte-specific T cells showed cytotoxic reactivity towards melanocytes (Ogg et al. 
1998). 
Histological studies of skin biopsies from vitiligo patients have demonstrated that 
infiltrating cytotoxic and helper T cells are most prominent at the periphery of vitiligo lesions 
(Al Badri et al. 1993b; van den Wijngaard et al. 2000). Many of the inflammatory cells are 
activated, as indicated by the expression of the MHC class II antigen HLA-DR, and a 
significant number also exhibit high levels of the receptor cutaneous lymphocyte-associated 
antigen, typical of skin-homing T cells (Al Badri et al. 1993b; van den Wijngaard et al. 
2000). Local activation of cytotoxic T cells at the perilesional epidermal/dermal junction of 
vitiliginous skin is also suggested by the presence of granzyme B+ and perforin+ cells (van 
den Wijngaard et al. 2000). There is evidence for IL-2 receptor and IFN-γ receptor 
expression by the lymphocytic infiltrate (Abdel-Naser et al. 1994), and also for down-
regulation of the helper T cell 2-dependent CDw60 molecule in the vitiliginous epidermis 
suggesting that infiltrating T cells may exhibit a helper T cell 1-type cytokine production 
pattern which is consistent with cell-mediated organ-specific autoimmunity (Le Poole et al. 
2003). In addition, perilesional T cell clones exhibit a predominant type-1-like cytokine 
secretion profile (Wankowicz-Kalinska et al. 2003). More recently it has been demonstrated 
that T lymphocytes obtained from perilesional skin biopsies are enriched for cytotoxic T cells 
that recognise melanocyte antigens tyrosinase, PMEL and MelanA (van den Boorn et al. 
2009). Moreover, upon infiltration of autologous pigmented skin, isolated perilesional T 
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lymphocytes efficiently kill melanocytes, providing direct evidence that cytotoxic T cells can 
cause the depigmentation seen in vitiligo (van den Boorn et al. 2009). 
 
1.3.9.7.5 Regulatory T lymphocytes 
Regulatory CD25
+
CD4
+
 T cells (Tregs) have been shown to inhibit CD25
+
CD4
+
 T effector 
cells and regulate autoreactive T and B cells and so may have an important role in controlling 
autoimmunity (Jonuleit et al. 2001; Danese and Rutella 2007). Tregs play a critical role in 
clearing self-reactive T cells that have escaped clonal deletion (Sakaguchi et al. 2001). 
Reduced numbers of Tregs have been observed in lesional, perilesional and non-lesional 
vitiligo skin in comparison to normal skin (Klarquist et al. 2010). Serum level of TGF-β, 
which is synthesised by Tregs, is also lower in vitiligo patients than in controls, and the level 
of reduction is correlated with the skin surface area involved (Basak et al. 2009; Tu et al. 
2011). The reduction in Tregs numbers and function may allow the unchecked destruction of 
melanocytes by cytotoxic T cells in vitiligo lesions (Klarquist et al. 2010). 
 
1.3.9.7.6 T helper 17 lymphocytes 
T helper 17 lymphocytes (Th17) cells have been implicated in the pathogenesis of many 
inflammatory disorders such as Crohn's disease, multiple sclerosis, psoriasis and rheumatoid 
arthritis (Matusevicius et al. 1999; Duerr et al. 2006; Kirkham et al. 2006; Krueger et al. 
2007; Miossec et al. 2009). Recently, the involvement of Th17 cells in vitiligo pathogenesis 
has been investigated. Reports of elevated levels of serum IL-17 (Basak et al. 2009) in 
vitiligo patients, and the presence of IL-17A
+
 T cells in the active border of vitiligo skin 
biopsies have been made (Wang et al. 2011). However, further studies are required to 
determine the exact role of Th17 cells in vitiligo pathogenesis. 
 
1.3.9.7.7 Cytokines 
An imbalance of several melanogenic cytokines that can affect melanocyte activity and 
survival has been shown in vitiligo lesional skin (Moretti et al. 2002a), and these are 
described in Section 1.3.7. Inflammatory cytokines have also been analysed in relation to 
vitiligo pathogenesis. For example, serum levels of soluble IL-2 receptor, which can be used 
to monitor in vivo immune activation, is significantly increased in vitiligo patients when 
compared with controls, indicating that the activation of T cells is a component in the 
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pathogenesis of vitiligo (Caixia et al. 1999; Galadari 2005). The production of IL-6 by 
mononuclear cells is also elevated in vitiligo patients (Yu et al. 1997). This cytokine can 
induce the expression of ICAM-1 on melanocytes thereby facilitating leukocyte-melanocyte 
interactions and consequently immunological damage (Kirnbauer et al. 1992; Moretti et al. 
2002b; Zailaie 2005). Increased production of IL-8, which can attract neutrophils to vitiligo 
lesions amplifying destructive inflammatory reactions, has also been reported in vitiligo 
patients (Yu et al. 1997; Zailaie 2005). Significantly higher expression of IFN-γ, IL-10, and 
IL-1β also occurs in the lesional and peri-lesional skin of vitiligo patients compared with skin 
of healthy control subjects (Grimes et al. 2004).  
The expression of TNF-α, an inflammatory mediator involved in the pathogenesis of 
autoimmune disease, is significantly elevated in vitiligo skin (Moretti et al. 2002b; Grimes et 
al. 2004; Zailaie 2005). The cytokine TNF-α can increase the production of H2O2 leading to 
oxidative stress and death of cells (Haycock et al. 2000; Dell'Anna and Picardo 2006). 
Moreover, TNF-α regulates the down-stream signaling molecule nuclear factor-κB (NF-κB) 
(Hsu et al. 1996), which promotes the expression of genes that prevent cell apoptosis (May 
and Ghosh 1998). Inhibition of NF-κB activation by TNF-α was found to induce apoptosis of 
cultured keratinocytes (Kim et al. 2007b). In vitiligo, it has been suggested that impaired NF-
κB activity can lead to TNF-α-dependent keratinocyte death and, consequently, melanocyte 
loss (Imokawa and Moretti 2010). The significant reduction in TNF-α in vitiligo skin after 
successful repigmentation induced by tacrolimus may also indicate a possible role of this 
cytokine in vitiligo pathogenesis (Grimes et al. 2004). 
Overall, the precise effects of abnormal alterations in inflammatory cytokine levels in 
the pathogenesis of vitiligo is not fully understood. Interestingly, certain inflammatory 
cytokines such as TNF-α, IL-1α and IL-6 have been found to act as paracrine inhibitors of 
melanocyte proliferation and of melanogenesis in a dose-dependent manner both in vivo and 
in vitro (Swope et al. 1991; Martinez-Esparza et al. 1998). 
 
1.3.10 The convergence theory 
The conversion theory suggests that several of the previously described factors could act 
synergistically or independently to induce the disappearance of melanocytes from the skin 
resulting in vitiligo, and that this could vary from patient to patient (Le Poole et al. 1993a) 
Furthermore, different clinical sub-types of vitiligo could result from different 
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pathomechanisms. For example, the neural theory (Lerner 1959; Cucchi et al. 2000) is often 
related to the development of segmental vitiligo while autoimmunity (Ongenae et al. 2003; 
Garbelli et al. 2005) is normally associated with non-segmental (generalised) vitiligo (Taïeb 
2000). 
More recently, Le Poole and Luiten (Le Poole and Luiten 2008) have described the 
elicitation phase of vitiligo as incorporating physical trauma to the skin (Gauthier et al. 
2003a), emotional stresses (Papadopoulos et al. 1998), and imbalances of endogenous neural 
factors (Lerner 1959; Cucchi et al. 2000), metabolites (Schallreuter et al. 1994a; Schallreuter 
et al. 1994b) or hormones (Pichler et al. 2006) (Figure 1.7). Such factors can lead to 
oxidative stress within melanocytes which respond by actively secreting HSP70 and 
chaperoned melanocyte antigens (Le Poole and Luiten 2008). Stimulated dendritic cells can 
then initiate an immune response against pigment cells in the activation phase (Le Poole and 
Luiten 2008) (Figure 1.7). To support this theory, a link and a temporal sequence between 
oxidative stress, autoimmune responses and depigmentation have been shown in vitiligo 
(Kroll et al. 2005). Once activated, dendritic cells migrate to the regional lymph nodes where 
presentation of the processed melanocyte antigen to T lymphocytes occurs. Autoreactive, 
anti-melanocyte cytotoxic T cells (van den Boorn et al. 2009) can subsequently destroy 
epidermal pigment cells. An absence of functional skin-infiltrating regulatory T cells may 
also contribute to the on-going immune response (Ben Ahmed et al. 2012). Autoantibodies 
against melanocyte proteins such as tyrosinase (Song et al. 1994; Baharav et al. 1996; Kemp 
et al. 1997a) are likely generated as a response to melanocyte damage, but it is possible they 
can damage pigment cells by complement activation and/or ADCC (Norris et al. 1988; 
Fishman et al. 1993; Gottumukkala et al. 2006). Overall, genetic susceptibility factors can 
influence the development of vitiligo, particularly in regard to the immune activation phase 
(Spritz 2007). 
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Figure 1.7: A schematic representation of the convergence theory for vitiligo aetiology.  
 
A theoretical explanation of the interaction between immunological and non-immune factors which can 
lead to vitiligo. The convergence theory suggests that several factors can act synergistically or 
independently to induce the disappearance of melanocytes. Genetic predisposition, metabolic deregulation 
together with impaired redox status, environmental aggressions and neural dysfunction probably act in an 
interrelated way to trigger local inflammation and damage of cells. These ‘danger’ signals can then 
promote the activation of antigen-presenting cells with the subsequent activation of anti-melanocyte 
autoreactive cytotoxic T lymphocytes. The decreased number and function of regulatory T cells may 
promote the loss of control of cytotoxic T lymphocytes. Drawn with information from (Ben Ahmed et al. 
2012). 
 
63 
 
1.4 Aims of Current Project 
Much evidence from recent studies supports a role for autoimmune factors in vitiligo 
pathogenesis (Rezaei et al. 2007) and, as discussed earlier (Section 1.3.9), several targets 
(autoantigens) of antibodies and autoreactive T cells have been documented in vitiligo (Baharav 
et al. 1996; Kemp et al. 1998a; Okamoto et al. 1998; Xie et al. 1999; Kemp et al. 2002; 
Waterman et al. 2002). Identifying and characterising the targets of vitiligo-associated antibodies 
would be of benefit in: 
 
(i) Providing diagnostic and prognostic tests, as well as a means for vitiligo 
classification and treatment monitoring. 
(ii) Defining the factors involved in vitiligo pathogenesis. For example, vitiligo-
associated autoantibodies, even if they are not inherently pathogenic, could serve as markers of T 
cell responses in patients with the disease. Such knowledge would help in the understanding of 
the aetiology and pathogenic mechanisms in vitiligo, which is essential for the development of 
better therapeutic measures. 
 
In the current project, antibodies to tyrosine hydroxylase (TH) will be investigated in vitiligo 
patients. This enzyme was previously reported as a putative autoantigen in vitiligo in 
experiments using phage-display technology (Waterman et al. 2010).  
 
The aims of this project were: 
 
(i) To investigate the frequency of TH antibodies in vitiligo patients using a 
radioimmunoassay specific for TH antibodies. 
(ii) To determine if there were any associations between the presence of TH antibodies 
and the clinical features of vitiligo. 
(iii) To analyse the vitiligo patient TH antibody binding sites (epitopes) on TH. This will 
be done using deletion derivatives of TH in radioimmunoassays. 
(iv) To evaluate the characteristics of TH antibodies in terms of titres, subclasses and 
avidities.  
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2. General Materials and Methods 
 
2.1 Participants 
Sera were obtained from 87 vitiligo patients who had attended either Dermatology (Professor 
David Gawkrodger) or Endocrinology (Professor Anthony Weetman) clinics in the Sheffield 
Teaching Hospitals NHS Trust, Sheffield, UK. Details of these patients are summarised in Table 
2.1. In addition, 28 healthy controls (10 male, 18 female; mean age: 34 years with range 21-59 
years), who had no present or past history of vitiligo or autoimmune disorders, were included in 
the study. Finally, 91 patients with autoimmmune diseases who had no concomitant vitiligo were 
also included as a disease control group. The patients were as follows: 27 with Graves’ disease 
(6 male, 21 female; mean age: 43 years with range 16-84 years); 19 with Addison’s disease (7 
male, 12 female; mean age: 49 years with range 26-77 years); 25 with autoimmune 
hypoparathyroidism (25 female; mean age: 51 years with range 25-74 years); and 20 with 
systemic lupus erythematosus (1 male, 19 female; mean age: 46 years with range 21-66 years). 
 Serum was separated from whole blood samples (10-20 ml) by centrifugation in a Sorvall 
RT6000-D centrifuge at 3,000 revolutions per minute (rpm) for 5-10 min. Sera were kept frozen 
at –80oC until required. 
 The study was approved by the Sheffield Research Ethics Committee, Sheffield, UK (REC 
Reference Number 09/H1308/91) and informed consent was obtained from participants. 
Research Governance for the project was administered by the Research Department, Sheffield 
Teaching Hospitals (STH) NHS Foundation Trust, Sheffield, UK (STH Number STH15257). 
 
2.2 Chemicals and plasticware   
The majority of chemicals and media components were purchased from either Sigma-Aldrich 
(Poole, UK) or Melford Laboratories (Ipswich, UK). Solvents and acids were obtained from 
Fisher Scientific UK Ltd. (Loughborough, UK). Where appropriate, the source of some 
chemicals and buffers is indicated in the text. Sterile plasticware was from Sarstedt Ltd.  
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Table 2.1: Details of vitiligo patients 
 
 
Patient detail 
 
 
Non-segmental 
vitiligo patients 
 
 
Segmental vitiligo 
patients 
 
Demographic details   
Number of patients 79 8 
Male/Female 30/49 3/5 
Mean age (range) 46 years (7-77 years) 33 years (16-58 years) 
Mean onset age  (range) 33 years (1-73 years) 33 years (14-54 years) 
Mean disease duration (range) 15 years (< 1-50 years) 2 years (< 1-4 years) 
Vitiligo clinical sub-type   
Symmetrical 63  
Symmetrical/periorificial 9  
Symmetrical with segmental patch 3  
Periorificial 2  
Universal 1  
Occupational 1  
Vitiligo activity
1   
Active vitiligo 64 3 
Stable vitiligo 15 5 
Vitiligo and autoimmune disease   
No associated autoimmune disease 55 6 
Autoimmune thyroid disease 14  
Autoimmune thyroid disease + Addison’s disease 1  
Autoimmune thyroid disease  + hyperparathyroidism 1  
Autoimmune thyroid disease + pernicious anaemia 1  
Alopecia areata 2 2 
Type 1 diabetes mellitus 1  
Psoriasis 1  
Systemic lupus erythematosus 2  
Scleroderma 1  
 
1
Active vitiligo was defined by currently progressing depigmentation. Stable vitiligo was defined by 
depigmentation that had shown no progression for the previous six months.  
  
67 
 
(Numbrecht, Germany), Starlab (UK) Ltd. (Milton Keynes, UK), Corning Incorporated 
(Corning, NY, USA) or Sterilin Ltd. (Caerphilly, UK). 
 
2.3 Bacterial strains 
The bacterial strains used in this study are derivatives of Escherichia coli K-12 and are given in 
Table 2.2. Derivatives of bacterial strains carrying plasmid vectors or recombinant plasmids were 
constructed by transformation (Section 2.15). 
 
2.4 Growth and storage of bacterial strains 
All E. coli strains were routinely grown from frozen stocks by initially streaking on to Luria 
Bertani (LB) agar plates (Section 2.5), containing selective antibiotic(s) where required (Section 
2.6). Plates were then incubated at 37˚C overnight. A single colony of the desired bacterial strain 
was then inoculated into LB broth with the appropriate antibiotic supplementation, and incubated 
at 37˚C overnight in a rotary incubator shaking at 250 rpm. For long-term storage at -80˚C, 0.7-
ml aliquots of an overnight-grown bacterial culture were mixed with 0.3-ml aliquots of sterile 
50% (v/v) glycerol in deionised water. 
 
2.5 Luria Bertani medium 
Luria Bertani (LB) broth was prepared in deionised water and contained: 1% (w/v) tryptone, 
0.5% (w/v) yeast extract and 1% (w/v) NaCl. Luria Bertani agar was prepared by adding 2% 
(w/v) agar to LB medium. After autoclaving, the agar was left to cool to about 40-45˚C before 
adding the appropriate antibiotic. The agar was poured into 90-mm petri-dishes and allowed to 
set. Plates were then dried and stored at 4˚C until required. 
 
2.6 Antibiotics 
Antibiotics were prepared as 1000x concentrated stocks in deionised water and sterilised by 
filtration through 0.22 micron Millex
®
 Filter Units (Millipore Corp., Bedford, MA, USA). 
Antibiotic solutions were stored at –20˚C and used at the following concentrations in culture 
medium and agar plates: ampicillin (sodium salt), 100 µg/ml; kanamycin sulphate, 50 µg/ml.  
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Table 2.2: Bacterial strains 
Strain
1
 Details Source 
JM109 
A bacterial strain used in the 
propagation of plasmid vectors 
and recombinant plasmids. 
Promega 
(Southampton, UK) 
JM109 pcDNA3 
Carries plasmid vector pcDNA3 
(Table 2.3). 
Dr. Helen Kemp (University of 
Sheffield, Sheffield, UK) 
JM109 pcDNA3-TH 
Carries recombinant plasmid 
pcDNA3-TH (Table 2.3). 
Dr. Helen Kemp (University of 
Sheffield, Sheffield, UK) 
JM109 pcMCHR1 
Carries recombinant plasmid 
pcMCHR1 (Table 2.3). 
Dr. Helen Kemp (University of 
Sheffield, Sheffield, UK) 
JM109 pSP64-Poly(A)-PAH 
Carries recombinant plasmid 
pSP64-Poly(A)-PAH (Table 
2.3). 
Dr. Helen Kemp (University of 
Sheffield, Sheffield, UK) 
JM109 pSP64-Poly(A)-TPH 
Carries recombinant plasmid 
pSP64-Poly(A)-TPH (Table 
2.3). 
Dr. Helen Kemp (University of 
Sheffield, Sheffield, UK) 
JM109 pcDNA3-TYR 
Carries recombinant plasmid 
pcDNA3-TYR (Table 2.3). 
Dr. Helen Kemp (University of 
Sheffield, Sheffield, UK) 
JM109 pTH140 
Carries recombinant plasmid 
pTH140 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH170 
Carries recombinant plasmid 
pTH170 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH200 
Carries recombinant plasmid 
pTH200 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH240 
Carries recombinant plasmid 
pTH240 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH280 
Carries recombinant plasmid 
pTH280 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH320 
Carries recombinant plasmid 
pTH320 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH360 Carries recombinant plasmid This study (Chapter 4) 
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pTH360 (Table 2.3). 
JM109 pTH400 
Carries recombinant plasmid 
pTH400 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH440 
Carries recombinant plasmid 
pTH440 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH480 
Carries recombinant plasmid 
pTH480 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH1-80 
Carries recombinant plasmid 
pTH1-80 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH81-140 
Carries recombinant plasmid 
pTH81-140 (Table 2.3). 
This study (Chapter 4) 
JM109 pTH141-497 
Carries recombinant plasmid 
pTH141-497 (Table 2.3). 
This study (Chapter 4) 
 
 
1
All strains are derivatives of Escherichia coli K-12. 
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2.7 Plasmids 
The plasmids used in this study are listed in Table 2.3. They were stored at –20˚C in sterile TE 
buffer (10 mM Tris-HCl; 1 mM ethylenediaminetetraacetic acid (EDTA); pH 8.0) (Promega, 
Southampton, UK). Diagrams of plasmids pcDNA3 (Invitrogen, Paisley, UK) and pcDNA3-TH 
(Dr. Helen Kemp, University of Sheffield, Sheffield, UK) are shown in Figures 2.1 and 2.2, 
respectively. 
 
2.8 Small-scale plasmid preparations 
The Wizard
®
 Plus SV Minipreps DNA Purification System (Promega) was used to purify 
plasmid DNA from a 5-10 ml overnight culture of the required bacterial strain, according to the 
manufacturer’s protocol. Briefly, a single colony of the desired bacterial strain was isolated by 
streaking out 20 µl of frozen bacterial stock on to LB agar containing the appropriate 
antibiotic(s). A single colony from the selective plate was then used to inoculate 10 ml of LB 
containing the relevant antibiotic(s) which was subsequently shaken in a rotary incubator at 250 
rpm at 37˚C overnight. The bacterial cell pellet was obtained by centrifugation at 10,000 g for 10 
min. The pellet was resuspended in 250 µl of Cell Resuspension Solution (50 mM Tris-HCl, pH 
7.5; 10 mM EDTA; 100 µg/ml RNase A), and the cells were lysed by the addition of 250 µl of 
Cell Lysis Solution (0.2 M NaOH; 1% (w/v) sodium dodecyl sulphate). The cell extract was then 
neutralised by the addition of 350 µl of Neutralisation Solution (0.759 M potassium acetate; 4.09 
M guanidine hydrochloride; 2.12 M glacial acetic acid; pH 4.2), mixed gently and centrifuged at 
10,000 g for 10 min at room temperature. The cleared lysate was then loaded on to a Wizard® 
SV Minicolumn which was centrifuged at 10,000 g for 1 min at room temperature and the flow- 
through discarded. The Minicolumn was washed with 750 µl of Column Wash Solution (60% 
(v/v) ethanol; 60 mM potassium acetate; 8.3 mM Tris-HCl; 0.04 mM EDTA) and then with 250 
µl of Column Wash Solution with centrifugation at for 2 min at room temperature each time. To 
recover the DNA bound to the column, 100 µl of nuclease-free water was added to the column 
and this was centrifuged at 10,000 g for 1 min at room temperature.  
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Table 2.3: Plasmids  
Plasmid Details Source 
pcDNA3 A 5.4-kb1 expression vector with a selectable 
resistance marker to ampicillin. Contains promoters for 
T7 and SP6 polymerases flanking a diverse multiple 
cloning site (Figure 2.1). 
Invitrogen  
(Paisley, UK)  
pcDNA3-TH pcDNA3 vector containing TH (isoform 2) cDNA 
(1.5-kb
1
) cloned into the HindIII-BamHI restriction site 
(Figure 2.3). 
Dr. Helen Kemp (University of 
Sheffield, Sheffield, UK) 
pcMCHR1 pcDNA3 vector containing melanin-concentrating 
hormone receptor 1 (MCHR1) cDNA (1.3 kb
1
) cloned 
into the EcoRI-XbaI restriction site. 
Dr. Helen Kemp (University of 
Sheffield, Sheffield, UK) 
pSP64-Poly(A)-
PAH 
pSP64-Poly(A) vector (Promega, Southampton, UK) 
containing phenylalanine hydroxylase (PAH) 
cDNA(1.4 kb
1
). 
Prof. Olle Kampe (University 
Hospital, Uppsala University, 
Uppsala, Sweden) 
pSP64-Poly(A)-
TPH 
pSP64-Poly(A) vector containing tryptophan 
hydroxylase (TPH) cDNA (1.3 kb
1
) cloned into the 
HindIII-BamHI restriction site. 
Prof. Olle Kampe (University 
Hospital, Uppsala University, 
Uppsala, Sweden) 
pcDNA3-TYR pcDNA3 vector containing tyrosinase cDNA (2.0 kb1) 
cloned into the KpnI-XbaI restriction site. 
Dr. Helen Kemp (University of 
Sheffield, Sheffield, UK) 
pTH140 pcDNA3 vector containing TH cDNA base pairs 1-420 
cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH170 pcDNA3 vector containing TH cDNA base pairs 1-510 
cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
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pTH200 pcDNA3 vector containing TH cDNA base pairs 1-600 
cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH240 pcDNA3 vector containing TH cDNA base pairs 1-720 
cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH280 pcDNA3 vector containing TH cDNA base pairs 1-840 
cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH320 pcDNA3 vector containing TH cDNA base pairs 1-960 
cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH360 pcDNA3 vector containing TH cDNA base pairs 1-
1080 cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH400 pcDNA3 vector containing TH cDNA base pairs 1-
1200 cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH440 pcDNA3 vector containing TH cDNA base pairs 1-
1320 cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH480 pcDNA3 vector containing TH cDNA base pairs 1-
1440 cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH1-80 pcDNA3 vector containing TH cDNA base pairs 1-240 
cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH81-140 pcDNA3 vector containing TH cDNA base pairs 241-
420 cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
pTH141-497 pcDNA3 vector containing TH cDNA base pairs 421-
1491 cloned into the HindIII-BamHI restriction site. 
This study (Chapter 4) 
 
1
kb, kilobase. 
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Figure 2.1: A map of the pcDNA3 vector. Restriction enzyme sites and sequencing primer 
binding sites are shown. 
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Figure 2.2: A map of the pcDNA3-TH plasmid. Restriction enzyme sites and sequencing 
primer binding sites are shown. TH cDNA is a 1.5-kb fragment cloned into the HindIII-BamHI 
cloning site. 
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2.9 Large-scale plasmid preparations 
A large-scale culture of the bacterial strain carrying the desired plasmid was prepared by 
inoculation of 0.5-1 litres of LB containing the appropriate antibiotic(s), with a 10-ml starter 
culture. This was followed by incubation overnight with shaking at 37˚C. The culture was then 
centrifuged at 4,000 g for 30 min and plasmid extracted from the cell pellet using a Qiagen 
Plasmid DNA Maxiprep Kit (Qiagen Ltd., Crawley, UK) as per the kit instructions. The bacterial 
cell pellet was first resuspended in 10 ml of P1 Buffer (50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 
100 μg/ml RNase A). An equal volume of P2 Buffer (0.2 M NaOH; 1% (w/v) sodium dodecyl 
sulphate) was then added to the resuspended cells and mixed by gentle inversion, followed by 
incubation at room temperature for 5 min.  The tube was then mixed gently again after the 
addition of 10 ml of P3 Buffer (1.32 M potassium acetate, pH 5.5) and incubated on ice for 20 
min. The mixture was subsequently centrifugated at 20,000 g for 30 min at 4
o
C resulting in a 
clear supernatant. A Qiagen column was equilibrated by adding QBT Buffer (750 mM NaCl; 50 
mM 3-[N-morpholino]propanesulphonic acid (MOPS), pH 7.0; 15% (v/v) isopropanol and 
0.15% (v/v) Triton X-100) and was allowed to empty by gravity flow. The clear supernatant was 
then loaded on to the column and left to flow through, followed by washing of the column twice 
with 30 ml of QC Buffer (1 M NaCl; 50 mM MOPS, pH 7.0; 15% (v/v) isopropanol).  Plasmid 
DNA was subsequently eluted with 15 ml of QF Buffer (1.25 M NaCl; 50 mM Tris-HCl, pH 8.5; 
15% (v/v) isopropanol) and precipitated by the addition of 10.5 ml of 100% isopropanol and 
centrifugation at 15,000 g for 30 min at 4
o
C.  The resulting DNA pellet was washed with 70% 
(v/v) ethanol, centrifuged at 15,000 g for 10 min at 4
oC and finally resuspended in 300 μl of TE 
buffer. The concentration of the DNA was ascertained by spectrophotometry at 260 nm using a 
NanoDrop ND-1000 Spectrometer (Labtech, Wilmington, DE, USA) and NanoDrop Software 
(Labtech). 
 
2.10 Agarose gel electrophoresis 
For analysis of DNA, agarose gels, 0.8-1% (w/v), were prepared by boiling molecular biology 
grade agarose (Sigma) in TAE electrophoresis buffer (40 mM Tris-acetate; 1 mM EDTA; pH 
8.3) (Promega) for 1-2 min in a microwave oven. One microlitre of ethidium bromide solution 
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(10 mg/ml) (Promega) was added for every 50 ml of the gel solution. The molten agarose was 
cooled and poured into the casting deck of a Sub-Cell
®
 Horizontal Electrophoresis System (Bio-
Rad Ltd., Hemel Hempstead, UK). After it had set, the combs were removed, and the 
electrophoresis tank was filled with TAE as a running buffer. Blue/Orange Loading Dye 6x 
(0.4% orange G; 0.03% (w/v) bromphenol blue; 0.03% xylene cyanol FF; 15% Ficoll
® 
400; 10 
mM Tris-HCl, pH 7.5; 50 mM EDTA, pH 8.0) (Promega) was added to the DNA sample at 1/6th 
of the volume, and the sample was then loaded into a gel slot. To size DNA products after they 
had migrated through the gel, a ‘marker’ lane was included. This contained a 0.5-1.0-μg sample 
of either HindIII-restricted bacteriophage λ DNA (125-23,130-bp DNA fragments) (Promega) or 
1-kb DNA Ladder (500-10,000-bp DNA fragments) (New England Biolabs
®
, Hitchin, UK). The 
gels were run in Sub-Cell
®
 Horizontal Electrophoresis System (Bio-Rad Ltd.) at 50-70 volts 
using a PowerPac Basic Power Supply (Bio-Rad Ltd.), and subsequently viewed and recorded 
using a GBOX Gel Documentation System (Syngene, Cambridge, UK) and GeneSnap Image 
Acquisition Software (Syngene). 
 
2.11 Restriction enzyme digests 
All restriction enzymes (Table 2.4) and restriction enzyme buffers (Table 2.4) were supplied by 
Promega. Restriction enzyme digests of plasmids and polymerase chain reaction (PCR) 
amplification products were carried out in 0.5 ml tubes in a volume not normally exceeding 25 μl 
and contained up to 1 μg of DNA, 10 units of enzyme(s) and 0.1 volumes of the appropriate 10x 
restriction enzyme buffer. Each reaction proceeded for 90 min at 37
o
C, unless otherwise stated. 
Restriction digests were analysed by agarose gel electrophoresis (Section 2.10). 
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Table 2.4: Restriction enzymes and buffers  
 
 
Enzyme
1
 
 
Buffer (10x concentration)
1
 
 
Restriction site 
BamHI Buffer E: 60 mM Tris-HCl, pH 7.5; 1 M NaCl; 60 
mM MgCl2; 10 mM dithiothreitol. 
5’-GGATCC-3’ 
HindIII Buffer E: 60 mM Tris-HCl, pH 7.5; 1 M NaCl; 60 
mM MgCl2; 10 mM dithiothreitol. 
5’-GAATTC-3’ 
 
1
All enzymes and buffers were supplied by Promega (Southampton, UK). 
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2.12 Polymerase chain reaction amplification 
Preceding the PCR amplification reaction, forward and reverse oligonucleotide primers were 
appropriately designed to amplify the required regions of a DNA fragment. Primers were 
synthesised to order by Eurofins Genetic Services Ltd. (London, UK) and were stored at -40
o
C in 
sterile, nuclease-free at a concentration of 100 pmol/µl. A list of the PCR primers used in this 
study is given in Table 2.5, and the exact primers used for PCR amplification of a particular 
DNA are given at the relevant points in the text. 
 Reactions were carried out in 0.5 ml tubes in 50-μl volumes comprising, unless indicated, 
50 ng of template DNA, 0.01-1 µM of each required (forward and reverse) primer, 1.25 units of 
GoTaq
®
 Flexi DNA polymerase (Promega), 0.2 mM deoxynucleotides (dATP, dGTP, dCTP and 
dTTP) (Promega), 1.5 mM MgCl2 (Promega) and 0.2 volumes of 5x GoTaq
®
 Flexi Buffer (50 
mM Tris-HCl, pH 8.5; 0.05% (w/v) gelatine; 250 mM KCl; 0.5% (v/v) Tween 20; 0.5% (v/v) 
Nonidet P-40) (Promega). Reactions without template DNA and without primers were included 
as controls. Each reaction was overlaid with mineral oil to prevent evaporation during heating, 
and was then subjected to PCR amplification in a DNA Thermal Cycler (Perkin-Elmer/Cetus 
Norwalk, CT, USA). 
 The cycling conditions were denaturation at 95
o
C for 1 min, annealing at 55
o
C for 1 min 
and extension at 72
o
C for 2 min for 30 cycles, unless stated otherwise. A final extension at 72
o
C 
for 10 min, followed by a soak at 4
o
C, completed the reactions. Amplification products were 
routinely analysed by agarose gel electrophoresis (Section 2.10). 
 
2.13 Extraction and purification of DNA fragments from agarose 
gels 
When electrophoresis was performed to purify a required DNA fragment, generated either from a 
PCR amplification reaction or a restriction enzyme digest, the DNA fragment was recovered 
from an agarose gel using a Wizard
®
 PCR Preps DNA Purification Kit (Promega).  Briefly, the 
area of the gel containing the relevant band of DNA was visualised using an ultra-violet 
transilluminator, excised using a clean scalpel and placed in a 1.5 ml Eppendorf tube. One 
millilitre of Wizard
®
 PCR Preps DNA Purification Resin was used to dissolve the gel slice and  
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Table 2.5: Oligonucleotide PCR amplification primers  
 
  
 
Primer
1
 
 
Sequence
2
 
 
THF1 5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
THR480 5’-aaggatcccgcctatcactccagggagcgccg-3’ 
THR440 5’-aaggatcccgcctatcaggcgtcactgaagct-3’ 
THR400 5’-aaggatcccgcctatcacaggagctccccgta-3’ 
THR360 5’-aaggatcccgcctatcaatccgaggcccccag-3’ 
THR320 5’-aaggatcccgcctatcagggcgaggacgcgtg-3’ 
THR280 5’-aaggatcccgcctatcacttcaggaagcggga-3’ 
THR240 5’-aaggatcccgcctatcacttcagcgtggtgta-3’ 
THR200 5’-aaggatcccgcctatcagcggtacacctggtc-3’ 
THR170 5’-aaggatcccgcctatcacacttttcttgggaa-3’ 
THR140 5’-aaggatcccgcctatcagtcccctcggcgcac-3’ 
THF141 5’-ttaagcttgccgccatgatgctggccgccctgctc-3’ 
THR497 5’-aaggatcccgcctatcagccaatggcactcag-3’ 
THF81 5’-ttaagcttgccgccatggtgctaaacctgctc-3’ 
THR80 5’-aaggatcccgcctatcaggccttcccctcctt-3’ 
 
 
1
All oligonucleotide PCR primers were supplied by Eurofins Genetic Services Ltd. (London, UK). 
2
The HindIII restriction site is underlined in the forward (F) primer. The BamHI restriction site is 
underlined in each of the reverse (R) primers. The ATG translation start codon in the forward primer is in 
bold type. The TGA and TAG translation stop codons in the reverse primers are in bold type. 
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the resulting mixture was applied via a 2 ml syringe to a Wizard
® 
Minicolumn followed by 2 ml 
of 80% (v/v) isopropanol. The Wizard
®
 Minicolumn was centrifuged at 10,000 g for 2 min, to 
remove excess isopropanol, prior to DNA elution with 30 μl of sterile TE buffer. The DNA then 
was stored at -20˚C until required. Purified DNA fragments were analysed by agarose gel 
electrophoresis (Section 2.10). 
 
2.14 DNA ligations 
Ligation of vector and DNA fragments was performed using T4 DNA ligase (Promega) in a 
reaction volume of 10-20 μl. An estimation of the concentration of each vector and insert was 
performed by agarose gel electrophoresis next to molecular size markers of a known 
concentration. Approximately 200 ng of vector DNA were mixed together with insert (the 
amount used was calculated using a vector:insert molar ratio of between 1 and 3) in a clean 0.5 
ml tube, and the required volume of nuclease-free water added. The mixture was heated to 65
o
C 
and gradually cooled to 16
o
C in a DNA Thermal Cycler (Perkin-Elmer/Cetus) to allow the DNA 
to anneal slowly before the addition of 1-2 units of T4 DNA ligase (Promega) and 0.1 volumes 
of 10x DNA ligase buffer (300 mM Tris-HCl, pH 7.8; 100 mM MgCl2; 100 mM dithiothreitol; 
10 mM ATP) (Promega). The reaction was subsequently incubated at 15
o
C overnight before 
using to transform bacterial cells (Section 2.15). 
 
2.15 Bacterial transformation 
When required, a 50-μl aliquot of chemically competent E. coli JM109 (Promega) cells was 
thawed from storage at -80
o
C. The appropriate DNA sample (plasmid DNA or DNA in a ligation 
reaction) was gently mixed with the cells and this was incubated on ice for 5-10 min. The cells 
were then heat shocked at exactly 42
o
C for 45 sec and returned to ice. After 2 min, the cells were 
transferred to a culture tube containing 900-950 μl of chilled SOC medium (2% (w/v) tryptone; 
0.5% (w/v) yeast extract; 10 mM NaCl; 2.5 mM KCl; 10 mM MgCl2; 10 mM MgSO4; 20 mM 
glucose) (Invitrogen). The culture tube was placed in the rotary incubator shaking at 150 rpm and 
grown for 1 h, to allow expression of the antibiotic resistance genes carried by the transforming 
plasmid DNA. A 100-μl aliquot of undiluted transformed cells, and of 1:10 and 1:100 dilutions, 
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were then spread on agar plates containing the appropriate antibiotic(s), and the plates incubated 
at 37
o
C overnight. As a control in each transformation experiment, an aliquot of untransformed 
cells was also plated on to selective medium. Individual colonies were subsequently purified by 
streaking on to fresh LB agar plates with selective antibiotic(s) for growth overnight at 37˚C. 
 
2.16 DNA sequencing 
Automated DNA sequencing was carried out by the Genetics Core Facility at the Medical 
School, University of Sheffield, Sheffield, UK. DNA templates (plasmids or PCR products) and 
oligonucleotide sequencing primers were provided to the service at 50-100 ng/μl and 1 pmol/μl, 
respectively. Sequencing primers M13 Forward, M13 Reverse, T7 and SP6 (Table 2.6) were 
purchased from Promega. Other primers (Table 2.6) were synthesised to order by Eurofins 
Genetic Services Ltd. (London, UK). Sequencing reactions were performed using a BigDye
®
 
Terminator Cycle Sequencing Kit Version 3.1 (Applied Biosystems, Foster City, CA, USA) and 
an ABI 3730 Capillary Sequencer (Applied Biosystems). 
 
2.17 DNA and protein analyses 
Protein and DNA homology searches against the GenBank database were performed using the 
BLAST service of the National Center for Biotehnology Information (NCIB) 
(http://www.ncbi.nlm.nih.gov/) (Bethesda, MD, USA). Other analyses of DNA and protein 
sequences were carried out using the network facilities of the European Bioinformatics Institute-
European Molecular Biology Laboratory (EBI-EMBL) (http://www.ebi.ac.uk/) (Cambridge, UK) 
and of the Bayler College of Medicine HGSC (http://searchlauncher.bcm.tmc.edu/) (Houston, 
TX, USA). 
 
2.18 In vitro coupled transcription-translation of cDNA 
A TnT
®
 T7- or SP6-Coupled Reticulocyte Lysate System (Promega) was used to produce the 
protein of interest labelled with [
35
S]-methionine. Reactions were set up in 0.5 ml tubes in 50-μl 
volumes containing: 0.5 μg of plasmid DNA carrying the appropriate cDNA, 0.5 volumes of 
TnT
®
 Rabbit Reticulocyte Lysate, 10 units of TnT
®
 T7 RNA Polymerase, 0.02 mM amino acid  
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Table 2.6: Oligonucleotide sequencing primers  
 
 
 
Primer
1
 
 
Sequence 
 
T7 5’-taatacgactcactataggg-3’ 
SP6 5’-attaaccctcactaaaggga-3’ 
M13 Reverse 5’-caggaaacagctatgac-3’ 
M13 Forward 5’-tgtaaaacgacggccagt-3’ 
THF400 5’-tcgtgcgcctcgaggt-3’ 
THF839 5’-aggagcgcacgggctt-3’ 
THF1239 5’-ccctgaggctgcgg-3’ 
THR1 5’-tgcctgcgcccaa-3’ 
 
 
1
Oligonucleotide sequencing primers were supplied by Promega (Southampton, UK) or Eurofins Genetic 
Services Ltd. (London, UK). 
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mixture minus methionine, 0.04 volumes of 25x TnT
®
 Reaction Buffer, 40 units of RNasin
®
 
Ribonuclease Inhibitor (Promega) and 0.04 volumes of 10 mCi/ml translation-grade [
35
S]-
methionine (1,000 Ci/mmol) (Perkin-Elmer LAS UK Ltd., Beaconsfield, UK). Reactions were 
incubated at 30
o
C for 120 min and then stored at -40
o
C until needed. 
 The percentage incorporation of [
35
S]-methionine was determined by trichloroacetic acid 
(TCA)-precipitation as detailed by the manufacturer (Promega). In brief, 2 µl of the reaction 
mixture were added to 98 µl of 1 M NaOH/2% H2O2 and incubated at 37
o
C for 10 min. 
Susequently, 900 µl of ice-cold 25% (w/v) TCA/2% (w/v) casamino acids (Difco, Detroit, MI, 
USA) were added and the reaction incubated on ice for 30 min. To collect the precipitated 
translation products, 250 µl of the TCA reaction mix were vacuum filtered on to a Whatman 
GF/A glass fibre filter (Whatman International Ltd., Maidstone, UK) pre-wetted with cold 5% 
(w/v) TCA. The filter was rinsed three times with 1 ml of ice-cold 5% (w/v) TCA, once with 1 
ml of acetone and then allowed to dry at room temperature before immersing in 3 ml of Ultima-
Gold
®
 XR scintillation fluid (Packard Bioscience, Groningen, The Netherlands) and counting in 
a Beckman LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter, Inc., Fullerton, CA, 
USA). To determine total counts per min (cpm) present in the reaction, a 5-µl aliquot of the TCA 
reaction mix was spotted directly on to a filter. This was dried for 10 min before counting as 
above. The percent incorporation of [
35
S]-methionine was determined as: 100 x (cpm of washed 
filter/cpm of unwashed filter x 50), and ranged from 7-15% depending on the protein being 
labeled. 
 Radiolabelled protein products were also analysed by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) (Section 2.19). 
 
2.19 SDS-PAGE and autoradiography 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of protein samples 
was performed in 8%, 10% or 12% (w/v) SDS-polyacrylamide resolving gels. The exact 
constitution of gels and associated buffers is shown in Table 2.7.  The percentage acrylamide of 
the gel varied according to the size of the protein products to be electrophoresed. 
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 The gels were created using a Bio-Rad Mini-Protean Tetra Cell apparatus (Bio-Rad Ltd.). 
Briefly, glass plates and spacers were assembled using the dedicated equipment according to the 
manufacturer’s instructions. The resolving gel solution was poured into the space between the 
plates and overlaid with 1 ml of butan-1-ol. After the gel had polymerized, the butanol was 
poured off and a gel comb was inserted before the solution for the stacking gel was poured in on 
top. Subsequently, the gel comb was removed and the full apparatus assembled into the gel 
running tank. Laemmli buffer (250 mM Tris-base; 0.1% (w/v) SDS; 0.2 M glycine) was poured 
into the tank until the bottom of the plates was covered and the top buffer reservoir was full.  
 Prior to loading, radiolabelled protein products made by in vitro coupled transcription-
translation (Section 2.18) were mixed with SDS-sample buffer (2% (w/v) SDS; 25% (v/v) 
glycerol; 0.01% (w/v) bromophenol blue; 2% (v/v) 2-mercaptoethanol; 62.5 mM Tris-HCl, pH 
6.8) (Bio-Rad Ltd.) and heated at 85
o
C for 5 min. Samples were  then loaded into the wells along 
with either Prestained SDS-PAGE Standards, Low Range (21-103 kDa) (Bio-Rad Ltd.) or 
Precision Plus Protein All Blue Standards (10-250 kDa) (Bio-Rad Ltd.). Gels were run at 35 milli-
amperes for 3-5 h or until the visible dye front had reached the bottom of the plates.  
 The apparatus was subsequently dismantled and the gel transferred to a plastic tray and 
covered with Coomassie
® 
Blue stain (0.05% (w/v) Coomassie
®
 Brilliant Blue (Bio-Rad Ltd.); 
10% (v/v) glacial acetic acid; 25% (v/v) isopropanol). This was placed on a rocking platform.  
After a minimum of 30 min staining, the gel was destained by repeated fresh additions of a 
solution containing 10% (v/v) glacial acetic acid and 25% (v/v) isopropanol, until the protein 
markers were clearly visible. The destain was discarded and the gel was soaked for 30 min in 
Amersham Amplify
TM
 Fluorographic Reagent (GE Healthcare Life Sciences, Little Chalfont, 
UK), before being dried for 2 h at 60
o
C on to 3MM Whatman paper (Whatman International 
Ltd.) in a Bio-Rad Gel Dryer 583 (Bio-Rad Ltd.). Dried gels were subjected to autoradiography 
by exposure to Fuji RX x-ray film (Genetic Research Instrumentation Ltd., Dunmow, UK) in a 
Hypercassette™ (GE Healthcare BioSciences) at room temperature for 24 h. The film was 
subsequently developed using Photosol CD18 x-ray developer (Photosol Ltd., Basildon, UK) for 
3 min, rinsed in water and then fixed for 3 min in Photosol CF40 fixer (Photosol Ltd.). 
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Table 2.7: Constituents of SDS-PAGE
1
 gels 
 
(a) Resolving gel  
 
 
Constituent 
 
Final concentration in gel 
 
Buffer A: 
Tris-base  
SDS
2
  
 
0.4 M 
0.1% (w/v) 
Acrylamide:bisacrylamide (37.5:1) 
(Bio-Rad Laboratories Ltd.) 
10-12% (w/v)  
Ammonium persulphate  0.04% (w/v) 
TEMED
3
  0.0004% (v/v) 
 
(b) Stacking gel 
 
 
Constituent 
 
 
Final concentration in gel 
 
Buffer B: 
Tris-Base 
SDS
2 
 
 
0.125 M 
0.1% (w/v) 
Acrylamide: bisacrylamide (37.5: 1) 4% (w/v) 
Ammonium persulphate 0.05% (w/v) 
TEMED
3 0.075% (v/v) 
 
1
SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis.  
2
SDS, sodium dodecyl sulphate. 
3TEMED, N, N, N, N’-tetramethylethylenediamine. 
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2.20 Radioimmunoassays 
For each radioimmunoassay (RIA) (Figure 2.3) reaction, a 1-2-μl aliquot of the required in vitro 
coupled transcription-translation reaction (equivalent to 10,000-20,000 cpm of TCA-precipitable 
material) was suspended in 50 μl immunoprecipitation buffer (20 mM Tris-HCl, pH 8.0; 150 
mM NaCl; 1% (v/v) Triton X-100; 10 mg/ml aprotinin) in a 1.5 ml tube. Serum or animal 
antiserum was then added to the required final dilution and the tube incubated overnight with 
shaking at 4
oC. 50 μl of protein G SepharoseTM 4 Fast Flow (GE Healthcare Life Sciences), 
prepared according to the manufacturer, were added to the tube which was then incubated for a 
further 90 min at 4
o
C. Subsequently, the protein G Sepharose-antibody-antigen complexes were 
collected by centrifugation at 5,000 g and washed six times for 15 min in immunoprecipitation 
buffer at 4
o
C. The complexes were then transferred to 1 ml of Ultima-Gold
®
 XR scintillation 
fluid contained in a 10 ml scintillation vial (Molecular Devices, Sunnyvale, CA, USA). 
Immunoprecipitated radioactivity was evaluated in a Beckman LS 6500 Multi-Purpose 
Scintillation Counter. Serum or antibody samples were always tested in duplicate in each 
experiment and the mean cpm was calculated from the two samples.  
 Antibody levels were expressed as an antibody (Ab) index. This was calculated for each 
serum tested as: cpm immunoprecipitated by tested serum/mean cpm immunoprecipitated by the 
population of healthy control sera. Each serum was tested in at least two experiments and the 
mean Ab index was calculated from these values. The upper limit of normal for RIAs was 
calculated using the mean Ab index + 3SD of the population of healthy controls. Any serum 
sample with an Ab index above the upper limit of normal was designated as positive for antibody 
reactivity. 
For analysis by SDS-PAGE and autoradiography, the protein G Sepharose-antibody 
complexes were resuspended in 100 μl of SDS-sample buffer, boiled, centrifuged and the 
supernatants recovered for electrophoresis in SDS-polyacrylamide gels (Section 2.19). 
To determine antibody titres, sera were analysed in RIAs at final dilutions of 1:100, 1:200, 
1:500, 1:1000 and 1:2000. An Ab index for each sample at each dilution was calculated as 
described above. Sera were tested in two experiments and the mean Ab index calculated.   
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Figure 2.3: Schematic representation of the radioimmunoassay protocol. 
 
  
1. In vitro translated protein 
and patient or control serum 
in immunoprecipitation buffer 
incubated overnight at 4oC.
Antibody molecules are 
represented as black line 
drawings. Protein molecules 
are represented as black 
spheres.
2. Add protein G 
Sepharose beads and 
incubate for 1 h at 4oC.
Protein G Sepharose
beads are represented as 
white spheres.
3. Spin down protein G 
Sepharose -antibody 
complexes and wash in 
immunoprecipitation buffer.
4. Measure 
immunoprecipitated
radioactivity in a 
scintillation counter.
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2.21 Animal antisera 
The animal antisera used in this study are listed in Table 2.8. All antisera were stored in 
accordance with the manufacturers’ instructions at –20˚C. 
 
2.22 Antibody absorption experiments using cell extracts 
All cell extracts used in antibody absorption experiments were a gift from Dr. Helen Kemp 
(Department of Human Metabolism, University of Sheffield, Sheffield, UK). Extracts had been 
prepared from untransfected human embryonic kidney 293 (HEK293) cells and from HEK293 
cells expressing TH, tyrosinase or MCHR1, resulting from prior transfection with pcDNA3-TH, 
pcDNA3-TYR or pcMCHR1 (Table 2.3), respectively. The expression of the heterologous 
proteins had been confirmed using immunoblotting with antigen-specific animal antisera (Table 
2.8). The cell extracts were in extract buffer (150 mM NaCl; 10 mM Tris-HCl, pH 7.4; 1% (v/v) 
Triton X-100; Protease Cocktail Inhibitor) (Sigma-Aldrich), contained equivalent amounts of 
total protein (1 mg/ml) and were stored at -80°C until required. 
 For antibody absorption experiments, 100-µl samples of sera were incubated at 4°C for 16 
h with 400 µl of cell extract made from either untransfected HEK293 cells or HEK293 cells 
containing expressed TH, tyrosinase or MCHR1. Sera were also incubated in cell extract buffer 
under the same conditions, but without any cell extract added. Anti-TH antiserum was also 
incubated in the same way to act as a positive control. Following incubation, samples were 
centrifuged at 4°C and 45,000 g for 1 h and the absorbed serum (supernatant) recovered. The TH 
antibody RIA was then set up as detailed previously (Section 2.20), to measure immunoreactivity 
against TH in the unabsorbed and pre-absorbed sera. 
 
2.23 Synthetic peptides 
The synthetic peptides used in this study were obtained from Severn Biotech Ltd. 
(Kidderminster, UK) and details of them are given in Table 2.9. They were stored at –80˚C until 
required. 
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Table 2.8: Animal antisera  
 
 
Antiserum
 
 
Details 
 
 
Source 
ab59276: Polyclonal 
rabbit anti-TH
1
 
antiserum 
Raised against a synthetic 
peptide close to the N-
terminus of human TH
1
.  
Abcam, Inc. 
(Cambridge, MA, 
USA) 
α-PEP7:Polyclonal 
rabbit anti-tyrosinase 
antiserum 
Raised against a synthetic 
peptide corresponding to 
the C-terminus of mouse 
tyrosinase. Cross reacts 
with human tyrosinase.  
Prof. Vincent Hearing 
(National Institutes of 
Health, Bethesda, MD, 
USA) 
MCHR11-S: Polyclonal 
rabbit anti-MCHR1
2
 
antiserum 
Raised against a 16-amino 
acid peptide close to the C-
terminus of human 
MCHR1
2
.  
Alpha Diagnostics 
International, Inc. (San 
Antonio, TX, USA) 
sc-15109: Polyclonal 
goat anti-PAH
3
 
antiserum 
Raised against a synthetic 
peptide close to the N-
terminus of human PAH
3
. 
Santa Cruz 
Biotechnology, Inc. 
(Santa Cruz, CA, USA) 
sc-15114: Polyclonal 
goat anti-TPH
4
 
antiserum 
Raised against a synthetic 
peptide in the internal 
region of human TPH
4
. 
Santa Cruz 
Biotechnology, Inc. 
(Santa Cruz, CA, USA) 
 
1
TH, tyrosine hydroxylase.
 
2
MCHR1, melanin-concentrating hormone receptor 1. 
3
PAH, phenylanine hydroxylase. 
4
TPH, tryptophan hydroxylase.  
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Table 2.9: Synthetic peptides  
 
 
 
Peptide
1
 
 
Sequence 
 
TH-1-14
2 MPTPDATTPQAKGF 
TH-15-29
2 RRAVSELDAKQAEAI 
TH-30-44
2 MSPRFIGRRQSLIED 
TH-45-60
2 ARKEREAAVAAAAAAV 
TH-61-80
2 PSEPGDPLEAVAFEEKEGKA 
MCHR1-105-118
3 ISYINIIMPSVFGT 
 
 
1
Synthetic peptides were supplied by Severn Biotech Ltd. (Kidderminster, U.K.). 
2
TH amino acid residue numbers for National Center for Biotechnology Information (NCBI) (Bethesda, 
MD, USA) sequence reference number NM000360.
 
3
MCHR1 amino acid residue numbers for NCBI sequence reference number NM005297. 
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2.24 Antibody absorption experiments using TH peptide fragments 
For use in antibody absorption experiments, unlabelled TH peptide fragments and MCHR1 were 
produced in an in vitro TnT
®
 T7-Coupled Reticulocyte Lysate System as detailed above (Section 
2.18), but using non-radiolabelled methionine in the reaction. In absorption experiments, sera at 
a 1:100 dilution in 50 µl of immunoprecipitation buffer were pre-incubated at 4
o
C for 2 h with 
10 µl of in vitro translation reaction which contained the appropriate non-radiolabelled TH 
fragment or non-radiolabelled MCHR1. Following the addition of in vitro translation reaction 
containing radiolabelled TH, the TH antibody RIA was completed as above (Section 2.20). 
 
2.25 Antibody absorption experiments using synthetic TH peptides 
In peptide absorption experiments, sera were pre-incubated at a dilution of 1:100 with synthetic 
peptides (Table 2.9) at 100 µg/ml in 50 µl of immunoprecipitation buffer. After incubation at 
4
o
C for 2 h, in vitro translation reaction containing radiolabelled TH was added to the samples 
which were then analysed in TH antibody RIAs as detailed above (Section 2.20). 
 
2.26 Peptide enzyme-linked immunosorbent assays 
For testing antibody reactivity against specific peptides in an enzyme-linked immunosorbent 
assay (ELISA) format, Corning polystyrene 96-well microtitre plates (Bibby Sterilin Ltd., Mid-
Glamorgan, UK) were coated with 3 μg of the required synthetic peptide in 50 μl of coating 
buffer (1.5 mM Na2CO3; 3.5 mM NaHCO3; pH 9.2). The plates were then incubated overnight at 
4
o
C. Wells were washed with phosphate-buffered saline (0.137 M NaCl; 0.0027M KCl; 0.0081 
Na2HPO4; 0.0015 M KH2PO4; pH7.4; PBS) (Oxoid, Basingstoke, UK)/0.1% (w/v) Tween-20, 
blocked with 3% (w/v) bovine serum albumin in PBS at room temperature for 1 h and then 
washed PBS/0.1% (w/v) Tween-20. Aliquots (100-µl) of serum at the required dilution were 
added to wells and PBS was applied as a control. The plates were incubated at room temperature 
for 2 h and then washed six times with PBS/0.1% (w/v) Tween-20. Aliquots (100-µl) of anti-
human IgG alkaline phosphatase conjugate (Sigma-Aldrich) diluted 1:1000 in PBS/0.1% (w/v) 
Tween-20 were added to the wells for 1 h at room temperature. After washing six times with 
PBS/0.1% (w/v) Tween-20, 100 µl of alkaline phosphatase substrate (Sigma Fast p-Nitrophenyl 
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Phosphate Tablet Set) (Sigma-Aldrich) were applied to each well and plates incubated at room 
temperature for 30 min. A LabSystems Integrated EIA Management System (Life Sciences 
International, Hampshire, UK) was used to read absorption of the wells at 405 nm. 
All sera were tested in at least duplicate and the average OD405 value taken. The binding 
reactivity of each patient and control sera to each TH peptide was expressed as an Ab index 
calculated as:  mean OD405 of tested serum/mean OD405 of the population of healthy control sera. 
Each serum was tested in two experiments and the mean Ab index was calculated from the 
resulting Ab index values. The upper limit of normal for each TH peptide ELISA was calculated 
using the mean Ab index + 3SD of the population of healthy control sera. Patient sera with an Ab 
index greater than the upper limit of normal were regarded as positive for binding to the TH 
peptide used in the ELISA. 
To determine antibody titres, sera were analysed in ELISAs at final dilutions of 1:100, 
1:200, 1:500, 1:1000 and 1:2000. An Ab index for each sample at each dilution was calculated as 
described above. Sera were tested in two experiments and the mean Ab index calculated. 
For TH antibody IgG subclass determination, anti-human IgG1, IgG2, IgG3 and IgG4 
AP-conjugates (SouthernBiotech, Birmingham, AL, USA) were applied as the secondary 
antibody in the ELISA experiments at a 1:1000 dilution. 
For avidity evaluations, sera were diluted at 1:100 in PBS/0.1% (w/v) Tween-20 
containing NaCl at concentrations of 0.15, 0.5, 1.5 and 3.0 M, prior to testing antibody binding 
in ELISA experiments. 
 
2.27 Statistical analyses 
Statistical analyses included: Fisher's exact tests for 2 x 2 contingency tables for categorical data; 
non-parametric Mann-Whitney U tests for comparing two unpaired groups for continuous data; 
and paired t tests for comparing two paired groups for continuous data. The tests were carried out 
as appropriate using GraphPad InStat 3 software (GraphPad Software, CA, USA). In all tests, P 
values < 0.05 (two-tailed) were regarded as significant. 
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CHAPTER 3 
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3. Detection of tyrosine hydroxylase antibodies in vitiligo 
patients using a radioimmunoassay 
 
3.1 Introduction 
 
3.1.1 Tyrosine hydroxylase 
Tyrosine hydroxylase (TH) catalyses the conversion of tyrosine to L-dopa, the precursor 
molecule of catecholamine (e.g., dopamine) biosynthesis (Lewis et al. 1993; Nagatsu 1995). 
Four isoforms of TH (TH1-TH4) exist, these differing in the N-terminal regulatory domain 
(Lewis et al. 1993; Nakashima et al. 2009). The most widely expressed forms are TH1 and TH2 
which are found mostly in the central nervous system (Lewis et al. 1993). Tyrosine hydroxylase 
expression and activity has also been shown in human keratinocytes (Ramchand et al. 1995; 
Marles et al. 2003). Controversy surrounds the presence of TH in melanocytes. Both TH1 
mRNA and active TH were reported in human epidermal melanocytes, the enzyme being located 
on the melanosomal membrane together with tyrosinase (Marles et al. 2003). This finding led to 
the suggestion that TH directly supplies the preferred substrate and activator L-dopa for 
tyrosinase, which then initiates melanin synthesis (Figure 3.1) (Marles et al. 2003). In contrast, 
undetectable or insignificant levels of TH mRNA were found in several melanocyte and 
melanoma cell lines (Kågedal et al. 2004). To date, the function of TH in melanogenesis is not 
clearly defined and the in vivo expression and activity of TH, which may be higher than that 
found in vitro (Kågedal et al. 2004) also remains to be thoroughly investigated. 
Tyrosine hydroxylase shows a high degree of amino acid homology with enzymes 
tryptophan hydroxylase (TPH) and PAH with an overall linear homology of about 35%, and in 
the catalytic domain, a homology of 70% (Figure 3.2) (Hufton et al. 1995). Both PAH and TPH 
are also involved in the synthesis of neurotransmitters: PAH catalyses the conversion of L-
phenylalanine to L-tyrosine, and TPH hydroxylates L-tryptophan as part of the serotonin 
biosynthetic pathway (Hufton et al. 1995). 
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The first 165 amino acid residues at the N-terminal of TH constitute a regulatory domain 
that can be removed without significantly altering the enzyme activity (Daubner et al. 1993). A 
recent study has shown that phosphorylation of serine residue 40 imparts greater flexibility on 
the regulatory domain of the enzyme, and it has been suggested that TH exists in open and closed 
conformations depending on phosphorylation at serine 40 (Wang et al. 2011). However, the lack 
of a structural model of the regulatory domain of TH has limited the understanding of the 
structural changes associated with regulatory mechanisms that modulate the activity of the 
enzyme. 
The active site of TH resides in the catalytic C-terminal and is dependent upon the 
presence of ferrous iron (Fitzpatrick 1989). The crystal structure of the catalytic and 
tetramerisation domains of TH have revealed a novel alpha-helical basket holding the catalytic 
iron and a 40-Ångstrom long anti-parallel coiled coil which forms the core of the tetramer 
(Goodwill et al. 1997). The catalytic iron is located 10 Ångstroms below the enzyme surface in a 
17-Ångstrom deep active site pocket and is coordinated by the conserved residues histidine 331, 
histidine 336 and glutamine 376 (Goodwill et al. 1997). 
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Figure 3.1: A possible role for tyrosine hydroxylase in melanogenesis. 
 
Tyrosine hydroxylase (TH) possibly directly supplies L-dopa to facilitate the activation of tyrosinase 
enzyme which subsequently initiates melanogenesis by converting L-tyrosine to dopaquinone. Drawn 
with information from (Marles et al. 2003). 
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TPH        -----------------MIEDNKEN-----------------KDHSLER----------- 15 
PAH        -----------------MSTAVLENPGLGRKLSDFGQETSYIEDNCNQN----------- 32 
TH         MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
                                                   
TPH        -------------------GRASLIFSLKNEVG-GLIKALKIFQEKHVNLLHIESRKSKR 55 
PAH        -------------------GAISLIFSLKEEVG-ALAKVLRLFEENDVNLTHIESRPSRL 72 
TH         PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
                                    
TPH        RNS---EFEIFVDCDIN-REQLNDIFHLLKSHTNVLSVNLPDNFTLKEDGMETVPWFPKK 111 
PAH        KKD---EYEFFTHLDKRSLPALTNIIKILRHDIGATVHELS-----RDKKKDTVPWFPRT 124 
TH         PRAGGPHLEYFVRLEVR-RGDLAALLSGVRQVSEDVRSPAG----------PKVPWFPRK 169 
             
TPH        ISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEI 171 
PAH        IQELDRFANQILSYGAELDADHPGFKDPVYRARRKQFADIAYNYRHGQPIPRVEYMEEEK 184 
TH         VSELDKCHHLVTKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEI 229 
            
TPH        KTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRP 231 
PAH        KTWGTVFKTLKSLYKTHACYEYNHIFPLLEKYCGFHEDNIPQLEDVSQFLQTCTGFRLRP 244 
TH         ATWKEVYTTLKGLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRP 289 
             
TPH        VAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQ 291 
PAH        VAGLLSSRDFLGGLAFRVFHCTQYIRHGSKPMYTPEPDICHELLGHVPLFSDRSFAQFSQ 304 
TH         VAGLLSARDFLASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQ 349 
            
TPH        EIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAG-LSSISELKHALSGHAKV 350 
PAH        EIGLASLGAPDEYIEKLATIYWFTVEFGLCKQGDSIKAYGAGLLSSFGELQYCLSEKPKL 364 
TH         DIGLASLGASDEEIEKLSTLYWFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEI 409 
            
TPH        KPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQIL 410 
PAH        LPLELEKTAIQNYTVTEFQPLYYVAESFNDAKEKVRNFAATIPRPFSVRYDPYTQRIEVL 424 
TH         RAFDPEAAAVQPYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDVL 469 
             
TPH        KDTKSITSAMNELQHDLDVVSDALAKVSRKPSI 443 
PAH        DNTQQLKILADSINSEIGILCSALQKIK----- 452 
TH         DSPQAVRRSLEGVQDELDTLAHALSAIG----- 497 
 
 
 
Figure 3.2: Amino acid sequence homologies of hydroxylase enzymes.  
 
The aligned amino acid sequences of TH (NCBI Reference Sequence: NM000360.3), phenylalanine 
hydroxylase (PAH) (NCBI Reference Sequence: NM000277.1), and tryptophan hydroxylase (TPH) 
(NCBI Reference Sequence: NM004179.2) are also shown. Identical amino acid residues in the three 
sequences are highlighted. Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, 
Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012).  
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3.1.2 Tyrosine hydroxylase as an autoantigen 
Tyrosine hydroxylase antibodies were reported first in APS1, also known as autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), patients, including 57% of 
those individuals displaying vitiligo as part of their clinical manifestations (Hedstrand et al. 
2000). However, a significant association was not noted between the presence of TH antibodies 
and vitiligo in APS1 patients. In contrast, immunoreactivity against TH was strongly associated 
with the presence of another ectodermal condition, alopecia areata (Hedstrand et al. 2000). 
Furthermore, TH was previously identified as a putative antibody target in vitiligo using phage-
display enrichment of a melanocyte cDNA phage-display library with vitiligo patient IgG 
(Section 1.4) (Kemp et al. 2002; Waterman et al. 2010). This finding was the foundation for the 
current study to investigate TH as a possible antibody target in vitiligo. Interestingly, the related 
enzymes PAH and TPH are also autoantigens in APS1 (Ekwall et al. 1999; Ekwall et al. 2000). 
 
3.1.3 Cloning of TH cDNA 
In order to investigate possible immunoreactivity against TH in vitiligo patient sera, it was 
necessary to clone TH cDNA so that it could be used to express TH protein which in turn could 
be employed as a ligand in RIAs (Kemp et al. 2002; Kemp et al. 2011b). In brief, TH cDNA was 
isolated as a 1.5-kilobase (kb) fragment by Dr. Helen Kemp (Department of Human Metabolism, 
University of Sheffield, Sheffield, UK) using reverse transcriptase (RT)-PCR. Melanocyte RNA 
was reversed transcribed with Moloney Murine Leukemia Virus (M-MLV) RT to isolate 
melanocyte cDNA. The cDNA was then subjected to PCR amplification with TH-specific 
forward and reverse primers, THF1 and THR497 (Table 2.5), respectively. Subsequently, the TH 
cDNA was cloned into pcDNA3 at the HindIII-BamHI restriction sites and the recombinant 
plasmid designated pcDNA3-TH (Figure 2.2). The TH cDNA was cloned in the correct 
orientation for expression of the protein from the T7 promoter in the pcDNA3 vector (Figure 
2.1). Sequencing of the cloned TH cDNA using primers T7, SP6, THR1, THF400, THF839 and 
THR1239 (Table 2.6) indicated that the cDNA corresponded to TH isoform 2 (Lewis et al. 1993; 
Kemp et al. 2011b) with NCBI sequence reference number NM000360. The DNA sequence and 
amino acid sequence of TH are given in Figures 3.3 and 3.4, respectively. 
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Figure 3.3: TH cDNA sequence. 
 
The cDNA sequence matches that of TH cDNA isoform 2 with National Center for Biotechnology 
Information (NCBI) (Bethesda, MD, USA) sequence reference number NM000360. The ATG translation 
start codon and the TAG translation termination codon are shown in bold-type face. The cDNA has 1491 
base pairs.
 
  
 
atgcccacccccgacgccaccacgccacaggccaagggcttccgcagggccgtgtctgagctggacgcc
aagcaggcagaggccatcatgtccccgcggttcattgggcgcaggcagagcctcatcgaggacgcccgc
aaggagcgggaggcggcggtggcagcagcggccgctgcagtcccctcggagcccggggaccccctggag
gctgtggcctttgaggagaaggaggggaaggccgtgctaaacctgctcttctccccgagggccaccaag
ccctcggcgctgtcccgagctgtgaaggtgtttgagacgtttgaagccaaaatccaccatctagagacc
cggcccgcccagaggccgcgagctgggggcccccacctggagtacttcgtgcgcctcgaggtgcgccga
ggggacctggccgccctgctcagtggtgtgcgccaggtgtcagaggacgtgcgcagccccgcggggccc
aaggtcccctggttcccaagaaaagtgtcagagctggacaagtgtcatcacctggtcaccaagttcgac
cctgacctggacttggaccacccgggcttctcggaccaggtgtaccgccagcgcaggaagctgattgct
gagatcgccttccagtacaggcacggcgacccgattccccgtgtggagtacaccgccgaggagattgcc
acctggaaggaggtctacaccacgctgaagggcctctacgccacgcacgcctgcggggagcacctggag
gcctttgctttgctggagcgcttcagcggctaccgggaagacaatatcccccagctggaggacgtctcc
cgcttcctgaaggagcgcacgggcttccagctgcggcctgtggccggcctgctgtccgcccgggacttc
ctggccagcctggccttccgcgtgttccagtgcacccagtatatccgccacgcgtcctcgcccatgcac
tcccctgagccggactgctgccacgagctgctggggcacgtgcccatgctggccgaccgcaccttcgcg
cagttctcgcaggacattggcctggcgtccctgggggcctcggatgaggaaattgagaagctgtccacg
ctgtactggttcacggtggagttcgggctgtgtaagcagaacggggaggtgaaggcctatggtgccggg
ctgctgtcctcctacggggagctcctgcactgcctgtctgaggagcctgagattcgggccttcgaccct
gaggctgcggccgtgcagccctaccaagaccagacgtaccagtcagtctacttcgtgtctgagagcttc
agtgacgccaaggacaagctcaggagctatgcctcacgcatccagcgccccttctccgtgaagttcgac
ccgtacacgctggccatcgacgtgctggacagcccccaggccgtgcggcgctccctggagggtgtccag
gatgagctggacacccttgcccatgcgctgagtgccattggctag 
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Figure 3.4: TH amino acid sequence. 
 
Amino acids are designated by their one letter symbol. The protein has 497 amino acids residues. 
 
 
  
 
MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAVPSEPGDPLEAVAFEE
KEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQRPRAGGPHLEYFVRLEVRRGDLAALLSGVRQ
VSEDVRSPAGPKVPWFPRKVSELDKCHHLVTKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYT
AEEIATWKEVYTTLKGLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFL
ASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASDEEIEKLSTLSWFTVE
FGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQPYQDQTYQSVYFVSESFSDAKDKLRSYASR
IQRPFSVKFDPYTLAIDVLDSPQAVRRSLEGVQDELDTLAHALSAIG 
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3.1.4 Anti-TH antibodies in vitiligo  
As stated above, TH was previously identified as a putative antibody target in vitiligo using 
phage-display enrichment of a melanocyte cDNA phage-display library with vitiligo patient IgG 
(Section 1.4) (Kemp et al. 2002; Waterman et al. 2010). The current study aimed to further 
investigate TH as a possible antibody target in vitiligo by measuring antibody reactivity against 
the enzyme in a panel of sera from patients with this cutaneous depigmenting disease.  
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3.2 Aims 
The aims of this part of the study were: 
 
 
 
 To develop a radioimmunoassay (RIA) to detect and measure antibodies against 
TH. 
 
 
 To investigate the frequency of TH antibodies in a panel of vitiligo patients 
using the RIA. 
 
 
 To determine any associations between the presence of TH antibodies and the 
clinical or demographic features of the vitiligo patients. 
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3.3 Experiments and Results 
 
3.3.1 Preparation of plasmid pcDNA3-TH 
Initially, E.coli JM109 pcDNA3-TH (Table 2.2) was streaked out from a frozen stock on to a LB 
agar plate containing 100 µg/ml ampicillin. The plate was incubated overnight at 37
o
C. A single 
colony was inoculated into 10 ml of LB with ampicillin at 100 μg/ml and grown for 6 h at 37oC. 
This starter culture was then inoculated into 500 ml of LB with ampicillin at 100 μg/ml and 
grown overnight at 37
o
C. Plasmid pcDNA3-TH was prepared from the culture using a Qiagen 
Plasmid DNA Maxiprep Kit (Section 2.9). The plasmid was analysed by agarose gel 
electrophoresis in a 0.8% (w/v) agarose gel (Section 2.10) and quantified using a NanoDrop ND-
1000 Spectrometer (Section 2.9). The results indicated successful purification of the pcDNA3-
TH plasmid, which is shown in Figure 3.5. The plasmid preparation had a concentration of 1.2 
mg/ml. 
 The plasmid was also checked for the presence of the correctly sized insert by restriction 
enzyme digestion with HindIII and BamHI. The 25-μl reactions contained 1 μg of pcDNA3-TH, 
10 units of HindIII and/or BamHI, and 2.5 μl of restriction buffer E (Table 2.4). The reactions 
were incubated for 90 min at 37
o
C before analysis by agarose gel electrophoresis in a 0.8% (w/v) 
agarose gel. The results showed a DNA insert at approximately 1.5 kb was released from 
pcDNA3-TH after restriction with both HindIII and BamHI (Figure 3.5). This estimated size was 
close to that of the expected size of 1491 base pairs as determined from previous sequencing of 
the TH cDNA fragment (Figure 3.3). 
 As a final check that the plasmid was correct, the prepared pcDNA3-TH was subjected to 
DNA sequencing (Section 2.16) using primers T7, SP6, THR1, THF400, THF839 and THR1239 
(Table 2.6). The results verified that the plasmid contained TH cDNA with the sequence 
matching that in Figure 3.3. 
 
3.3.2 In vitro transcription-translation of TH cDNA 
In order to produce [
35
S]-TH for use in a RIA, plasmid pcDNA3-TH was transcribed and 
translated in a TnT
®
 T7-Coupled Reticulocyte Lysate System as detailed in Section 2.18. To  
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Figure 3.5: Agarose gel electrophoresis of plasmid pcDNA3-TH. 
 
The unrestricted plasmid and plasmid restricted with HindIII and/or BamHI were subjected to 
electrophoresis in a 0.8% (w/v) agarose gel. The gel shows: HindIII-restricted bacteriophage λ DNA with 
DNA fragments from 0.1-23 kb (lane 1); unrestricted pcDNA3-TH (lane 2); HindIII-restricted pcDNA3-
TH (lane 3); BamHI-restricted pcDNA3-TH (lane 4); HindIII and BamHI-restricted pcDNA3-TH (lane 5). 
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analyse the radiolabelled product qualitatively, a 5-µl aliquot of the in vitro transcription-
translation reaction containing [
35
S]-TH was added to 20 µl of SDS-sample buffer (Section 2.19) 
and heated to 85
o
C for 5 min before analysing a 10-µl sample by SDS-PAGE in a 10% (w/v) 
SDS-polyacrylamide gel and subsequent autoradiography (Section 2.19).  
 The results revealed a protein product with an estimated molecular weight of 
approximately 59 kDa (Figure 3.6), which agreed well with the molecular weight of 55 kDa 
predicted from the amino acid sequence of the protein with 497 residues (Figure 3.4).  
 
3.3.3 Immunoreactivity of [
35
S]-TH in a TH antibody RIA 
In order to analyse the immunoreactivity of the in vitro transcribed and translated [
35
S]-TH, a TH 
antibody RIA was carried out (Section 2.20) using a panel of animal antisera raised against 
different antigens (Table 2.8). Antiserum dilutions used in duplicate in the RIA are given in 
parentheses: ab59276 (anti-TH; 1:500), α-PEP7 (anti-tyrosinase; 1:100), MCHR11-S (anti-
MCHR1; 1:100), sc-15109 (anti-PAH; 1:100) and sc-15114 (anti-TPH; 1:100). An 
immunoprecipitation reaction without antiserum was also included as a background control. In 
each TH antibody RIA experiment, a TH Ab index was calculated for each antiserum as: cpm 
immunoprecipitated by tested antiserum/cpm immunoprecipitated by the background control. 
Each antiserum was tested in four experiments and the mean TH Ab index was calculated from 
these values. The TH Ab indices of the different antisera were compared using Mann-Whitney 
tests (Section 2.27). In all tests, P values <0.05 (two-tailed) were regarded as significant. 
 The mean TH Ab index ± SD for each antiserum was: ab59276 (4.12 ± 0.53), α-PEP7 
(1.06 ± 0.03), MCHR11-S (1.06 ± 0.11), sc-15109 (0.91 ± 0.10) and sc-15114 (0.85 ± 0.15) 
(Figure 3.7). In Mann-Whitney tests, the TH Ab index of ab59276 was significantly higher when 
compared with that of either α-PEP7, MCHR11-S, sc-15109 or sc-15114: P values were all 
<0.05, indicating a specific immunoprecipitation reaction between [
35
S]-TH and the anti-TH 
antiserum. No significant differences were detected when comparing the TH Ab indices of the 
other animal antisera to each other: P values were all > 0.05. 
 To analyse qualitatively the TH protein immunoprecipitated in the TH antibody RIA by 
antiserum ab59276, protein G Sepharose-antibody-antigen complexes were suspended in 50 μl of 
SDS-sample buffer, heated at 85
o
C for 5 min, centrifuged and the supernatant recovered for  
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Figure 3.6: SDS-PAGE and autoradiography of [
35
S]-TH and immunoprecipitated [
35
S]-
TH. 
 
Radiolabelled TH was produced in vitro in a TnT
®
 T7-Coupled Reticulocyte Lysate System using 
plasmid pcDNA3-TH. [
35
S]-TH was then immunoprecipitated in a TH antibody RIA with anti-TH 
antiserum ab59276. Immunoprecipitated proteins were analysed by SDS-PAGE in a 10% (w/v) SDS-
polyacrylamide gel followed by autoradiography. The results are shown for: In vitro translated, non-
immunoprecitated [
35
S]-TH (lane 1); [
35
S]-TH immunoprecipitated with anti-TH antiserum ab59276 (lane 
2). Prestained SDS-PAGE Standards, Low Range (Bio-Rad Ltd.) are indicated. This gel was run and 
processed by Dr. Helen Kemp (Department of Human Metabolism, University of Sheffield, Sheffield, 
UK). 
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Figure 3.7: TH antibody RIA using different animal antisera. 
 
The immunoreactivity of the in vitro transcribed and translated [
35
S]-TH was tested in the TH antibody 
RIA with animal antisera ab59276 (anti-TH), α-PEP7 (anti-tyrosinase), MCHR11-S (anti-MCHR1), sc-
15109 (anti-PAH) and sc-15114 (anti-TPH). An immunoprecipitation reaction without any serum was 
included as a background control. The mean TH Ab index (± SD) of four experiments is shown for each 
antiserum: ab59276 (4.12 ± 0.53), α-PEP7 (1.06 ± 0.03), MCHR11-S (1.06 ± 0.11), sc-15109 (0.91 ± 
0.10) and sc-15114 (0.85 ± 0.15). 
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SDS-PAGE in a 10% (w/v) SDS-polyacrylamide gel (Section 2.19). The gel was then subjected 
to autoradiography (Section 2.19). 
The results showed that the antiserum ab59276 immunoprecipitated a protein band 
equivalent in size (59 kD) to that of in vitro translated [
35
S]-TH (Figure 3.6). 
 Overall, the results of these experiments indicated that, potentially, radiolabelled TH could 
be used as an antigen in a RIA to detect TH antibodies. 
 
3.3.4 Analysis of the specificity of anti-TH antiserum ab59276 
In order to analyse the specificity of the antiserum ab59276, it was used in RIAs with a panel of 
different radiolabelled antigens including: tyrosinase, MCHR1, PAH and TPH. 
 Radiolabelled [
35
S]-tyrosinase and [
35
S]-MCHR1 were produced in a TnT
®
 T7-Coupled 
Reticulocyte Lysate System (Section 2.18) from plasmids pcDNA3TYR (Table 2.3) and 
pcMCHR1 (Table 2.3), respectively. Labelled proteins [
35
S]-PAH and [
35
S]-TPH were 
transcribed and translated from plasmids pSP64-Poly(A)-PAH (Table 2.3) and pSP64-Poly(A)-
TPH (Table 2.3), respectively, in a TnT
®
 SP6-Coupled Reticulocyte Lysate System (Section 
2.20). RIAs using these labeled antigens with duplicate samples of antiserum ab59276 at a 1:100 
(1:500 for TH antigen) dilution were carried out as detailed in (Section 2.20). Appropriate 
positive control antisera were included in each RIA at the dilution given in parentheses: α-PEP7 
(1:100), MCHR11-S (1:100), sc-15109 (1:500) and sc-15114 (1:500). An immunoprecipitation 
reaction without antiserum was also included in each RIA as a background control. In each RIA 
experiment, an Ab index was calculated for each antiserum as: cpm immunoprecipitated by 
tested antiserum/cpm immunoprecipitated by the background control. Each antiserum was tested 
in four experiments and the mean Ab index was calculated from these values. Ab indices were 
compared using Mann-Whitney tests (Section 2.27). In all tests, P values <0.05 (two-tailed) were 
regarded as significant. 
 The mean Ab index ± SD for the antiserum ab59276 in RIAs against the different 
antigens was: TH (4.12 ± 0.53), tyrosinase (0.77 ± 0.10), MCHR1 (1.03 ± 0.05), PAH (0.88 ± 
0.07) and TPH (0.77 ± 0.02) (Figure 3.8). The mean Ab index (± SD) for the antisera α-PEP7, 
MCHR11-S, sc-15109 and sc-15114 in RIAs against their respective antigens was: tyrosinase 
(14.34 ± 1.49), MCHR1 (10.06 ± 0.39), PAH (5.34 ± 0.23) and TPH (7.93 ± 0.50) (Figure 3.8).   
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Figure 3.8: RIAs with different antigens and with anti-TH antiserum ab59276. 
 
The immunoreactivity of the anti-TH antiserum ab59276 was tested against in vitro transcribed and 
translated [
35
S]-TH, [
35
S]-tyrosinase, [
35
S]-MCHR1 [
35
S]-PAH [
35
S]-TPH in RIAs. Animal antisera α-
PEP7 (anti-tyrosinase), MCHR11-S (anti-MCHR1), sc-15109 (anti-PAH) and sc-15114 (anti-TPH) were 
included in RIAs as positive controls for immunoprecipitation of their respective antigens. An 
immunoprecipitation reaction without any serum was included as a background control in each RIA. The 
mean Ab index (± SD) of four experiments is shown for the antiserum ab59276 in RIAs against the 
different antigens: TH (4.12 ± 0.53), tyrosinase (0.77 ± 0.10), MCHR1 (1.03 ± 0.05), PAH (0.88 ± 0.07) 
and TPH (0.77 ± 0.02). The mean Ab index (± SD) of four experiments is also shown for the antisera α-
PEP7, MCHR11-S, sc-15109 and sc-15114 in RIAs against their respective antigens: tyrosinase (14.34 ± 
1.49), MCHR1 (10.06 ± 0.39), PAH (5.34 ± 0.23) and TPH (7.93 ± 0.50).  
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In Mann-Whitney U tests, the Ab index of the antiserum ab59276 in the different RIAs 
was compared to that of the positive control antiserum for the particular RIA in question. In all 
cases, the Ab index of ab59276 was significantly lower: P values were all < 0.05, indicating 
there was no significant immunoprecipitation of other antigens by the anti-TH antiserum.  
  Overall, the results of these experiments indicated that antiserum ab59276 did not 
immunopreciptate either homologous proteins PAH and TPH or vitiligo-associated antigens 
tyrosinase and MCHR1. It could be used therefore as a positive control for TH antibodies in TH 
antibody RIAs. 
 
3.3.5 TH antibody RIA using patient and control sera 
To analyse patient and control sera for the presence of TH antibodies, TH antibody RIAs were 
carried as detailed in (Section 2.22) using [
35
S]-TH as the radiolabelled antigen. The sera 
analysed were from patients with: non-segmental vitiligo (n=79), segmental vitiligo (n=8), 
Graves’ disease (n=27), autoimmune hypothyroidism (n=25), Addison’s disease (n=19) and 
systemic lupus erythematosus (n=20), and from healthy controls (n=28) (Section 2.1; Table 2.1). 
All sera were assayed in duplicate at a final dilution of 1:100. Antiserum ab59276 was included 
in each assay set as a positive control at a dilution of 1:500. 
 In each assay set, antibody levels were expressed as a TH Ab index. This was calculated 
for each serum tested as: cpm immunoprecipitated by tested serum/mean cpm 
immunoprecipitated by 28 healthy control sera. Each serum was tested in at least two 
experiments and the mean TH Ab index was calculated from these values. The upper limit of 
normal for the assay was calculated using the mean TH Ab index + 3SD of the population of 28 
healthy controls. Any serum sample with a TH Ab index above the upper limit of normal was 
designated as positive for TH antibody reactivity. 
 The results of the TH antibody RIAs are shown in Table 3.1 and Figure 3.9, and indicated 
that the upper limit of normal for the RIA was a TH Ab index of 1.09, calculated as above from 
the TH Ab indices of the control group. Healthy controls, patients with segmental vitiligo, and 
patients with other autoimmune diseases were all TH antibody-negative. Of the 79 non-
segmental vitiligo patient sera, 18 (23%) were considered TH antibody-positive, as their TH Ab 
indices (Table 3.2) were above the upper limit of normal value of 1.09.   
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Table 3.1: Results of TH antibody RIAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Patient sera with a TH Ab index above the upper limit of normal value of 1.09, calculated from the mean 
TH Ab index + 3SD of 28 healthy controls, were considered positive for TH antibodies. 
  
 
Patient or control group 
 
 
TH antibody 
indices 
(mean ± SD) 
 
 
TH antibody 
indices 
(range) 
 
Number 
positive for 
TH 
antibodies
1 
 
Non-segmental vitiligo 1.25 ± 0.63 0.83-3.39 18/79 
Segmental vitiligo 1.03 ± 0.04 0.94-1.06 0/8 
Graves’ disease 1.00 ± 0.04 0.85-1.08 0/27 
Addison’s disease 1.00 ± 0.04 0.92-1.07 0/19 
Autoimmune hypothyroidism 1.01 ± 0.04 0.93-1.07 0/25 
Systemic lupus erythematosus 1.00 ± 0.02 0.96-1.04 0/20 
Healthy controls 1.00 ± 0.03 0.95-1.08 0/28 
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Figure 3.9: RIA for TH antibodies in patient and control sera. 
 
Patient and control sera were evaluated for TH antibodies in the TH antibody RIA. The TH Ab indices are 
shown for sera from non-segmental vitiligo (NSV) (n=79), segmental vitiligo (SV) (n=8), systemic lupus 
erythematosus (SLE) (n=20), Graves’ disease (GD) (n=27), autoimmune hypothyroidism (AH) (n=25), 
and Addison’s disease (AD) (n=19) patients, and healthy controls (C) (n=28). The TH Ab index shown 
for each serum is the mean of at least two experiments. The upper limit of normal (mean TH Ab index + 
3SD of 28 healthy controls) for the TH antibody RIA was a TH Ab index of 1.09, and this is shown by 
the dotted line. Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, Southern Gate, 
Chichester, West Sussex, PO19 8SQ, UK) from (Kemp et al. 2011a).  
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Table 3.2: TH antibody indices of TH antibody-positive vitiligo patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
The TH Ab index shown for each TH antibody-positive vitiligo patient serum is the mean (±SD) of at 
least two experiments.  
  
 
Patient 
 
 
TH antibody 
index
1
 
 
V4 2.93 (± 0.06) 
V8 2.53 (± 0.22) 
V9 2.83 (± 0.05) 
V10 2.43 (± 0.14) 
V20 3.39 (± 0.04) 
V25 2.74 (± 0.13) 
V27 1.73 (± 0.05) 
V30 1.81 (± 0.08) 
V33 2.78 (± 0.07) 
V39 2.75 (± 0.33) 
V62 3.05 (± 0.31) 
V63 1.30 (± 0.03) 
V64 1.28 (± 0.07) 
V69 1.22 (± 0.03) 
V70 1.25 (± 0.04) 
V82 1.21 (± 0.03) 
V86 1.78 (± 0.06) 
V87 2.84 (± 0.13) 
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 To analyse qualitatively proteins immunoprecipitated in the TH antibody RIA by vitiligo 
patients and control sera, protein G Sepharose-antibody-antigen complexes were suspended in 50 
μl of SDS-sample buffer, heated at 85oC for 5 min, centrifuged and the supernatant recovered for 
SDS-PAGE in 10% (w/v) SDS-polyacrylamide gels and subsequent autoradiography (Section 
2.19). 
 The results indicated that all of the 18 TH antibody-positive vitiligo sera tested 
immunoprecipitated a protein band of 59 kDa, which is of the expected size for TH in SDS-
polyacrylamide gels. Figure 3.10 illustrates the results for three TH antibody-positive vitiligo 
patient sera and three healthy control sera. 
 
3.3.6 Analysis of TH antibody frequency in vitiligo patients and healthy 
controls 
The frequency of TH antibodies was compared between vitiligo patient groups and healthy 
controls in Fisher's exact tests for 2 x 2 contingency tables (Section 2.27). P values <0.05 (two-
tailed) were regarded as significant. 
 Table 3.3 shows the comparison of TH immunoreactivity in vitiligo patients and controls. 
Compared to controls, a significant increase in TH antibody frequency was noted in non-
segmental vitiligo patients: P value was < 0.05. The frequency of TH antibodies was also 
significantly increased in the patient groups with active vitiligo compared to the patient cohorts 
with stable disease: P value was < 0.05. However, there was no difference in TH antibody 
frequency when comparing vitiligo patients with autoimmune diseases to those without 
autoimmune disorders: P value was > 0.05. 
 
3.3.7 Determination of TH antibody titres in vitiligo patients  
In order to measure TH antibody titres, all of the 18 TH antibody-positive vitiligo patient and 6 
healthy control sera were analysed in the TH antibody RIA at final dilutions of 1:100, 1:200, 
1:500, 1:1000 and 1:2000. TH Ab indices were calculated for each serum tested as: cpm 
immunoprecipitated by tested serum at each dilution/the cpm immunoprecipitated by six healthy 
control sera at each dilution. Samples were tested in two experiments and the mean TH Ab index 
was calculated from these values for each serum.  
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Figure 3.10: SDS-PAGE and autoradiography of [
35
S]-TH and immunoprecipitated [
35
S]-
TH. 
 
Radiolabelled TH was produced in vitro in a TnT
®
 T7-Coupled Reticulocyte Lysate System and then 
immunoprecipitated in TH antibody RIAs with either vitiligo or healthy control sera.  Immunoprecipitated 
proteins were analysed by SDS-PAGE in a 10% (w/v) SDS-polyacrylamide gel followed by 
autoradiography. The results are shown for 3 vitiligo patient and 3 healthy control sera: In vitro translated, 
non-immunoprecitated [
35
S]-TH (lane 1); [
35
S]-TH immunoprecipitated with: anti-TH antiserum ab59276 
(lane 2); serum from TH antibody-positive vitiligo patient V4 (lane 3); serum from TH antibody-positive 
vitiligo patient V20 (lane 4); serum from TH antibody-positive vitiligo patient V62 (lane 5); serum from 
healthy controls - C1, C2 and C3 (lanes 6-8). Prestained SDS-PAGE Standards, Low Range (Bio-Rad 
Ltd.) are indicated. This gel was run and processed by Dr. Helen Kemp (Department of Human 
Metabolism, University of Sheffield, Sheffield, UK). Taken with kind permission from John Wiley & 
Sons Ltd. (The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Kemp et al. 
2011a). 
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Table 3.3: Analysis of immunoreactivity against TH in vitiligo patient and control sera  
 
Detail of group analysed in TH antibody 
RIA 
 
TH antibody- 
positive samples 
 
 
P value
1
 
 
P value
2
 
Patient or control group    
Non-segmental vitiligo 18/79 (23%) 0.003 - 
Segmental vitiligo 0/8 (0%) - - 
Autoimmune disease (without vitiligo) 0/91 (0%) - - 
Healthy controls 0/28 (0%) - - 
Non-segmental vitiligo sub-type    
Symmetrical 13/63 (21%) 0.008 - 
Symmetrical/periorificial 4/9 (44%) 0.002 - 
Symmetrical with segmental patch 1/3 (33%) 0.100 - 
Periorificial 0/2 (0%) - - 
Universal 0/1 (0%) - - 
Occupational 0/1 (0%) - - 
Vitiligo activity    
Active vitiligo (all patients) 18/67 (27%) 0.001 0.009 
Stable vitiligo (all patients) 0/20 (0%) - 
Active non-segmental vitiligo 18/64 (28%) 0.001 0.017 
Stable non-segmental vitiligo 0/15 (0%) - 
Vitiligo and autoimmune disease    
Vitiligo with autoimmune disease 
(all patients) 
4/26 (15%) 0.047  
0.567 
Vitiligo with no autoimmune disease 
(all patients) 
14/61 (23%) 0.040 
Non-segmental vitiligo with autoimmune  
disease 
4/24 (17%) 0.039  
0.561 
Non-segmental vitiligo with no autoimmune 
disease 
14/55 (25%) 0.002 
 
1
P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.27) for comparing the 
prevalence of TH antibody reactivity in vitiligo patient and control groups. P < 0.05 was considered 
significant. 
2
P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.27) for comparing the 
prevalence of TH antibody reactivity in vitiligo patient groups (e.g., active versus stable vitiligo; vitiligo 
with versus with no autoimmune disease). P < 0.05 was considered significant. 
-, P values were not determined due to lack of TH antibody-positive samples. 
Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, Southern Gate, Chichester, West 
Sussex, PO19 8SQ, UK) from (Kemp et al. 2011a).  
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 The results of the dilution experiments showed that TH antibodies could still be detected at 
levels above the upper limit of normal in serum dilutions of 1:500, 1:1000, 1:2000, in 8, 6 and 4 
patient samples, respectively (Figure 3.11). The TH antibody titres in the vitiligo patient sera are 
summarised in Table 3.4. 
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Figure 3.11: TH antibody titres in vitiligo patients. 
 
The 18 TH antibody-positive vitiligo (V) sera and 6 healthy control (C) sera were analysed in the TH 
antibody RIA at dilutions of 1:100, 1:200, 1:500, 1:1000, and 1:2000. The TH Ab index (± SD) of each 
serum at each dilution is shown and is the mean of two experiments. The results are shown for the 18 
vitiligo patients and for 1 control. 
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Table 3.4: TH antibody titres in TH antibody-positive vitiligo patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
The TH antibody titre is given as the dilution at which immunoreactivity of the serum sample could still 
be detected at levels above the upper limit of normal in the TH antibody RIA. 
  
 
Patient 
 
 
TH antibody 
titre
1
 
 
V4 1:500 
V8 1:1000 
V9 1:2000 
V10 1:1000 
V20 1:2000 
V25 1:1000 
V27 1:500 
V30 1:1000 
V33 1:1000 
V39 1:2000 
V62 1:1000 
V63 1:500 
V64 1:500 
V69 1:500 
V70 1:500 
V82 1:500 
V86 1:500 
V87 1:2000 
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3.3.8 Evaluation of the specificity of TH antibodies in vitiligo patients 
Absorption experiments were carried out to determine whether or not vitiligo patient TH 
antibodies reacted specifically against TH. In these experiments, sera from the 18 TH-antibody 
positive vitiligo patients and six healthy controls were mixed with extract made from either 
untransfected HEK293 cells or HEK293 cells containing either expressed TH, tyrosinase or 
MCHR1 (Section 2.22). Following absorption with cell extracts, duplicate serum samples 
(equivalent to a 1:100 dilution of the original serum) were tested in the TH antibody RIA for 
binding to [
35
S]-TH. A TH Ab index was calculated for each serum tested as: cpm 
immunoprecipitated by tested serum/the cpm immunoprecipitated by six healthy control sera. 
Samples were tested in two experiments and the mean TH Ab index was calculated from these 
values. The TH Ab indices for the absorbed and unabsorbed vitiligo patient sera were compared 
using paired t tests (Section 2.27). In all tests, P values <0.05 (two-tailed) were regarded as 
significant. 
 The results of the absorption experiments are shown in Figures 3.12, where the TH Ab 
index for each sample is shown for unabsorbed sera and sera pre-absorbed with either 
untransfected HEK293 cell extract or extract made from HEK293 cells expressing TH, 
tyrosinase or MCHR1. TH Ab indices were compared in paired t tests. The tests indicated that 
compared to unabsorbed sera, the TH Ab indices of the TH-antibody positive vitiligo patient sera 
were significantly reduced when pre-absorbed with extract made from HEK293 cells expressing 
TH: P values were < 0.05 (Table 3.5). In contrast, significant reductions in TH Ab indices were 
not observed when TH-antibody positive vitiligo patient sera were pre-absorbed with extract 
prepared from untransfected HEK293 cells, HEK293 cells expressing tyrosinase or HEK293 
cells expressing MCHR1: P values were > 0.05. 
The absorption experiments indicated that sera from all the 18 TH antibody-positive 
vitiligo patients contained TH antibodies which specifically recognised the antigen and did not 
cross-react with either tyrosinase or MCHR1. 
 
3.3.9 Analysis of vitiligo patient sera for tyrosinase and MCHR1 antibodies 
Radioimmunoassays for tyrosinase and MCHR1 antibodies (Kemp et al. 1997a; Kemp et al. 
2002) were carried out on all the vitiligo patient sera, in order to determine if there was any   
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Figure 3.12: Antibody absorption experiments.  
 
The 18 TH antibody-positive vitiligo (V) patient sera and 6 healthy control (C) sera were pre-absorbed 
with extract prepared from either untransfected HEK293 cells or from HEK293 cells expressing tyrosine 
hydroxylase (TH), tyrosinase (TYR) or melanin-concentrating hormone receptor 1 (MCHR1). 
Unabsorbed and pre-absorbed serum samples were then analysed in the TH antibody RIA. The results 
show the mean TH Ab index (± SD) of two experiments for unabsorbed and pre-absorbed sera. The 
results are shown for the 18 vitiligo patients and for 1 control.  
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Table 3.5: Comparison of TH Ab indices in antibody absorption experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
P values were calculated in paired t tests (Section 2.27) for comparing the TH Ab indices of TH 
antibody-positive patient sera without pre-absorption to those with pre-absorption using extract from 
HEK293 cells expressing TH. P values < 0.05 (two-tailed) were regarded as significant.   
 
Patient 
 
P value
1
 
 
V4 0.02 
V8 0.04 
V9 0.04 
V10 0.02 
V20 0.04 
V25 0.002 
V27 0.03 
V30 0.04 
V33 0.04 
V39 0.04 
V62 0.04 
V63 0.03 
V64 0.03 
V69 0.04 
V70 0.02 
V82 0.04 
V86 0.004 
V87 0.002 
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association between the presence of TH antibodies and the occurrence of antibodies against 
either tyrosinase or MCHR1. 
 Firstly, in order to produce [
35
S]-tyrosinase and [
35
S]-MCHR1 for use in RIAs, plasmids 
pcDNA3TYR (Table 2.3) and pcMCHR1 (Table 2.3), respectively, were transcribed and 
translated in a TnT
®
 T7-Coupled Reticulocyte Lysate System (Section 2.18). The radiolabelled 
antigens (Figure 3.13) were then used to analyse patient and control sera for the presence of 
either tyrosinase or MCHR1 antibodies in RIAs, which were carried out as detailed in (Section 
2.20). The sera analysed were from patients with non-segmental vitiligo (n=79) and segmental 
vitiligo (n=8), and from healthy controls (n=28) (Table 2.1; Section 2.1). All sera were assayed 
in duplicate at a final dilution of 1:100. As appropriate, either antiserum α-PEP7 (Table 2.8) or 
antiserum MCHR11-S (Table 2.8) was included in each assay set as a positive control at a 
dilution of 1:100 (Figure 3.13). 
 In each assay set, antibody levels were expressed as an Ab index. This was calculated for 
each serum tested as: cpm immunoprecipitated by tested serum/mean cpm immunoprecipitated 
by 28 healthy control sera. Each serum was tested in at least two experiments and the mean Ab 
index was calculated from these values. The upper limit of normal for the assay was calculated 
using the mean Ab index + 3SD of the population of 28 healthy controls. Any serum sample with 
an Ab index above the upper limit of normal was designated as positive for either tyrosinase or 
MCHR1 antibody reactivity. 
 The results of the tyrosinase and MCHR1 antibody RIAs are shown in Table 3.6. All 
healthy controls and patients with segmental vitiligo were negative for tyrosinase and MCHR1 
antibodies. Of the 79 non-segmental vitiligo patient sera, 11 (14%) and 14 (18%) were 
considered positive for antibodies against tyrosinase and MCHR1, respectively, with Ab indices 
above the upper limits of normal at values of 1.29 for the tyrosinase antibody RIA (Table 3.7), 
and 1.45 for the MCHR1 antibody RIA (Table 3.8). The tyrosinase and MCHR1 antibody 
frequencies were found to be similar to those reported in previous studies (Kemp et al. 1997a; 
Kemp et al. 2002). 
 The frequencies of tyrosinase and MCHR1 antibodies were compared between the non-
segmental vitiligo patients and healthy controls in Fisher's exact tests for 2 x 2 contingency 
tables (Section 2.27). P values < 0.05 (two-tailed) were regarded as significant. The results   
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Figure 3.13: SDS-PAGE and autoradiography of [
35
S]-tyrosinase and [
35
S]-MCHR1 and 
immunoprecipitated [
35
S]-tyrosinase and [
35
S]-MCHR1. 
 
Radiolabelled tyrosinase and MCHR1 were produced in vitro in a TnT
®
 T7-Coupled Reticulocyte Lysate 
System using plasmids pcDNA3TYR and pcMCHR1, respectively. [
35
S]-tyrosinase and [
35
S]-MCHR1 
were then immunoprecipitated in RIAs with antiserum α-PEP7 or antiserum MCHR11-S, respectively. 
Immunoprecipitated proteins were analysed by SDS-PAGE in a 10% (w/v) SDS-polyacrylamide gel 
followed by autoradiography. The results are shown for: (a) In vitro translated, non-immunoprecitated 
[
35
S]-tyrosinase (57 kDa) (lane 1); [
35
S]-tyrosinase immunoprecipitated with antiserum α-PEP7 (lane 2). 
(b) In vitro translated, non-immunoprecitated [
35
S]-MCHR1 (45 kDa) (lane 1); [
35
S]-MCHR1 
immunoprecipitated with antiserum MCHR11-S (lane 2). Prestained SDS-PAGE Standards, Low Range 
(Bio-Rad Ltd.) are indicated. These gels were run and processed by Dr. Helen Kemp (Department of 
Human Metabolism, University of Sheffield, Sheffield, UK). 
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Table 3.6: Results of RIAs for antibodies against tyrosinase, MCHR1, PAH and TPH  
 
 
 
 
1
Patient sera with an Ab index above the upper limit of normal, calculated from the mean Ab index + 3SD 
of 28 healthy controls, were considered positive for antibodies. The upper limits of normal were: 1.29, 
1.45, 1.15 and 1.21, for the tyrosinase, MCHR1, PAH and TPH antibody RIAs, respectively. 
 
 
  
 
Patient or control group → 
 
Non-
segmental 
vitiligo 
patients 
(n=79) 
 
Segmental 
vitiligo 
patients 
(n=8) 
 
Healthy 
controls 
(n=28) 
 
Antibody RIA 
↓ 
 
Tyrosinase antibody RIA
1 
 
    
Tyrosinase Ab indices (mean ± SD) 1.20 ± 0.50 1.02 ± 0.07 1.02 ± 0.09 
Tyrosinase Ab indices (range) 0.82-3.37 0.87-1.12 0.82-1.14 
Number positive for tyrosinase antibodies 11 (14%) 0 (0%) 0 (0%) 
 
MCHR1 antibody RIA
1 
 
   
MCHR1Ab indices (mean ± SD) 1.14 ± 0.68 0.90 ± 0.25 0.96 ± 0.16 
MCHR1Ab indices (range) 0.44-3.81 0.76-1.42 0.72-1.25 
Number positive for MCHR1 antibodies 14 (18%) 0 (0%) 0 (0%) 
 
PAH antibody RIA
1 
 
   
PAH Ab indices (mean ± SD) 1.00 ± 0.04 1.01 ± 0.04 1.05 ± 0.05 
PAH Ab indices (range) 0.93-1.08 0.96-1.07 0.85-1.06 
Number positive for PAH antibodies 0 (0%) 0 (0%) 0 (0%) 
 
TPH antibody RIA
1 
 
   
TPH Ab indices (mean ± SD) 0.98 ± 0.06 0.96 ± 0.07 1.00 ± 0.07 
TPH Ab indices (range) 0.85-1.12 0.89-1.05 0.79-1.18 
Number positive for TPH antibodies 0 (0%) 0 (0%) 0 (0%) 
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Table 3.7: Tyrosinase antibody indices of tyrosinase antibody-positive vitiligo patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
The tyrosinase Ab index shown for each tyrosinase antibody-positive vitiligo patient serum is the 
mean (±SD) of two experiments. 
  
 
Patient 
 
 
Tyrosinase 
antibody index
1
 
 
V10 1.68 (± 0.09) 
V18 1.43 (± 0.11) 
V21 1.52 (± 0.12) 
V27 1.93 (± 0.05) 
V38 1.86 (± 0.14) 
V53 2.16 (± 0.08) 
V54 3.36 (± 0.32) 
V55 2.37 (± 0.07) 
V63 1.59 (± 0.03) 
V78 2.11 (± 0.13) 
V82 2.43 (± 0.21) 
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Table 3.8: MCHR1 antibody indices of MCHR1 antibody-positive vitiligo patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
The MCHR1 Ab index shown for each MCHR1 antibody-positive vitiligo patient serum is the mean 
(±SD) of two experiments. 
  
 
Patient 
 
 
MCHR1 
antibody index
1
 
 
V6 2.18 (± 0.10) 
V9 3.11 (± 0.29) 
V12 2.01 (± 0.05) 
V13 1.71 (± 0.08) 
V18 3.22 (± 0.77) 
V29 2.82 (± 0.36) 
V44 1.64 (± 0.23) 
V46 1.77 (± 0.16) 
V50 1.53 (± 0.01) 
V52 1.86 (± 0.12) 
V54 1.58 (± 0.09) 
V55 3.79 (± 0.72) 
V62 3.81 (± 0.28) 
V82 1.72 (± 0.14) 
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indicated that antibodies against MCHR1, but not against tyrosinase, were significantly more 
frequent in non-segmental vitiligo patients than in controls: P values were 0.019 and 0.063, 
respectively. 
 
3.3.10 Analysis of vitiligo patient sera for PAH and TPH antibodies 
Radioimmunoassays for detecting PAH and TPH antibodies (Ekwall et al. 1999; Ekwall et al. 
2000) were carried out on all the vitiligo patient sera, in order to determine if antibodies to these 
closely related proteins, in terms of amino acid sequence, were present in vitiligo patients. 
 Firstly, in order to produce [
35
S]-PAH and [
35
S]-TPH for use in RIAs, plasmids pSP64-
Poly(A)-PAH (Table 2.3) and pSP64-Poly(A)-TPH (Table 2.3), respectively, were transcribed 
and translated in a TnT
®
 SP6-Coupled Reticulocyte Lysate System (Section 2.18). The 
radiolabelled antigens (Figure 3.14) were then used to analyse patient and control sera for the 
presence of either PAH or TPH antibodies in RIAs which were carried out as detailed in (Section 
2.20). The sera analysed were from patients with non-segmental vitiligo (n=79) and segmental 
vitiligo (n=8), and from healthy controls (n=28) (Table 2.1; Section 2.1). All sera were assayed 
in duplicate at a final dilution of 1:100. As appropriate, either antiserum sc-15109 (Table 2.8) or 
antiserum sc-15114 (Table 2.8) was included in each assay set as a positive control at a dilution 
of 1:500 (Figure 3.14). 
 In each assay set, antibody levels were expressed as an Ab index. This was calculated for 
each serum tested as: cpm immunoprecipitated by tested serum/mean cpm immunoprecipitated 
by 28 healthy control sera. Each serum was tested in at least two experiments and the mean Ab 
index was calculated from these values. The upper limit of normal for the assay was calculated 
using the mean Ab index + 3SD of the population of 28 healthy controls. Any serum sample with 
an Ab index above the upper limit of normal was designated as positive for either PAH or TPH 
antibody reactivity. 
 The results of the PAH and TPH antibody RIAs are shown in Table 3.6. Immunoreactivity 
to either PAH or TPH was not apparent in any vitiligo patient sera or control sera with all PAH 
and TPH Ab indices below the upper limits of normal at values of 1.15 for the PAH antibody 
RIA, and 1.21 for the TPH antibody RIA. These results indicated that patient TH antibodies were  
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Figure 3.14: SDS-PAGE and autoradiography of [
35
S]-PAH and [
35
S]-TPH and 
immunoprecipitated [
35
S]-PAH and [
35
S]-TPH. 
 
Radiolabelled PAH and TPH were produced in vitro in a TnT
®
 SP6-Coupled Reticulocyte Lysate System 
using plasmids pSP64-Poly(A)-PAH and pSP64-Poly(A)-TPH, respectively. [
35
S]-PAH and [
35
S]-TPH 
were then immunoprecipitated in RIAs with antiserum sc-15109 and antiserum sc-15114, respectively. 
Immunoprecipitated proteins were analysed by SDS-PAGE in a 10% (w/v) SDS-polyacrylamide gel 
followed by autoradiography. The results are shown for: (a) In vitro translated, non-immunoprecitated 
[
35
S]-PAH (50 kDa) (lane 1); [
35
S]-PAH immunoprecipitated with antiserum antiserum sc-15109 (lane 2). 
(b) In vitro translated, non-immunoprecitated [
35
S]-TPH (49 kDa) (lane 1); [
35
S]-TPH 
immunoprecipitated with antiserum sc-15114 (lane 2). Prestained SDS-PAGE Standards, Low Range 
(Bio-Rad Ltd.) are indicated. These gels were run and processed by Dr. Helen Kemp (Department of 
Human Metabolism, University of Sheffield, Sheffield, UK). 
  
 
   1        2 
77 kDa 
50 kDa 
34 kDa 
(a) 
 
   1        2 
34 kDa 
77 kDa  
50 kDa 
(b) 
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not cross-reactive with either PAH or TPH, probably recognising unique epitopes, despite a high 
degree of homology between the amino acid sequences of the three enzymes. 
 
3.3.11 Co-incidence of TH, tyrosinase and MCHR1 antibody reactivity in the 
non-segmental vitiligo patients 
The co-incidence of TH, tyrosinase and MCHR1 antibody reactivity in the non-segmental 
vitiligo patient group is illustrated in Figure 3.15. Only 1/79 (1.3%) of the patients was positive 
for antibody reactivity to all three antigens. An antibody response to one and to two of the 
antigenic targets, respectively, was detected in 24/79 (30%) and in 8/79 (10%) of the patients. In 
addition, the prevalence of tyrosinase and MCHR1 antibodies was not significantly increased in 
non-segmental vitiligo patients with TH antibodies when compared to those without TH 
antibodies (Table 3.9). Overall, there was no indication that the presence of antibodies to the 
different target antigens was associated.  
 
3.3.12 Comparison of the demographic, clinical and serological details of the 
TH antibody-positive and TH antibody-negative non-segmental vitiligo 
patient groups 
The demographic, clinical and serological details of the TH antibody-positive and TH antibody-
negative non-segmental vitiligo patient groups were compared in Fisher's exact tests for 2 x 2 
contingency tables (Section 2.27) or in Mann-Whitney tests, as appropriate (Section 2.27). P 
values <0.05 (two-tailed) were regarded as significant.  
 The results are summarised in Table 3.9. No significant difference was observed between 
the two groups either in terms of gender, age of patients, disease duration, age at onset of 
vitiligo, presence of additional autoimmune diseases, the clinical subtype of non-segmental 
vitiligo or the presence of specific antibodies against tyrosinase, MCHR1, PAH and TPH: P 
values were >0.05. However, the frequency of patients with active vitiligo was significantly 
higher in the TH antibody-positive patient group: P value was <0.05. 
 The demographic, clinical and serological details of the 18 TH antibody-positive non-
segmental vitiligo patients are summarised in Table 3.10.  
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Figure 3.15: A schematic representation of the antibody response to TH, tyrosinase and 
MCHR1. 
 
Of 79 non-segmental vitiligo patients, only one was positive for antibody reactivity to all three antigens. 
An antibody response to one and to two of the antigenic targets, respectively, was detected in 24/79 and 
in 8/79 of the patients. Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, Southern 
Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Kemp et al. 2011a). 
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Table 3.9: Comparison of the demographic, clinical and serological details in non-
segmental vitiligo patients with and without TH antibodies 
 
Patient detail 
 
TH antibody-
positive non-
segmental vitiligo 
patients 
(n=18) 
 
TH antibody-
negative non-
segmental vitiligo 
patients 
(n=61) 
 
P value 
Demographic details    
Sex: Male/Female 8/10 (44%/56%) 22/39 (35%/64%) 0.5861 
Mean age (range) 47 y (7-77 y) 47 y (14-74 y) 0.8362 
Mean onset age  (range) 28y (5-70 y) 35 y (<1-73 y)  0.1572 
Mean disease duration (range) 18 y (1-50 y)  13 y (<1-49 y)  0.5502 
Non-segmental vitiligo clinical sub-type    
Symmetrical 13 (72%) 50 (82%) 0.5041 
Symmetrical/periorificial 4 (22%) 5 (8%) 0.1981 
Symmetrical with segmental patch 1 (6%) 2 (3%) 0.5271 
Periorificial 0 (0%) 2 (3%) 1.0001 
Universal 0 (0%) 1 (2%) 1.0001 
Occupational 0 (0%) 1 (2%) 1.0001 
Vitiligo activity    
Active vitiligo 18 (100%) 46 (75%) 0.0171 
Stable vitiligo 0 (0%) 15 (25%) 0.0171 
Vitiligo and autoimmune disease    
With autoimmune disease 4 (22%) 20 (33%) 0.5611 
With no autoimmune disease 14 (78%) 41 (67%) 0.5611 
Antibody reactivity    
Tyrosinase antibody-positive 4 (22%) 7 (11%) 0.2611 
MCHR1 antibody-positive 3 (17%) 11 (18%) 1.0001 
PAH antibody-positive 0 (0)% 0 (0)% - 
TPH antibody-positive 0 (0)% 0 (0)% - 
 
1
P value calculated using Fisher’s exact test for 2 x 2 contingency tables (Section 2.27) for comparing the 
prevalence of demographic, clinical and serological features in the TH antibody-positive and TH 
antibody-negative non-segmental vitiligo patient groups. P values <0.05 were considered significant. 
2
P value calculated using Mann-Whitney tests (Section 2.27) for comparing the age, onset age and disease 
duration in the TH antibody-positive and TH antibody-negative non-segmental vitiligo patient groups. P 
values <0.05 were considered significant. 
-, P values were not determined due to lack of antibody-positive samples. 
Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, Southern Gate, Chichester, West 
Sussex, PO19 8SQ, UK) from (Kemp et al. 2011a). 
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Table 3.10: Clinical demographic and serological details of non-segmental vitiligo patients with TH antibodies 
 
 
Patient 
 
Sex 
 
Autoimmune 
disease 
 
 
Vitiligo subtype 
 
Disease 
activity 
 
Age at 
sample 
(y) 
 
Onset 
age (y) 
 
 
Disease 
duration  
(y) 
 
Tyrosinase 
antibodies
1
 
 
MCHR1 
antibodies
1
 
 
 
V4 
 
M - 
Symmetrical and peri-
orificial Active  77 70 7 
 
- 
 
0.97 (± 0.07) -      0.93 (± 0.05) 
 
V8 
 
F - 
Symmetrical with 
segmental patch 
 
Active  37 10 27 
 
- 
 
1.03 (± 0.09) -      1.04 (± 0.07) 
V9 F - Symmetrical  Active  76 40 36 -  0.99 (± 0.10) +     3.11 (± 0.29) 
V10 M - Symmetrical  Active  60 56 4 + 1.68 (± 0.09) -     0.47 (± 0.06) 
V20 M Alopecia areata Symmetrical  Active  70 20 50 -  0.94 (± 0.04) -      0.59 (± 0.04 ) 
V25 F - Symmetrical  Active  19 6 13 -  0.92 (± 0.03) -      0.43 (± 0.03) 
V27 F - Symmetrical  Active  23 19 4 + 1.93 (± 0.05) -     0.84 (± 0.07) 
V30 F - Symmetrical  Active  53 52 1 -  1.03 (± 0.08) -      1.15 (± 0.07) 
V33 F - Symmetrical  Active  54 51 3 -  0.96 (± 0.06) -      0.68 (± 0.10) 
V39 M - Symmetrical  Active  32 13 19 -  0.95 (± 0.01) -      1.06 (± 0.29) 
 
V62 
 
F 
Autoimmune 
thyroid disease Symmetrical 
 
Active  27 7 20 
 
- 
 
0.99 (± 0.08) +     3.81 (± 0.28) 
V63 M - Symmetrical  Active  45 44 1 + 1.59 (± 0.03) - 1.09 (± 0.10) 
V64 M Psoriasis Symmetrical  Active  47 5 42 -  1.08 (± 0.07) -      0.97 (± 0.12) 
 
V69 
 
F - 
Symmetrical and peri-
orificial  
 
Active  70 39 31 
 
- 
 
0.98 (± 0.11) -      0.93 (± 0.11) 
 
V70 
 
F 
Autoimmune 
thyroid disease 
Symmetrical and peri-
orificial  
 
Active  48 20 28 
 
- 
 
0.94 (± 0.05) -      0.90 (± 0.04) 
V82 F - Symmetrical Active  7 6 1 + 2.43 (± 0.21) +     1.72 (± 0.14) 
V86 M - Symmetrical Active  76 35 41 -  1.01 (± 0.02) -      0.86 (± 0.07) 
 
V87 
 
M - 
Symmetrical and peri-
orificial  
 
Active  23 19 4 
 
- 
 
0.96 (± 0.04) -      0.81 (± 0.07) 
 
1
+, positive for antibody reactivity; -, negative for antibody reactivity. The mean Ab indices (±SD) are shown. 
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3.4 Summary of Results 
The results indicated that: 
 
 A TH antibody RIA could be used to detect and measure TH antibodies. 
 
 
 TH antibodies were present in 18/79 (23%) of patients with non-segmental vitiligo. 
 
 
 Immunoreactivity against TH was not evident in any of the 8 patients with segmental  
vitiligo. 
 
 
 Antibodies against TH were not found in patients with other autoimmune diseases or 
in healthy controls. 
 
 
 The frequency of TH antibodies was significantly increased in the patient group with 
active vitiligo compared to the patient cohort with stable disease. 
 
 
 The frequency of patients with active non-segmental vitiligo was significantly higher 
in the TH antibody-positive patient group than the TH antibody-negative patient 
group. 
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 TH antibodies did not cross-react with tyrosinase or MCHR1, targets of antibodies 
which can be associated with vitiligo. 
 
 
 Antibodies against PAH and TPH were not detected in vitiligo patients. 
 
 
 Antibodies against tyrosinase and MCHR1 were detected at frequencies comparable 
to those in earlier studies. 
 
 
 The presence of TH antibodies was not associated with the occurrence of antibodies 
against either tyrosinase or MCHR1. 
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3.5 Discussion 
The enzyme TH catalyses the conversion of tyrosine to L-dopa, the precursor molecule in 
catecholamine neurotransmitter biosythesis (Lewis et al. 1993; Nagatsu 1995). Antibodies 
against TH were reported first in APS1 patients, including 57% of those individuals displaying 
vitiligo as part of their clinical manifestations (Hedstrand et al. 2000), although the association 
was not significant. Initial evidence for its potential as an autoantigen in vitiligo arose from the 
enrichment of the TH peptide from a melanocyte cDNA expression phage-display library in 
biopanning experiments with vitiligo patient IgG (Kemp et al. 2002; Waterman et al. 2010). In 
the current study, we investigated the prevalence of immunoreactivity to TH in vitiligo patients. 
TH antibodies were demonstrated in 23% (18/79) of those individuals with a non-
segmental pattern of disease. The TH antibody response was detected using TH2 as the assay 
ligand, although four isoforms of TH (TH1-TH4) do exist which differ in the N-terminal 
regulatory domain (Lewis et al. 1993; Nakashima et al. 2009). It is likely that vitiligo patient TH 
antibodies also recognise other forms of the enzyme which are highly similar in amino acid 
sequence (Nagatsu 1995) and, indeed, this has been shown for TH antibodies in APS1 patients 
(Hedstrand et al. 2000). 
Although the frequency of TH antibodies in vitiligo patients at 23% appears to be 
relatively low, earlier studies have detected antibodies to several autoantigens in patients with the 
disease at a similarly low prevalence: tyrosinase antibodies at 11% (Kemp et al. 1997a), TYRP1 
antibodies at 5% (Kemp et al. 1998c), DCT antibodies at 5% (Kemp et al. 1997b), PMEL 
antibodies at 5% (Kemp et al. 1998b), and MCHR1 antibodies at 16% (Kemp et al. 2002). 
 Autoimmunity has been suggested to play a role in the development of non-segmental 
vitiligo: it is frequently associated with autoimmune disorders (Taïeb 2000; Alkhateeb et al. 
2003), responds less well to autologous melanocyte grafting (Gauthier and Surleve-Bazeille 
1992; Taïeb 2000) and is responsive to treatment with immunosuppressive agents (Lepe et al. 
2003). In contrast, it has been proposed that segmental vitiligo has an aetiology which does not 
involve autoimmune pathomechanisms (Taïeb 2000). In keeping with this, TH antibody 
responses were only detected in non-segmental vitiligo patients. However, samples from only 
eight segmental vitiligo patients were available for testing, so firm conclusions cannot be drawn 
as to prevalence of antibody reactivity in this disease sub-type. 
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Notably, TH was an antibody target in patients with or without concomitant autoimmune disease. 
This finding contrasts to previous studies in which antibodies directed against melanocyte-
specific proteins PMEL, TYRP1 and DCT were only detected in vitiligo patients who had other 
autoimmune diseases (Kemp et al. 1997b; Kemp et al. 1998b; Kemp et al. 1998c). Tyrosinase 
and transcription factor SOX10 antibodies were also predominantly detected in vitiligo patients 
with additional autoimmune disorders (Kemp et al. 1997a; Hedstrand et al. 2001). In addition, 
the results demonstrated that the frequency of TH antibodies was significantly increased in the 
group of non-segmental vitiligo patients with active disease. However, only 15 patients with 
stable disease were available for study, so further verification of this result is necessary. 
 A comparison of TH antibody-positive and TH antibody-negative vitiligo patients 
demonstrated no significant association between the presence of TH antibodies and either disease 
duration, patient age, patient gender or age at disease onset, although an association with vitiligo 
activity was noted. 
Interestingly, antibodies against TPH and PAH, enzymes involved in neurotransmitter 
biosynthesis which are closely related to TH, have also been detected in patients with APS1 
(Ekwall et al. 1999; Ekwall et al. 2000). Again, PAH and TPH antibody responses were apparent 
in APS1 patients with vitiligo, but no association between the incidence of either PAH or TPH 
antibodies and depigmentation was evident. In this study and in contrast to TH, 
immunoreactivity to either PAH or TPH was not demonstrated in our vitiligo patient cohort, 
indicating that these enzymes are not autoantigens in isolated vitiligo and that TH antibodies in 
vitiligo patients do not cross-react with TPH or PAH. A further enzyme which also functions in 
the production of neurotransmitters, namely aromatic amino acid decarboxylase, is an additional 
target of the antibody response in APS1 patients where it does significantly associate with the 
presence of vitiligo (Husebye et al. 1997). It would therefore be of interest to determine if 
immune responses to aromatic amino acid decarboxylase occur in patients with isolated vitiligo 
and, if so, whether or not this correlates with the presence of TH antibodies. 
Due to the intracellular location of the enzyme, TH antibodies most probably arise by 
exposure of the antigen following damage to melanocytes by oxidative stress (Kroll et al. 2005; 
Schallreuter et al. 2005; Dell'Anna and Picardo 2006; Shalbaf et al. 2008) or cytotoxic T cells 
(Ogg et al. 1998; Lang et al. 2001; Palermo et al. 2001; van den Boorn et al. 2009). In this 
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respect, it is interesting that a significantly increased frequency of TH antibodies occurred in 
patients with actively progressing vitiligo lesions. Several possibilities including the formation of 
neo-antigens, the exposure of cryptic epitopes and the modification of proteins during apoptosis 
have been suggested to account for immune responses to intracellular melanocyte antigens 
(Namazi 2007; Westerhof and d'Ischia 2007). Following processing by mature Langerhans cells, 
antigenic peptides could be presented to autoreactive T cells which have escaped clonal deletion 
or to naïve T lymphocytes which have not been tolerised against cryptic epitopes (Namazi 2007; 
Westerhof and d'Ischia 2007). Antibodies could then be produced following the stimulation of 
autoreactive B lymphocytes by activated autoreactive CD4+ T cells (Namazi 2007) and activated 
autoreactive cytotoxic T cells could directly attack melanocytes expressing antigenic peptides on 
their surface in the context MHC class I molecules (Hedley et al. 1998; Namazi 2007; Westerhof 
and d'Ischia 2007). Indeed, many studies have underlined the role of cytotoxic T cells in the 
initiation and progression of vitiligo: melanocyte-specific T lymphocytes against tyrosinase, 
MelanA (MART-1) and PMEL are present in perilesional vitiligo skin (Ogg et al. 1998; Lang et 
al. 2001; Palermo et al. 2001; van den Boorn et al. 2009), melanocyte-specific T lymphocytes 
can have cytotoxic activity against pigment cells (Ogg et al. 1998; Lang et al. 2001; Palermo et 
al. 2001; van den Boorn et al. 2009), and melanocyte-specific T lymphocytes can have the 
capacity to destroy melanocytes within skin tissue (van den Boorn et al. 2009). With regard to 
this, studies to identify T cell reactivity to TH would be of interest. 
With limited access to the target antigen within viable cells, TH antibodies are unlikely to 
have any adverse effects upon the function of TH and, although the destruction of melanocytes 
by vitiligo-associated antibodies has been reported involving either complement-mediated 
mechanisms (Norris et al. 1988) or ADCC (Norris et al. 1988; Gilhar et al. 1995), TH antibodies 
may only serve as markers for melanocyte disruption and/or a cellular immune response against 
TH. 
In summary, TH has been identified as a novel B cell autoantigen in vitiligo which needs 
to be further characterised.  
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CHAPTER 4 
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4. Mapping of the B cell epitopes of vitiligo patient TH 
antibodies 
 
4.1 Introduction 
 
4.1.1 Antibody-antigen interactions  
In order for binding to take place between an antibody and its antigen, there must be 
complementarity between surface structures on the antigen and the combining site of the 
antibody. The precise region of the antibody’s combining site which contacts with the antigen is 
termed the paratope, and the part of the antigen recognised by the paratope is termed the epitope.  
Antigens are highly diverse in size and primary sequence, as well as in their secondary structure 
which can be adapted by post-translational modifications such as glycosylation (Westwood and 
Hay 2001). Consequently, antigenic epitopes are extremely varied but can be loosely classified 
in two categories as: (i) linear or continuous epitopes which constitute part of a linear amino acid 
sequence on a polypeptide chain, and (ii) conformational or discontinuous epitopes which are 
formed by two or more stretches of the primary sequence that are distant from each other, but are 
brought together in the folded secondary or tertiary structure of the antigen. The size of an 
epitope is subject to controversy, but it is thought that linear epitopes can range in length from 5-
6 amino acids (Roitt and Delves 1997) to up to 15-22 amino acids (von Mikecz et al. 1995) and 
that conformational epitopes can consist of approximately discontinuous 16 amino acid side-
chains (Roitt and Delves 1997). The specificity of a particular antibody is not absolute, given 
that both paratope and epitope are deformable, and there is the possibility of an antibody binding 
to multiple cross-reactive epitopes. 
In contrast to the processed linear epitopes presented to T cells, B lymphocytes usually 
recognise antigen in the context of the native molecule. The most likely areas of a protein to 
contain B cell epitope regions are, therefore, parts of peptide chains that protrude from the 
globular surface. These external structures are likely to be hydrophilic. Using this information, 
and the fact that some amino acids are thought to be more antigenic than others (Westwood and 
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Hay 2001), it is possible to predict areas of probable antigenicity on a particular protein.  
However, in order to determine the exact location of epitopes on an antigen, experimental 
epitope mapping techniques need to be applied. 
 
4.1.2 Methods used for mapping B cell epitopes 
The techniques currently available for mapping linear and conformational B cell epitopes are 
summarised in Table 4.1. The most precise available method of defining the area of an antigen 
making contact with an antibody is x-ray crystallography of the antigen-antibody complex.  This 
technique has the advantage of allowing the study of the three-dimensional structures and, 
therefore, can yield information about conformational epitopes. However, it is costly and 
requires sufficiently large quantities of a pure monoclonal antibody (or fragment of) and its 
antigen to produce crystal. 
When the primary amino acid sequence of the antigen is known, there are two main 
approaches to B cell epitope mapping. The first method relies on molecular manipulation at the 
cDNA level using techniques such as PCR, site-directed mutagenesis, and restriction with DNA 
exonuclease and endonucleases. Substitutions and/or deletions are created in the amino acid 
sequence followed by comparative analysis of the immunoreactivity of these recombinant 
proteins by either immunoblotting, immunoprecipitation or ELISA (Pettersson 1992). Examples 
of studies in which B cell epitopes have been identified in autoimmune disease using 
recombinant proteins are given in Table 4.2. The second technique begins at the peptide level 
and involves the analysis of antibody reactivity to either synthetic peptides or enzymatically 
digested protein fragments (Pettersson 1992).  However, both these methods can only accurately 
detect linear epitopes and short sequences that may constitute part of a conformational epitope. 
More recently, the use of phage-display technology has allowed the identification of 
conformational peptide epitopes (Williams et al. 2001), which can also be defined using 
chimeric molecules (Hu et al. 2007). 
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Table 4.1: Techniques for mapping linear and conformational B cell epitopes 
 
 
Technique 
 
 
Suitable for type/s of 
epitope 
 
 
Reference 
X-RAY CRYSTALLOGRAPHY
1
 Conformational and linear (Amit et al. 1986) 
PHAGE-DISPLAY
2
 
i) Random-peptide library 
 
ii) Single chain Fv3 fragment (scFv) 
library 
Conformational and linear (Williams et al. 2001) 
SYNTHETIC PEPTIDES
4
 
i) Peptide synthesiser 
(Generates peptides >10 amino acid 
residues)  
 
ii) ‘PEPSCAN’5 
(Peptides ≤ 10 amino acid residues) 
Mostly linear (Pettersson 1992) 
 
 
 
 
(Sumar 2001) 
PEPTIDE FRAGMENTS
6
 
Derived enzymatically from the whole 
protein 
Mostly linear (Pettersson 1992) 
RECOMBINANT PROTEIN
7
 
Subcloning and expression8 of cDNA 
encoding peptide fragments generated 
by: 
i) Naturally occurring restriction sites 
ii) Exonuclease digestion 
iii) Polymerase chain reaction (PCR) 
iv) Site-directed mutagenesis 
Mostly linear (Pettersson 1992) 
(Perdue 2001) 
 
1
Allows direct analysis of the 3-dimensional structure of an antigen-antibody complex. 
2
Epitope regions are determined by affinity selection screening with either (i) antibody, or (ii) antigen. 
3
Fv, variable region of the fragment with antigen binding (Fab) of an immunoglobulin. 
4
Can be used in a number of different assay systems including enzyme-linked immunosorbent assay 
(ELISA) and immunoprecipitation using monoclonal antibody (mAb) or polyclonal sera. 
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5‘PEPSCAN’ involves the synthesis of short overlapping peptide sequences on to solid supports 
(polystyrene pins) which are then used in a modified ELISA. 
6
Can be used in a number of different assay systems including ELISA and immunoprecipitation using 
mAb or polyclonal sera. 
7
Can be used in a number of different assay systems including immunoblotting, ELISA, 
immunoprecipitation and radioimmunoassays (RIA) using mAb or polyclonal sera.  
8
A variety of expression vectors/systems may be used. Vectors may fuse a tag to the protein for 
purification, or allow the incorporation of a radiolabelled amino acid into the recombinant protein for 
RIA. 
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Table 4.2: Examples of previous studies employing recombinant proteins to map B cell 
epitopes in autoimmune disease 
 
 
Antigen 
 
Disease 
 
Techniques 
 
Reference 
 
Thyroid-stimulating 
hormone receptor  
 
Graves’ disease 
 
Subcloning of cDNA amplified 
by PCR. Expressed in bacteria. 
Immunoprecipitation 
experiments with patient sera. 
 
(Burch et al. 
1993) 
 
Steroid 17α-hydroxylase 
 
Autoimmune 
Addison’s disease 
 
Subcloning of endonuclease 
restricted cDNA fragments and 
exonuclease digestion. 
Expressed in bacteria and 
immunoblotted with patient 
sera. 
 
(Peterson and 
Krohn 1994) 
 
 
Steroid 21-hydroxylase 
 
Autoimmune 
Addison’s disease 
 
Subcloning of endonuclease 
restricted cDNA fragments. 
Site-directed mutagenesis. 
Expressed in bacteria. 
Immunoprecipitation 
experiments with patient sera. 
 
(Volpato et al. 
1998) 
 
Ribosomal protein L7 
 
Systemic lupus 
erythematosus and 
mixed connective 
tissue disease  
 
Subcloning of cDNA amplified 
by PCR.  Expressed in bacteria 
and immunoblotted with patient 
sera. Also immunoprecipitation 
experiments with patient sera. 
 
(von Mikecz et al. 
1995) 
 
 
Glutamate decarboxylase  
 
Type 1 diabetes 
mellitus 
 
Subcloning of endonuclease 
restricted cDNA fragments and 
cDNA amplified by PCR. 
Expressed in bacteria. 
Immunoprecipitation 
experiments with patient sera. 
 
(Daw et al. 1996) 
 
‘BP 180’  
(collagen XVII) 
 
Bullous pemphigoid 
 
Subcloning of cDNA amplified 
by PCR. Expressed in bacteria 
and immunoblotted with patient 
sera. 
 
(Lin et al. 1999) 
 
 
Sodium iodide symporter  
 
Autoimmune thyroid 
disease 
 
Subcloning of cDNA amplified 
by PCR. Expressed in bacteria.  
Immunoprecipitation 
experiments with patient sera. 
 
(Kemp et al. 
2001) 
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4.1.3 The role of studying autoantigen B cell epitopes in autoimmune disease  
Mapping of B cell epitopes on autoantigens can provide an understanding of the association of 
an autoantigen with autoimmune pathogenesis. For example, epitopes may reside in functional 
domains of autoantigenic proteins. Indeed, autoantibodies in myasthenia gravis, directed against 
the acetylcholine receptor, are known to bind to an epitope in the acetylcholine-binding site 
which can directly inhibit the receptor function (Holbrook et al. 1989). Similarly, the autoantigen 
epitopes in systemic lupus erythematosus have been found to reside in highly conserved regions 
of proteins and can thus inhibit functions of both structural proteins and enzymes (Casiano and 
Tan 1996). For example, anti-nuclear antibodies targeting tRNA synthetase and DNA 
polymerase delta auxillary protein have been shown to functionally inhibit the aminoacylation of 
tRNA and DNA replication and repair, respectively, in in vitro studies (Tan et al. 1994). 
Epitope mapping may provide insights into the initiation of the autoimmune process. 
Autoimmunity may be triggered by an initial infection with a foreign pathological organism 
(Wucherpfennig 2001). One of the mechanisms by which this might induce immune disease is 
the phenomenon of molecular mimicry, in which a microbial peptide has sufficient structural 
similarity with a self-peptide to evoke a cross-reactive autoimmune response. For example, 
similarities between epitopes on the parasite Trypanosoma cruzi and the cardiac muscle protein 
myosin cause the aberrant immune response in Chagas’ disease (Roitt and Delves 1997). In 
addition, bacterial and viral proteins have homology with endothelial cell components which can 
be damaged by cross-reacting antibodies resulting from infections (Luo et al. 2010; Liu et al. 
2011). 
As well as providing insights into the mechanisms of autoimmune pathogenesis, the 
molecular characterisation of B cell epitopes can also allow for new and more specific assays to 
be established (Lernmark 2001). For example, if the epitope of a pathogenic antibody can be 
precisely defined, recombinant proteins containing only the significant epitope region could be 
used to measure titres of pathogenic antibodies within the heterogeneous antibody population of 
a patient’s serum (Ishii et al. 1997). 
Finally, B cell epitope mapping studies have given interesting information with regard to 
the overlapping binding sites of several autoimmune disease-specific antibodies which otherwise 
have different functionalities (Kemp et al. 2010; Majumdar et al. 2012). Examples include 
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antibodies against the thyroid-stimulating hormone and calcium-sensing receptors (Kemp et al. 
2010; Majumdar et al. 2012). In the case of thyroid peroxidase, a major autoantigen in 
autoimmune thyroid disease, epitope identification has also subsequently enabled the 
characterisation of thyroid peroxidase antibodies with respect to their restricted light chain gene 
usage (McIntosh et al. 1997). 
 
4.1.4 TH antibodies in vitiligo 
The previous chapter of this study described the identification of antibodies against TH in 
vitiligo patients. In this part of the study, the binding sites (epitopes) of TH antibodies were to be 
determined as this might give a better understanding of the association of the humoral immune 
response against TH with vitiligo. 
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4.2 Aims 
The aims of this part of the study were: 
 
 
 
 To construct a series of deletion derivatives of TH cDNA using PCR 
amplification and subcloning. 
 
 
 To express the TH cDNA deletion derivatives in an in vitro transcription-
translation system to produce radiolabelled TH fragments. 
 
 
 To investigate the immunoreactivity of vitiligo patient sera against the TH 
fragments using RIAs and so determine the antibody binding sites (epitopes) on 
TH. 
 
 
 To confirm immunoreactivity of vitiligo patient sera against any identified TH 
epitopes by using ELISAs with synthetic TH peptides containing the putative 
TH antibody binding site(s). 
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4.3 Experiments and Results 
 
4.3.1 Patients and controls 
Participants were 18 vitiligo patients (8 male, 10 female; mean age, 47 years with range 7-77 
years; mean disease duration, 18 years with range 1-50 years; mean age at disease onset 28 years 
with range 5-70 years) with active, non-segmental disease and TH antibodies (Chapter 3). 
Fourteen patients had no other autoimmune disorder and no family history of autoimmune 
disease. Four patients had one other autoimmune disorder: autoimmune thyroid disease 2; 
alopecia areata, 1; psoriasis, 1. Twenty-eight healthy individuals (10 male, 18 female; mean age, 
34 years; age range 21-59 years) were used as controls. 
 
4.3.2 Construction of a series of deletion derivatives of TH cDNA  
Thirteen TH cDNA fragments of varying lengths were generated from TH cDNA present in 
pcDNA3-TH (Figure 2.2) by PCR amplification. The required TH cDNA fragments and the 
oligonucleotide primers used to generate them are shown in Table 4.3. Restriction sites for 
HindIII and BamHI were incorporated into the 5’ and 3’ oligonucleotide primers, respectively, in 
order to allow cloning of the PCR amplification products between the HindIII and BamHI 
restriction enzyme sites in pcDNA3 (Figure 2.1). 
 
4.3.2.1 PCR amplification of fragments of TH cDNA  
The composition of each PCR amplification reaction was as previously described (Section 2.12), 
and contained 50 ng of pcDNA3-TH DNA which were subjected to 30 cycles of amplification in 
a DNA Thermal Cycler using the following conditions: 95
o
C, 1 min; 55
o
C, 1 min; 72
o
C, 2 min; 
and 72
o
C for 10 min to terminate the reaction (Section 2.12). To check for the correctly sized 
PCR products, a 5-μl aliquot of each PCR amplification reaction was electrophoresed in a 0.8% 
(w/v) agarose gel (Section 2.10). The results are shown in Figures 4.1a-d. In all cases, products 
of the estimated size in base pairs were visible. 
Subsequently, each of the 13 PCR amplification products was purified from a 0.8% (w/v) 
agarose gel using a Wizard PCR Preps DNA Purification System (Section 2.13). The total of   
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Table 4.3: Oligonucleotide primers used to generate TH cDNA fragments by PCR 
amplification  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Numbers correspond to the base pair of TH cDNA with the A residue of the initiating ATG codon 
assigned as base pair number one. 
2
The HindIII and BamHI restriction sites are underlined. The translation initiation codon (ATG) and the 
translation termination codons (TGA and TAG) in the forward (F) and reverse (R) primers, respectively, 
are shown in bold-type face.  
 
TH base pairs
1 
(size in base 
pairs) 
 
 
Primer name 
 
Primer sequence
2
 
 
1-420 (420) THF1 
THR140 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcagtcccctcggcgcac-3’ 
1-510 (510) THF1 
THR170 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcacacttttcttgggaa-3’ 
1-600 (600) THF1 
THR200 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcagcggtacacctggtc-3’ 
1-720 (720) THF1 
THR240 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcacttcagcgtggtgta-3’ 
1-840 (840) THF1 
THR280 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcacttcaggaagcggga-3’ 
1-960 (960) THF1 
THR320 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcagggcgaggacgcgtg-3’ 
1-1080 (1080) THF1 
THR360 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcaatccgaggcccccag-3’ 
1-1200 (1200) THF1 
THR400 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcacaggagctccccgta-3’ 
1-1320 (1320) THF1 
THR440 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcaggcgtcactgaagct-3’ 
1-1440 (1440) THF1 
THR480 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcactccagggagcgccg-3’ 
1-240 (240) THF1 
THR80 
5’-ttaagcttgccgccatgcccacccccgacgcc-3’ 
5’-aaggatcccgcctatcaggccttcccctcctt-3’ 
241-420 (180) THF81 
THR140 
5’-ttaagcttgccgccatggtgctaaacctgctc-3’ 
5’-aaggatcccgcctatcagtcccctcggcgcac-3’ 
421-1491 (1071) THF141 
THR497 
5’-ttaagcttgccgccatgatgctggccgccctgctc-3’ 
5’-aaggatcccgcctatcagccaatggcactcag-3’ 
 150 
 
 
 
 
 
 
 
Figure 4.1a: Agarose gel of PCR amplification products amplified from pcDNA3-TH. 
 
Plasmid pcDNA3-TH was subjected to PCR amplification using appropriately designed oligonucleotide 
primers. The PCR amplification products were analysed by electrophoresis in a 0.8% (w/v) agarose gel. 
The gel shows: Lambda DNA/HindIII Markers with DNA fragments from 125 to 23,130 bp (lane M);   
Plasmid pcDNA3-TH amplified with primers THF1 and THR480 (lane 1); Control - no DNA with 
primers THF1 and THR480 (lane 2); Plasmid pcDNA3-TH amplified with primers THF1 and THR440 
(lane 3); Control - no DNA with primers THF1 and THR440 (lane 4); Plasmid pcDNA3-TH amplified 
with primers THF1 and THR400 (lane 5); Control - no DNA with primers THF1 and THR400 (lane 6); 
Plasmid pcDNA3-TH amplified with primers THF1 and THR360 (lane 7); Control - no DNA with 
primers THF1 and THR360 (lane 8); Plasmid pcDNA3-TH amplified with primers THF1 and THR320 
(lane 9); Control - no DNA with primers THF1 and THR320 (lane 10).  
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Figure 4.1b: Agarose gel of PCR amplification products amplified from pcDNA3-TH. 
 
Plasmid pcDNA3-TH was subjected to PCR amplification using appropriately designed oligonucleotide 
primers. The PCR amplification products were analysed by electrophoresis in a 0.8% (w/v) agarose gel. 
The gel shows: Lambda DNA/HindIII Markers with DNA fragments from 125 to 23,130 bp (lane M); 
Plasmid pcDNA3-TH amplified with primers THF1 and THR280 (lane 1); Control - no DNA with 
primers THF1 and THR280 (lane 2); Plasmid pcDNA3-TH amplified with primers THF1 and THR240 
(lane 3); Control - no DNA with primers THF1 and THR240 (lane 4); Plasmid pcDNA3-TH amplified 
with primers TH-F1 and THR200 (lane 5); Control - no DNA with primers THF1 and THR200 (lane 6); 
Plasmid pcDNA3-TH amplified with primers THF1 and THR170 (lane 7); Control - no DNA with 
primers THF1 and THR170 (lane 8); Plasmid pcDNA3-TH amplified with primers TH-F1 and TH-R140 
(lane 9); Control - no DNA with primers THF1 and THR140 (lane 10).  
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Figure 4.1c: Agarose gel of PCR amplification products amplified from pcDNA3-TH. 
 
Plasmid pcDNA3-TH was subjected to PCR amplification using appropriately designed oligonucleotide 
primers. The PCR amplification products were analysed by electrophoresis in a 0.8% (w/v) agarose gel. 
The gel shows: 1-kb DNA Markers with DNA fragments from 500 to 10,000 bp (M); Plasmid pcDNA3-
TH amplified with primers THF1 and THR80 (lane 1); Control - no DNA with primers THF1 and THR80 
(lane 2); Plasmid pcDNA3-TH amplified with primers THF81 and THR140 (lane 3); Control - no DNA 
with primers THF81 and THR140 (lane 4). 
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Figure 4.1d: Agarose gel of PCR amplification product amplified from pcDNA3-TH. 
 
Plasmid pcDNA3-TH was subjected to PCR amplification using appropriately designed oligonucleotide 
primers. The PCR amplification products were analysed by electrophoresis in a 0.8% (w/v) agarose gel. 
The gel shows: Lambda DNA/HindIII Markers with DNA fragments from 500 to 23,130 bp (lane M); 
Plasmid pcDNA3-TH amplified with primers THF141 and THR497 (lane 1); Control - no DNA with 
primers THF141 and THR497 (lane 2). 
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each of the recovered products was restricted in a 40-µl reaction with HindIII and BamHI 
(Section 2.11) and then re-purified from a 0.8% (w/v) agarose gel using a Wizard PCR Preps 
DNA Purification System. Finally, a 3-μl aliquot of each restricted and purified product was 
analysed by agarose gel electrophoresis in a 0.8% (w/v) gel, and then stored at -20
o
C ready for 
cloning into pcDNA3. 
 
4.3.2.2 Preparation of vector pcDNA3 
For cloning of the PCR products, 1 μg of vector pcDNA3 was digested with HindIII and BamHI 
in a 25-μl reaction. The linearised vector was purified from a 0.8% (w/v) agarose gel using a 
Wizard PCR Preps DNA Purification System. A 3-μl aliquot of the restricted and purified vector 
was checked on a 0.8% (w/v) agarose gel, before storage at -20
o
C. 
 
4.3.2.3 Cloning of TH cDNA fragments into pcDNA3 
The HindIII and BamHI-restricted TH cDNA fragments were cloned into HindIII and BamHI-
digested pcDNA3 by setting up 20-µl ligation reactions as described in Section 2.14. A 5-µl 
aliquot of each ligation reaction was then used to transform 50 µl of chemically competent E. 
coli JM109 cells (Section 2.15), with transformants being selected on LB agar (Section 2.5) 
containing ampicillin at 100 µg/ml (Section 2.6). Following overnight incubation at 37
o
C, 10 
individual bacterial colonies from each transformation were purified by streaking on to fresh LB 
agar containing ampicillin at 100 µg/ml and subsequently incubating at 37
o
C overnight. 
 
4.3.2.4 Screening of E. coli JM109 transformants for recombinant plasmids 
For screening of E. coli JM109 transformants for recombinant plasmids that contained the 
correct TH cDNA fragment, 10 individual bacterial clones from each transformation were 
inoculated separately into 10 ml of LB with ampicillin at 100 µg/ml, and then incubated at 37
o
C 
overnight. Plasmid DNA was purified from individual transformants using a Wizard Miniprep 
DNA Purification System (Section 2.8). Plasmids were then checked for the presence of the 
correctly sized DNA insert by restriction enzyme digestion of a 0.5-µg sample with HindIII and 
BamHI in a 25-µl reaction, followed by analysis by electrophoresis in 0.8% (w/v) agarose gels. 
 155 
 
The frequency of recombinant plasmids for each cloning experiment was 100%, with 
10/10 plasmids having a DNA insert. One recombinant plasmid from each of the cloning 
experiments is shown in an agarose gel in Figures 4.2a-e, which illustrate that a DNA insert at 
approximately the correct size in base pairs was released from the plasmids after restriction with 
both HindIII and BamHI. The recombinant plasmids are listed in Table 4.4.  
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Figure 4.2a: Agarose gel of pcDNA3-TH deletion plasmids. 
 
The pcDNA3-TH deletion plasmids were restricted with HindIII and BamHI to show the presence of a 
TH cDNA insert. The gel shows: 1-kb DNA Markers with DNA fragments from 500-10,000 bp (lane M); 
unrestricted pcDNA3 (lane 1); HindIII and BamHI-restricted pcDNA3 (lane 2); unrestricted pcDNA3-TH 
(lane 3); HindIII and BamHI-restricted pcDNA3-TH (lane 4); unrestricted pTH140 (lane 5); HindIII and 
BamHI-restricted pTH140 (lane 6); unrestricted pTH170 (lane 7); HindIII and BamHI-restricted pTH170 
(lane 8); unrestricted pTH200 (lane 9); HindIII and BamHI-restricted pTH200 (lane 10); unrestricted 
pTH240 (lane 11); HindIII and BamHI-restricted pTH240 (lane 12) ; unrestricted pTH280 (lane 13); 
HindIII and BamHI-restricted pTH280 (lane 14). 
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Figure 4.2b: Agarose gel of pcDNA3-TH deletion plasmids.  
 
The pcDNA3-TH deletion plasmids were restricted with HindIII and BamHI to show the presence of a 
TH cDNA insert. The gel shows: 1-kb DNA Markers with DNA fragments from 500 to 10,000 bp (lane 
M); unrestricted pcDNA3 (lane 1); HindIII and BamHI-restricted pcDNA3 (lane 2); unrestricted 
pcDNA3-TH (lane 3); HindIII and BamHI-restricted pcDNA3-TH (lane 4); unrestricted pTH320 (lane 5); 
HindIII and BamHI-restricted pTH320 (lane 6); unrestricted pTH360 (lane 7); HindIII and BamHI-
restricted pTH360 (lane 8); unrestricted pTH400 (lane 9); HindIII and BamHI-restricted pTH400 (lane 
10); unrestricted pTH440 (lane 11); HindIII and BamHI-restricted pTH440 (lane 12); unrestricted 
pTH480 (lane 13); HindIII and BamHI-restricted pTH480 (lane 14). 
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Figure 4.2c: Agarose gel of pcDNA3-TH deletion plasmid.  
 
The pcDNA3-TH deletion plasmid was restricted with HindIII and BamHI to show the presence of a TH 
cDNA insert. The gel shows: 1-kb DNA Markers with DNA fragments from 500 to 10,000 bp (lane M); 
unrestricted pcDNA3 (lane 1); HindIII and BamHI-restricted pcDNA3 (lane 2); unrestricted pTH1-80 
(lane 3); HindIII and BamHI-restricted pTH1-80 (lane 4). 
 
  
←240 bp 
fragment 
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Figure 4.2d: Agarose gel of pcDNA3-TH deletion plasmid.  
 
The pcDNA3-TH deletion plasmid was restricted with HindIII and BamHI to show the presence of a TH 
cDNA insert. The gel shows: 1-kb DNA Markers with DNA fragments from 500 to 10,000 bp (lane M); 
unrestricted pcDNA3 (lane 1); HindIII and BamHI-restricted pcDNA3 (lane 2); unrestricted pTH81-140 
(lane 3); HindIII and BamHI-restricted pTH81-140 (lane 4). 
  
←180 bp 
fragment 
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Figure 4.2e: Agarose gel of pcDNA3-TH deletion plasmid.  
 
The pcDNA3-TH deletion plasmid was restricted with HindIII and BamHI to show the presence of a TH 
cDNA insert. The gel shows: 1-kb DNA Markers with DNA fragments from 500 to 10,000 bp (lane M); 
unrestricted pcDNA3 (lane 1); HindIII and BamHI-restricted pcDNA3 (lane 2); unrestricted pTH141-497 
(lane 3); HindIII and BamHI-restricted pTH141-497 (lane 4). 
  
←1071 bp 
fragment 
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Table 4.4: Details of recombinant plasmids from cloning of TH cDNA fragments into 
vector pcDNA3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Numbers correspond to the amino acid residues of TH with the initiating methionine as residue number 
one. 
2
Numbers correspond to the base pair of TH cDNA with the A residue of the initiating ATG codon 
assigned as base pair number one.
  
  
 
Plasmid 
 
TH amino acids encoded
1 
(base pairs included
2
)
 
 
pTH140 1-140 (1-420) 
pTH170 1-170 (1-510) 
pTH200 1-200 (1-600) 
pTH240 1-240  (1-720) 
pTH280 1-280 (1-840) 
pTH320 1-320 (1-960) 
pTH360 1- 360 (1-1080) 
pTH400 1- 400 (1-1200) 
pTH440 1-440 (1-1320) 
pTH480 1- 480 (1-1440) 
pTH1-80 1-80 (1-240) 
pTH81-140 81-140 (241-420) 
pTH141-497 141-497 (421-1491) 
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4.3.2.5 Sequencing of cloned TH cDNA fragments  
As a final check that the recombinant plasmids were correct and to verify that no sequence errors 
had been introduced to the TH cDNA fragment during PCR amplification, all plasmids were 
subjected to DNA sequencing (Section 2.16) using primers T7, SP6, THR1, THF400, THF839 
and THR1239, as required (Table 2.6). The results verified that each recombinant plasmid 
contained the correct TH cDNA fragment when compared with the sequence of full-length TH 
cDNA (Appendices I and II) using the ClustalW2 Multiple Sequence Alignment tool at the 
network facilities of the EBI-EMBL (Section 2.17). 
 
4.3.3 In vitro transcription-translation of TH cDNA deletion derivatives 
Each TH cDNA fragment was inserted in pcDNA3 in the correct orientation to allow expression 
of the encoded TH peptide from the T7 promoter (Figure 2.1). Each DNA template also 
contained appropriate start and stop codons to ensure accurate translation. To produce and label 
TH deletion derivatives with [
35
S]-methionine for use in RIAs, the plasmid constructs listed in 
Table 4.4 were used in a TnT
®
 T7-Coupled Reticulocyte Lysate System (Section 2.18). Full-
length TH was also produced and radiolabelled by using pcDNA3-TH in TnT
®
 T7-Coupled 
Reticulocyte Lysate System. Transcription-translation reactions were stored at –20oC until 
needed. 
 To analyse the radiolabelled products qualitatively, a 5-µl aliquot of each the in vitro 
transcription-translation reactions was added to 20 µl of SDS-sample buffer (Section 2.19) and 
heated to 85
o
C for 5 min before analysing a 10-µl sample by SDS-PAGE in a SDS-
polyacrylamide gel with subsequent autoradiography (Section 2.19). 
 The results revealed a major band representing the [
35
S]-labelled TH protein fragment 
(Figure 4.3 and Table 4.5). The estimated molecular weight of each TH protein fragment agreed 
well with the molecular weight predicted from the amino acid sequence of the deleted protein 
(Table 4.5).  
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Figure 4.3: SDS-polyacrylamide gel electrophoresis and autoradiography of products 
arising from in vitro translation of TH cDNA deletion derivatives. 
 
TH cDNA deletion derivatives were translated in vitro in a TnT
®
 T7 Coupled Reticulocyte Lysate System 
from the appropriate plasmid. Subsequently, 5 µl of the reaction were added to 20 µl of SDS sample 
buffer, boiled for 5 min, and 10 µl of this mixture were then analysed by SDS-PAGE in a 12.5 or 15% 
(w/v) SDS-polyacrylamide gel. The results are shown for: (a) Deletion derivatives of TH in vitro 
translated from: pTH480 (lane 1); pTH440 (lane 2); pTH400 (lane 3); pTH360 (lane 4); pTH320 (lane 5); 
pTH141-497 (lane 6). Prestained SDS-PAGE Standards, Low Range (Bio-Rad Ltd.) are indicated. (b) 
pTH280 (lane 1); pTH240 (lane 2); pTH200 (lane 3); pTH170 (lane 4); pTH140 (lane 5); pTH1-80 (lane 
6); pTH81-140 (lane 7). Precision Plus Protein All Blue Standards (Bio-Rad Ltd.) are indicated. These 
gels were run and processed by Dr. Helen Kemp (Department of Human Metabolism, University of 
Sheffield, Sheffield, UK). 
  
(a) 
 
 
1      2     3        4       5      6 
50 kDa→ 
 34 kDa→ 
 77 kDa→ 
20 kDa→ 
 
 1       2      3      4        5       6      7 
37 kDa→ 
25 kDa→ 
(b) 
15 kDa→ 
10 kDa→ 
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Table 4.5: TH protein fragments encoded by recombinant plasmids  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Predicted from the amino acid sequence of the protein. 
2
kD, kilodalton. 
3
Estimated from the mobility of the protein in SDS-polyacrylamide gels. 
 
 
  
 
Plasmid 
 
Protein 
 
Predicted molecular 
weight of protein
1 
(kD
2
) 
 
 
Estimated molecular 
weight of protein
3 
(kD
2
) 
 
pTH140 TH140 15.4 16 
pTH170 TH170 18.7 20 
pTH200 TH200 22.0 23 
pTH240 TH240 26.4 27 
pTH280 TH280 30.8 32 
pTH320 TH320 35.2 38 
pTH360 TH360 39.6 41 
pTH400 TH400 44.0 45 
pTH440 TH440 48.4 51 
pTH480 TH480 52.8 53 
pTH1-80 TH1-80 8.8 10 
pTH81-140 TH81-140 6.6 8 
pTH141-497 TH141-497 39.3 40 
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4.3.4 Radioimmunoassays with TH fragments and vitiligo patient and control 
sera 
To localise the antibody epitope regions on TH, radiolabelled TH fragments containing amino 
acids 1-140, 1-170, 1-200, 1-240, 1-280, 1-320, 1-360, 1-400, 1-440, 1-480 and 141-497 (Section 
4.3.3) were used in RIAs (Section 2.20) to test the immunoreactivity of sera from 18 TH 
antibody-positive vitiligo patients and 28 healthy controls. All sera were assayed in duplicate at a 
final dilution of 1:100. Antiserum ab59276 was included in each assay set as a positive control at 
a dilution of 1:500. 
 In each assay set, antibody binding was expressed as an Ab index, which was calculated 
for each serum tested as: cpm immunoprecipitated by tested serum/mean cpm 
immunoprecipitated by 28 healthy control sera. Each serum was tested in at least two 
experiments and the mean Ab index was calculated from these values. The upper limit of normal 
for each RIA was calculated using the mean Ab index + 3SD of the population of 28 healthy 
controls. Any serum sample with an Ab index above the upper limit of normal was designated as 
positive for antibody reactivity against the TH ligand used in the RIA. 
 The results of the RIAs are shown in Figure 4.4 and summarised in Tables 4.6 and 4.7. In 
summary, none of the healthy individuals was positive for antibodies against the TH fragments 
used as radiolabelled ligands in the RIAs (Table 4.6). In addition, none of the 18 TH antibody-
positive vitiligo patient sera or antiserum ab59276 was positive for antibodies against the TH 
fragment containing amino acids 141-497 (Table 4.6). In contrast, all of the 18 (100%) TH 
antibody-positive vitiligo patient sera and antiserum ab59276 were positive for immunoreactivity 
against TH fragments containing amino acids 1-140, 1-170, 1-200, 1-240, 1-280, 1-320, 1-360, 
1-400, 1-440 and 1-480 (Table 4.6 and 4.7). The results suggested that the binding sites for 
vitiligo patient TH antibodies were present at the N-terminus of the protein between amino acids 
1-140, with no epitopes being detected in the remainder of the protein.  
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Figure 4.4: Immunoreactivity of vitiligo patient and control sera against TH deletion 
derivatives. 
 
Serum samples from 18 vitiligo (V) patient and 28 healthy controls (C) were evaluated for antibodies 
against TH fragments in RIAs. The Ab index is shown for each sample in each RIA and is the mean Ab 
index of at least two experiments. The upper limits of normal (mean Ab index + 3SD of 28 healthy 
controls)  were Ab indices of 1.18, 1.12, 1.12, 1.06, 1.15, 1.15, 1.18, 1.15, 1.12, 1.18 and 1.09 for TH1-
480, TH1-440, TH1-400, TH1-360, TH1-320, TH1-280, TH1-240, TH1-170, TH1-140 and TH141-497 
antibody RIAs, respectively. Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, 
Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012). 
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Table 4.6: Results of RIAs using TH fragments as the radiolabelled ligands 
 
 
 
 
 
1
Sera with an Ab index above the upper limit of normal value, calculated from the mean Ab index + 3SD 
of 28 healthy controls, were considered positive for antibodies against the TH ligand used in the RIA. 
 
 
  
 
TH 
fragment  
used in 
RIA 
 
Mean Ab index 
± SD  of vitiligo 
patient group 
 
Mean Ab 
indices ± SD of 
control group 
 
 
Upper 
limit of 
normal for 
the RIA 
 
Number of 
vitiligo 
patients 
positive for 
TH 
antibodies
1 
 
 
Number of 
healthy 
controls 
positive for 
TH 
antibodies
1 
 
 
Mean Ab 
index ± SD 
of positive 
control 
antiserum 
ab59276 
TH140 2.59 ± 0.76 
(range: 1.63-3.65) 
1.00 ± 0.06 
(range: 0.90-1.15) 
1.18 18/18 0/28 3.24 ± 0.13 
TH170 2.41 ± 0.59 
(range: 1.58-3.36) 
1.00 ± 0.04 
(range: 0.94-1.06) 
1.12 18/18 0/28 3.60 ± 0.26 
TH200 2.35 ± 0.61 
(range: 1.52-3.44) 
1.00 ± 0.04 
(range: 0.90-1.10) 
1.15 18/18 0/28 3.88 ± 0.14 
TH240 2.22 ± 0.69 
(range: 1.33-3.47) 
1.00 ± 0.06 
(range: 0.88-1.14) 
1.18 18/18 0/28 3.61 ± 0.07 
TH280 2.18 ± 0.70 
(range: 1.27-3.54) 
1.00 ± 0.05 
(range: 0.92-1.10) 
1.15 18/18 0/28 3.64 ± 0.14 
TH320 3.02 ± 0.96 
(range: 1.68-4.37) 
1.00 ± 0.05 
(range: 0.89-1.08) 
1.15 18/18 0/28 3.84 ± 0.07 
TH360 2.29 ± 0.71 
(range: 1.35-3.17) 
0.99 ± 0.02 
(range: 0.95-1.04) 
1.06 18/18 0/28 3.56 ± 0.90 
TH400 2.23 ± 0.75 
(range: 1.23-3.35) 
1.00 ± 0.04 
(range: 0.90-1.07) 
1.12 18/18 0/28 2.84 ± 0.10  
TH440 2.24 ± 0.76 
(range: 1.23-3.33) 
1.00 ± 0.04 
(range: 0.95-1.07) 
1.12 18/18 0/28 3.02 ± 0.22 
TH480 2.25 ± 0.75 
(range: 1.25-3.42) 
1.00 ± 0.06 
(range: 0.90-1.11) 
1.18 18/18 0/28 2.91 ± 0.21 
TH141-497 0.95 ± 0.04 
(range: 0.87-1.03) 
0.96 ± 0.04 
(range: 0.88-1.04) 
1.09 0/18 0/28 0.91 ± 0.05 
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Table 4.7: Antibody indices of vitiligo patient sera in RIAs using TH fragments as the 
radiolabelled ligands 
Patient Ab 
index 
with 
TH1401 
Ab 
index 
with 
TH1701 
Ab index 
with  
TH2001 
Ab 
index 
with 
TH2401 
Ab  
index 
with 
TH2801 
Ab  
index  
with 
TH3201 
Ab 
index 
with 
TH3601 
Ab 
index 
with 
TH4001 
Ab 
index 
with 
TH4401 
Ab 
index 
with 
TH4801 
V4 3.76 
± 
0.07  
+ 3.15 
± 
0.17  
+ 3.00 ± 
0.22 
+ 2.73 
± 
0.30 
+ 2.48  ± 
0.08 
+ 3.74 
± 
0.02 
+ 2.89 
± 
0.08 
+ 2.81 
± 
0.05  
+ 2.91 
± 
0.08  
+ 2.91 
± 
0.04  
+ 
V8 2.33 
± 
0.12  
+ 2.31 
± 
0.02  
+ 2.42 ± 
0.01  
+ 2.50 
± 
0.13 
+ 2.33 ± 
0.00 
+ 3.73 
± 
0.04 
+ 2.89 
± 
0.10  
+ 2.75 
± 
0.05  
+ 2.68 
± 
0.00  
+ 2.64 
± 
0.02  
+ 
V9 3.06 
± 
0.13  
+ 2.86 
± 
0.55  
+ 2.70 ± 
0.51  
+ 2.73 
± 
0.17 
+ 2.68 ± 
0.26 
+ 4.08 
± 
0.16 
+ 2.92 
± 
0.13  
+ 2.87 
± 
0.03  
+ 2.88 
± 
0.01  
+ 2.93 
± 
0.05  
+ 
V10 2.65 
± 
0.00  
+ 2.55 
± 
0.12  
+ 2.51 ± 
0.01  
+ 2.86 
± 
0.23 
+ 2.99 ± 
0.38 
+ 3.63 
± 
0.18 
+ 2.81 
± 
0.25  
+ 2.58 
± 
0.07  
+ 2.52 
± 
0.09  
+ 2.47 
± 
0.08  
+ 
V20 3.65 
± 
0.13  
+ 3.36 
± 
0.07  
+ 3.44 ± 
0.03  
+ 3.47 
± 
0.07 
+ 3.54 ± 
0.15 
+ 4.47 
± 
0.12 
+ 3.15 
± 
0.01  
+ 3.35 
± 
0.17  
+ 3.33 
± 
0.04  
+ 3.42 
± 
0.04  
+ 
V25 3.07 
± 
0.16  
+ 3.07 
± 
0.31  
+ 2.92 ± 
0.12  
+ 2.90 
± 
0.42 
+ 3.02 ± 
0.58 
+ 3.72 
± 
0.08 
+ 2.57 
± 
0.05  
+ 2.62 
± 
0.06  
+ 2.70 
± 
0.03  
+ 2.76 
± 
0.06  
+ 
V27 2.02 
± 
0.09  
+ 1.93 
± 
0.04  
+ 1.91 ± 
0.11  
+ 1.84 
± 
0.04 
+ 1.80  ± 
0.01 
+ 2.26 
± 
0.02 
+ 1.93 
± 
0.24  
+ 1.84 
± 
0.16  
+ 1.72 
± 
0.06  
+ 1.76 
± 
0.04  
+ 
V30 1.79 
± 
0.14  
+ 1.82 
± 
0.09  
+ 1.80 ± 
0.07  
+ 1.80 
± 
0.07 
+ 1.76 ±  
0.07 
+ 2.13 
±  
0.02 
+ 1.76 
± 
0.09  
+ 1.84 
± 
0.07  
+ 1.82 
± 
0.07  
+ 1.84 
± 
0.02  
+ 
V33 3.00 
± 
0.03  
+ 2.67 
± 
0.41  
+ 2.70 ± 
0.29  
+ 2.61 
± 
0.44 
+ 2.57 ± 
0.56 
+ 3.40 
± 
0.01 
+ 2.84 
± 
0.13  
+ 2.70 
± 
0.02  
+ 2.73 
± 
0.05  
+ 2.77 
± 
0.03  
+ 
V39 3.20 
± 
0.07 
+ 2.61 
± 
0.22 
+ 2.72 ± 
0.21  
+ 2.46 
± 
0.28 
+ 2.42 ± 
0.41 
+ 3.50 
± 
0.00 
+ 2.75 
± 
0.13  
+ 2.78 
± 
0.01  
+ 2.85 
± 
0.19  
+ 2.79 
± 
0.06 
+ 
V62 3.59 
± 
0.11  
+ 3.17 
± 
0.01  
+ 3.12 ± 
0.01  
+ 2.82 
± 
0.32 
+ 2.79 ± 
0.41 
+ 4.37 
± 
0.02 
+ 3.17 
± 
0.10  
+ 3.14 
± 
0.01  
+ 3.21 
± 
0.04  
+ 3.10 
± 
0.04  
+ 
V63 1.78 
± 
0.01  
+ 1.75 
± 
0.01  
+ 1.60 ± 
0.04  
+ 1.45 
± 
0.04 
+ 1.44 ± 
0.05 
+ 1.68 
± 
0.02 
+ 1.41 
± 
0.21  
+ 1.23 
± 
0.02  
+ 1.28 
± 
0.07  
+ 1.36 
± 
0.06  
+ 
V64 1.63 
± 
0.05  
+ 1.58 
± 
0.06  
+ 1.52 ± 
0.01 
+ 1.36 
± 
0.03 
+ 1.40 ± 
0.01 
+ 1.73 
± 
0.00 
+ 1.35 
± 
0.04 
+ 1.27 
± 
0.07  
+ 1.23 
± 
0.05  
+ 1.31 
± 
0.00  
+ 
V69 1.85 
± 
0.07  
+ 1.67 
± 
0.16  
+ 1.60 ± 
0.04  
+ 1.36 
± 
0.07 
+ 1.29 ± 
0.04 
+ 1.85 
± 
0.01 
+ 1.36 
± 
0.08  
+ 1.26 
± 
0.04  
+ 1.23 
± 
0.02  
+ 1.29 
± 
0.00  
+ 
V70 1.63 
± 
0.02  
+ 1.68 
± 
0.09  
+ 1.58± 
0.00  
+ 1.33 
± 
0.06 
+ 1.27 ± 
0.08 
+ 2.03 
± 
0.07 
+ 1.40 
± 
0.15  
+ 1.25 
± 
0.03  
+ 1.29 
± 
0.02  
+ 1.25 
± 
0.00  
+ 
V82 1.96 
± 
0.13  
+ 2.17 
± 
0.45  
+ 2.03 ± 
0.47  
+ 1.37 
± 
0.02 
+ 1.37 ± 
0.09 
+ 1.96 
± 
0.09 
+ 1.34 
± 
0.09  
+ 1.26 
± 
0.05  
+ 1.26 
± 
0.04  
+ 1.30 
± 
0.01  
+ 
V86 2.22 
± 
0.08  
+ 2.24 
± 
0.08  
+ 2.05 ± 
0.07  
+ 1.65 
± 
0.27 
+ 1.59 ± 
0.17 
+ 2.96 
± 
0.02 
+ 1.87 
± 
0.15  
+ 1.80 
± 
0.09  
+ 1.82 
± 
0.06  
+ 1.70 
± 
0.06  
+ 
V87 3.45
± 
0.12  
+ 2.86
± 
0.58  
+ 2.77 ± 
0.52  
+ 2.64 
± 
0.27 
+ 2.59 ± 
0.23 
+ 3.21 
± 
0.07 
+ 2.87 
± 
0.07  
+ 2.84 
± 
0.08  
+ 2.81 
± 
0.01  
+ 2.86
± 
0.00  
+ 
 
1
The Ab index shown for each vitiligo patient serum is the mean ± SD of at least two 
experiments; +, denotes positive for antibody reactivity. 
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4.3.5 Absorption of TH antibodies by TH peptide fragments  
The use of several TH fragments enabled the identification of a major epitope region 
corresponding to amino acids 1-140 (Section 4.3.4). To further identify epitopes within this TH 
domain, non-radiolabelled TH fragments containing amino acids 1-80 and 81-140 were used in 
absorption experiments to investigate their effects on the binding of TH antibodies to in vitro 
translated TH. 
Non-radioactive TH fragments containing amino acids 1-80 and 81-140 (Table 4.5) 
were produced in an in vitro TnT
®
 T7-Coupled Reticulocyte Lysate System (Section 2.18), 
using non-radiolabelled methionine in the reaction. Unlabelled MCHR1 was also synthesised in 
vitro from plasmid pcMCHR1 (Table 2.3) and was then used as an experimental control. 
For absorption experiments, duplicate serum samples from 18 TH antibody-positive 
vitiligo patients and 6 healthy controls were pre-incubated at 4
o
C for 2 h with 10 µl of in vitro 
translation reaction which contained the appropriate non-radiolabelled TH fragment or non-
radiolabelled MCHR1. Sera were at a 1:100 dilution in 50 µl of immunoprecipitation buffer. 
Following the addition of in vitro translation reaction containing radiolabelled TH, the TH 
antibody RIA was completed as previously detailed (Section 2.20). Samples of unabsorbed 
vitiligo patient and control sera were included in each assay set. 
 For each serum sample, TH antibody binding was expressed as a TH Ab index which was 
calculated as: cpm immunoprecipitated by tested serum/mean cpm immunoprecipitated by 6 
healthy control sera. Each serum was tested in at least two experiments and the mean TH Ab 
index was calculated from these values. The TH Ab indices for the pre-absorbed and 
unabsorbed vitiligo patient sera were compared using paired t tests (Section 2.27). In all tests, P 
values < 0.05 (two-tailed) were regarded as significant. 
The results are shown in Figure 4.5. The immunoreactivity of all 18 vitiligo patient sera 
against TH was significantly reduced when pre-absorbed with TH fragment 1-80, in comparison 
to unabsorbed serum samples (P values were < 0.05) (Table 4.8). This contrasted to the results 
obtained when prior absorption was with TH fragment 81-140 or with MCHR1, where no 
significant effects on TH antibody binding were observed (P values were > 0.05). The data 
indicated that at least one TH epitope(s), for patient TH antibodies, was located between amino 
acids 1-80.   
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Figure 4.5: Absorption of TH antibodies by TH peptide fragments. 
 
Non-radiolabelled TH fragments containing amino acids 1-80 and 81-140 were used to pre-absorb 18 TH 
antibody-positive vitiligo (V) patient sera prior to the analysis of immunoreactivity against TH in TH 
antibody RIAs. In vitro translated, non-radiolabelled MCHR1 was used as a pre-absorption control 
peptide. The TH Ab index (± SD) is shown for each patient serum sample with and without pre-
absorption and is the mean of two experiments. Taken with kind permission from John Wiley & Sons Ltd. 
(The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012). 
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Table 4.8: Comparison of the TH Ab indices of vitiligo patient sera with and without pre-
absorption with TH fragment 1-80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
P values were calculated using paired t tests (Section 2.27) for comparing the TH Ab indices of TH 
antibody-positive patient sera without pre-absorption to those with pre-absorption using TH fragment 1-
80. P values < 0.05 (two-tailed) were regarded as significant.  
 
 
Patient 
 
P value
1
 
 
V4 0.04 
V8 0.02 
V9 0.04 
V10 0.004 
V20 0.03 
V25 0.02 
V27 0.01 
V30 0.02 
V33 0.04 
V39 0.003 
V62 0.04 
V63 0.03 
V64 0.04 
V69 0.03 
V70 0.04 
V82 0.04 
V86 0.02 
V87 0.03 
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4.3.6 Absorption of TH antibodies by synthetic TH peptides 
To identify epitope(s) located between amino acids 1-80 of TH, a second series of absorption 
experiments were carried out using synthetic peptides corresponding to TH amino acids 1-14, 
15-29, 30-44, 45-60 and 61-80 (Table 2.9). MCHR1 peptide (amino acids 105-118 of MCHR1) 
was used as a control (Table 2.9). The effects of the peptides on TH antibody binding to in vitro 
translated TH were then investigated using TH antibody RIAs. 
For absorption experiments, 18 TH antibody-positive vitiligo patient and 6 healthy 
control sera were pre-incubated at a dilution of 1:100 with synthetic peptides at 100 µg/ml in 50 
µl of immunoprecipitation buffer. After incubation at 4
o
C for 2 h, in vitro translation reaction 
containing radiolabelled TH was added to the samples which were then analysed in TH antibody 
RIAs as previously detailed (Section 2.20). Samples of unabsorbed vitiligo patient and control 
sera were included in each assay set. 
For each serum sample, TH antibody binding was expressed as a TH Ab index which was 
calculated as: cpm immunoprecipitated by tested serum/mean cpm immunoprecipitated by 6 
healthy control sera. Each serum was tested in at least two experiments and the mean TH Ab 
index was calculated from these values. The TH Ab indices for the pre-absorbed and unabsorbed 
vitiligo patient sera were compared using paired t tests (Section 2.27). In all tests, P values <0.05 
(two-tailed) were regarded as significant. 
The results are given in Figure 4.6. TH antibody binding to TH in 17/18 (94%) patient 
sera was significantly reduced in the presence of TH peptide 1-14 (P values were <0.05) (Table 
4.9), when compared with unabsorbed samples. Similarly, 11/18 (61%) patient sera were 
significantly pre-absorbed of TH antibodies with TH peptide 61-80 (P values were <0.05) (Table 
4.9). In contrast, a significant decrease in TH immunoreactivity did not occur following pre-
incubation with TH peptides 15-29, 30-44 and 45-60, and control MCHR1 peptide (all P values 
were > 0.05). The results suggested the presence of TH antibody binding sites between amino 
acids 1-14 and 61-80, with the majority (10/18 = 56%) of patient sera displaying 
immunoreactivity against both these epitopes.  
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Figure 4.6: Absorption of TH antibodies by synthetic TH peptides. 
 
Synthetic peptides corresponding to TH amino acids 1-14, 15-29, 30-44, 45-60 and 61-80 were used to 
pre-absorb 18 TH antibody-positive vitiligo (V) patient sera prior to the analysis of immunoreactivity 
against TH in TH antibody RIAs. Synthetic MCHR1 peptide was used as a pre-absorption control 
peptide. The TH Ab index (± SD) is shown for each patient serum sample with and without pre-
absorption and is the mean of two experiments. Taken with kind permission from John Wiley & Sons Ltd. 
(The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012).  
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Table 4.9: Comparison of the TH Ab indices of vitiligo patient sera with and without pre-
absorption with synthetic TH peptides 1-14 and 61-80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
P values were calculated using paired t tests (Section 2.27) for comparing the TH Ab indices of TH 
antibody-positive patient sera without pre-absorption to those with pre-absorption using synthetic TH 
peptides 1-14
2
 and 61-80
3
. P values < 0.05 (two-tailed) were regarded as significant. 
   
 
Patient 
 
P value
1,2
 
 
 
P value
1,3
 
 
V4 0.005 0.004 
V8 0.04 0.01 
V9 0.02 0.003 
V10 0.03 0.03 
V20 0.04 0.02 
V25 0.04 0.04 
V27 0.02 0.37 
V30 0.13 0.007 
V33 0.03 0.04 
V39 0.01 0.03 
V62 0.03 0.03 
V63 0.02 0.12 
V64 0.02 0.30 
V69 0.04 0.66 
V70 0.03 0.22 
V82 0.03 0.11 
V86 0.02 0.13 
V87 0.006 0.02 
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4.3.7 TH peptide ELISAs with vitiligo patient and control sera 
To confirm immunoreactivity of vitiligo patient sera against TH epitopes 1-14 and 61-80, 
samples from 18 vitiligo and 10 healthy controls were analysed in an ELISA format with 
peptides TH-1-14 and TH-61-80 as antigen (Table 2.9).
 
TH peptide TH-30-44 was used as a 
control (Table 2.9) and ELISAs were carried out as detailed in Section 2.26. All sera were 
assayed in duplicate at a final dilution of 1:100. In each assay set, the binding reactivity of each 
patient and control sera to each TH peptide was expressed as an Ab index calculated as:  mean 
OD405 of tested serum/mean OD405 of a population of 10 healthy control sera. Each serum was 
tested in two experiments and the mean Ab index was calculated from the resulting Ab index 
values. The upper limit of normal for each TH peptide ELISA was calculated using the mean Ab 
index + 3SD of 10 control sera. Patient sera with an Ab index greater than the upper limit of 
normal were regarded as positive for binding to the TH peptide used in the ELISA. 
The results of the TH peptide ELISAs are shown in Figure 4.7 and summarised in Tables 
4.10 and 4.11. All control sera were negative for antibody reactivity against all the TH peptides 
tested, and all samples were negative for anti-TH peptide TH-30-44 antibodies (Table 4.10). Of 
the vitiligo patient sera analysed, 17/18 (94%) and 11/18 (61%), respectively, were positive for 
antibody reactivity against TH peptides TH-1-14 and TH-61-80, and immunoreactivity against 
both epitopes was evident in 10/18 (56%) of the patients (Tables 4.10 and 4.11). The results 
correlated with the findings of the peptide displacement experiments for each of the vitiligo 
patient samples.  
 
4.3.8 Comparison of patient details with TH antibody responses 
The demographic, clinical and MCHR1 and tyrosinase antibody details of the vitiligo patients are 
given in Table 4.12 along with TH antibody epitopes recognised by the patient sera. There was 
no apparent association of patient gender, disease duration, age of disease onset, the presence of 
tyrosinase or MCHR1 antibodies, or the presence of autoimmune disease with recognition of the 
different TH antibody-binding sites.  
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Figure 4.7: Immunoreactivity of vitiligo patient and control sera in TH peptide ELISAs.  
 
Serum samples from 18 vitiligo (V) patient and 10 control (C) sera were analysed for antibody binding to 
TH peptides in an ELISA format. The Ab index is shown for each sample in each ELISA and is the mean 
Ab index of at least two experiments. The upper limits of normal (mean Ab index + 3SD of 10 healthy 
controls) were Ab indices of 1.69, 1.31 and 1.24 for TH peptide 1-14, 61-80 and 30-44 ELISAs, 
respectively. Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, Southern Gate, 
Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012).  
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 Table 4.10: Results of ELISAs using TH peptides 
 
 
 
 
 
 
1
Sera with an Ab index above the upper limit of normal value, calculated from the mean Ab index + 3SD 
of 10 healthy controls, were considered positive for antibodies against the TH peptide used in the ELISA. 
  
 
TH 
peptide 
used in 
ELISA 
 
Mean Ab index ± 
SD  of vitiligo 
patient group 
 
Mean Ab indices 
± SD of control 
group 
 
 
Upper 
limit of 
normal 
for the 
ELISA 
 
 
Number of 
vitiligo 
patients 
positive for 
antibodies
1 
 
 
Number of 
healthy 
controls 
positive for 
antibodies
1 
 
TH-1-14 8.92 ± 4.73 
(range: 1.39-17.00) 
1.02 ± 0.22 
(range: 0.79-1.48) 
1.69 17/18 0/10 
TH-61-80 2.97 ± 2.64 
(range: 0.51-8.99) 
1.02 ± 0.10 
(range: 0.90-1.19) 
1.31 11/18 0/10 
TH-30-44 0.98 ± 0.09 
(range: 0.75-1.11) 
0.98 ± 0.09 
(range: 0.81-1.11) 
1.24 0/18 0/10 
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Table 4.11:  Antibody indices of vitiligo patient sera in ELISAs using TH peptides  
 
 
 
 
Patient 
 
Ab index with 
TH peptide 
TH-1-14
1 
 
 
 
Ab index with 
TH peptide 
TH-61-80
1
  
V4 9.98 ± 1.91 + 3.30 ± 0.17 + 
V8 15.70 ± 1.78 + 8.57 ± 0.53 + 
V9 17.00 ± 2.20 + 2.14 ± 0.10 + 
V10 10.66 ± 1.13 + 5.60 ± 0.33 + 
V20 7.26 ± 1.02 + 3.61 ± 0.20 + 
V25 6.86 ± 0.89 + 3.37 ± 0.18 + 
V27 6.26 ± 0.69 + 0.56 ± 0.01 - 
V30 1.39 ± 0.10 - 8.99 ± 0.56 + 
V33 10.44 ± 2.06 + 3.57 ± 0.19 + 
V39 12.85 ± 2.85 + 4.10 ± 0.13 + 
V62 16.43 ± 2.01 + 3.32 ± 0.18 + 
V63 7.59 ± 1.13 + 0.54 ± 0.04 - 
V64 3.52 ± 0.80 + 0.51 ± 0.06 - 
V69 3.35 ± 0.75 + 0.54 ± 0.08 - 
V70 3.13 ± 0.69 + 0.70 ± 0.09 - 
V82 8.07 ± 1.28 + 0.54 ± 0.03 - 
V86 6.74 ± 1.85 + 0.54 ± 0.03 - 
V87 13.25 ± 1.98 + 3.02 ± 0.16 + 
 
 
1
The Ab index shown for each vitiligo patient serum is the mean ± SD of at least two experiments; +, denotes 
positive for antibody reactivity; -, denotes negative for antibody reactivity. 
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Table 4.12:  TH antibody epitope reactivity shown with the demographic and clinical 
details as well as antibody responses of TH antibody-positive vitiligo patients 
 
 
Patient Sex Autoimmune 
disease
1
 
Onset 
age 
(years) 
Disease 
duration 
(years) 
Antibodies
2
 
MCHR1
3
 TYR
3
 TH epitope 
1-14 
antibodies 
 
TH epitope  
61-80 
antibodies 
V4 M None 70 7 - - + + 
V8 F None 10 27 - - + + 
V9 F None 40 36 + - + + 
V10 M None 56 4 - + + + 
V20 M AA 20 50 - - + + 
V25 F None 6 13 - - + + 
V27 F None 19 4 - + + - 
V30 F None 52 1 - - - + 
V33 F None 51 3 - - + + 
V39 M None 13 19 - - + + 
V62 F ATD 7 20 + - + + 
V63 M None 44 1 - + + - 
V64 M Psoriasis 5 42 - - + - 
V69 F None 39 31 - - + - 
V70 F ATD 20 28 - - + - 
V82 F None 6 1 - - + - 
V86 M None 35 41 + + + - 
V87 M None 19 4 - - + + 
 
 
1
ATD, autoimmune thyroid disease; AA, alopecia areata.
 
2
+, denotes positive for antibody reactivity; -, denotes negative for antibody reactivity. 
3
Tyrosinase (TYR) and MCHR1
 
antibody data are taken from Chapter 3. 
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4.3.9 Sequence analysis of the antibody binding sites on TH  
The amino acid sequence of TH (NCBI Reference Sequence: NM000360.3) was compared with 
related proteins PAH (NCBI Reference Sequence: NM000277.1) and TPH (NCBI Reference 
Sequence: NM004179.2) using the ClustalW2 Multiple Sequence Alignment tool at the network 
facilities of the EBI-EMBL (Section 2.17). The results indicated that the TH epitopes mapped to 
regions of the protein that were not homologous (Figure 4.8). In addition, the antibody binding 
sites identified were present in the more specific regulatory N terminal domain of the TH 
molecule and not in the highly homologous catalytic domain at the C-terminus of the protein 
(Figure 4.8) (Ekwall et al. 2000). 
Amino acid sequence homologies between the characterised TH epitopes and microbial 
and viral polypeptides were not demonstrated in searches against international databases 
performed using the BLAST service of the NCIB (Section 2.17). 
  
 181 
 
 
TPH        -----------------MIEDNKEN-----------------KDHSLER----------- 15 
PAH        -----------------MSTAVLENPGLGRKLSDFGQETSYIEDNCNQN----------- 32 
TH         MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
                                                   
TPH        -------------------GRASLIFSLKNEVG-GLIKALKIFQEKHVNLLHIESRKSKR 55 
PAH        -------------------GAISLIFSLKEEVG-ALAKVLRLFEENDVNLTHIESRPSRL 72 
TH         PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
                                    
TPH        RNS---EFEIFVDCDIN-REQLNDIFHLLKSHTNVLSVNLPDNFTLKEDGMETVPWFPKK 111 
PAH        KKD---EYEFFTHLDKRSLPALTNIIKILRHDIGATVHELS-----RDKKKDTVPWFPRT 124 
TH         PRAGGPHLEYFVRLEVR-RGDLAALLSGVRQVSEDVRSPAG----------PKVPWFPRK 169 
             
TPH        ISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEI 171 
PAH        IQELDRFANQILSYGAELDADHPGFKDPVYRARRKQFADIAYNYRHGQPIPRVEYMEEEK 184 
TH         VSELDKCHHLVTKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEI 229 
            
TPH        KTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRP 231 
PAH        KTWGTVFKTLKSLYKTHACYEYNHIFPLLEKYCGFHEDNIPQLEDVSQFLQTCTGFRLRP 244 
TH         ATWKEVYTTLKGLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRP 289 
             
TPH        VAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQ 291 
PAH        VAGLLSSRDFLGGLAFRVFHCTQYIRHGSKPMYTPEPDICHELLGHVPLFSDRSFAQFSQ 304 
TH         VAGLLSARDFLASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQ 349 
            
TPH        EIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAG-LSSISELKHALSGHAKV 350 
PAH        EIGLASLGAPDEYIEKLATIYWFTVEFGLCKQGDSIKAYGAGLLSSFGELQYCLSEKPKL 364 
TH         DIGLASLGASDEEIEKLSTLYWFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEI 409 
            
TPH        KPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQIL 410 
PAH        LPLELEKTAIQNYTVTEFQPLYYVAESFNDAKEKVRNFAATIPRPFSVRYDPYTQRIEVL 424 
TH         RAFDPEAAAVQPYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDVL 469 
             
TPH        KDTKSITSAMNELQHDLDVVSDALAKVSRKPSI 443 
PAH        DNTQQLKILADSINSEIGILCSALQKIK----- 452 
TH         DSPQAVRRSLEGVQDELDTLAHALSAIG----- 497 
 
 
Figure 4.8: Amino acid sequence homologies between tyrosine hydroxylase, phenylalanine 
hydroxylase and tryptophan hydroxylase. 
 
The amino acid sequences of TH epitopes recognised by vitiligo patient TH antibodies are underlined at 
amino acids 1-14 and 61-80 at the N terminus of TH (NCBI Reference Sequence: NM000360.3). Aligned 
amino acid sequences of phenylalanine hydroxylase (PAH) (NCBI Reference Sequence: NM000277.1) 
and tryptophan hydroxylase (TPH) (NCBI Reference Sequence: NM004179.2) are also shown. Identical 
amino acid residues in the three proteins are highlighted. Taken with kind permission from John Wiley & 
Sons Ltd. (The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 
2012).
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4.4 Results Summary 
The results indicated that: 
  
 
 Two major binding sites for TH antibodies in vitiligo patients were located at the N-
terminus of the protein between amino acids 1-14 and 61-80.  
 
 Of 18 vitiligo patients, 17 (94%) had antibodies against epitope 1-14, and 11 (61%) 
displayed immunoreactivity against epitope 61-80. 
 
 Immunoreactivity against both epitopes was evident in 10/18 (56%) of the vitiligo 
patients, suggesting that the humoral immune response to TH in vitiligo is 
heterogeneous in nature. 
 
 There was no apparent association of patient gender, disease duration, age of disease 
onset, the presence of tyrosinase or MCHR1 antibodies, or the presence of 
autoimmune disease with recognition of the different TH antibody-binding sites. 
 
 The TH epitopes mapped to regions of TH that were not homologous with related 
proteins TPH and PAH. 
 
 Amino acid sequence homologies between the characterised TH epitopes and 
microbial and viral polypeptides were not demonstrated. 
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4.5 Discussion 
In this part of the study, radiolabelled TH protein fragments coupled with absorption experiments 
enabled the identification of two major autoantibody specificities at the N-terminus of TH 
between amino acid residues 1 and 14 (epitope 1-14) and 61 and 80 (epitope 61-80). 
Subsequently, antibody binding to the identified epitopes in vitiligo patient sera was confirmed 
in ELISAs. Of 18 vitiligo patients, 17 (94%) had antibodies against epitope 1-14, and 11 (61%) 
displayed immunoreactivity against epitope 61-80. It was not apparent that epitope recognition 
was associated with patient gender, disease duration, age of disease onset, the presence of 
tyrosinase or MCHR1 antibodies or the presence of autoimmune disease. 
Immunoreactivity to both epitopes was detected in the majority (10/18 = 56%) of vitiligo 
patients, indicating a heterogeneous humoral immune response to TH. Similarly, antibodies in 
autoimmune thyroid disease and type 1 diabetes mellitus have been reported to react against 
multiple epitopes on thyroid peroxidase and tyrosine phosphatase-like IA-2 autoantigens, 
respectively (Zanelli et al. 1992; Lampasona et al. 1996). This has been explained by 
intramolecular spreading of an autoimmune response from a single or few epitope(s) to multiple 
epitopes during disease progression. For example, in type 1 diabetes mellitus, a temporal 
spreading of the antibody responses has been described from immunodominant epitopes in an 
early pre-clinical phase to lesser immunogenic domains at the manifestation of disease (Naserke 
et al. 1998). In the absence of longitudinal serum samples, however, no evidence of TH epitope 
spreading in the patients could be ascertained. 
Although TH shares a high degree (approximately 35%) of amino acid sequence 
homology with both the related enzymes TPH and PAH (Ekwall et al. 2000), neither antigen-
specific nor cross-reacting antibodies to either protein were detected in vitiligo patients 
displaying a humoral immune response to TH (Chapter 3) (Kemp et al. 2011a). In keeping with 
this previous finding (Kemp et al. 2011a), major TH epitopes were demonstrated in areas of the 
protein which had no homology with TPH or PAH.
 
Likewise, although their exact positions have 
not been mapped, epitopes unique for TH have also been proposed for TH antibodies found in 
patients with APS1 (Ekwall et al. 2000).  
The potential applications of the molecular characterisation of B cell epitopes in vitiligo 
include: (i) a greater understanding of the association of an autoantigen with disease 
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pathogenesis, (ii) possible insights into the initiation of the disease process, and (iiii) the 
establishment of novel and more specific assays for measuring antibodies in patient sera.  The 
ways in which these criteria were met by the study undertaken are discussed below. 
Firstly, an association of TH as an autoantigen with vitiligo pathogenesis may be revealed 
by examining the location of the identified epitopes with respect to the functional domains of the 
protein. For example, if the epitopes reside in, or contribute to, the structure of the active site of 
TH, antibodies targeting these epitopes might inhibit enzyme activity. However, the antibody 
binding sites identified did not map to the C-terminal catalytic domain of the enzyme (Ekwall et 
al. 2000), which indicates that the epitope-specific TH antibodies characterised here may not 
have functional effects. Even so, it will be important to undertake further investigations in 
relation to the possible functional effects of TH antibodies in vitiligo patients, since functional 
TH antibodies may well recognise conformational epitopes not identified by the method used 
here. Interestingly, a previous study concerning APS1 patients has demonstrated inhibitory 
effects of TH antibodies on TH function (Hedstrand et al. 2000).  
Secondly, no apparent homology was identified between the specified epitope regions 
and any microbial proteins, suggesting that molecular mimicry does not initiate the production of 
TH antibodies in vitiligo patients. However, as yet uncharacterised B cell epitopes on TH, which 
may be revealed by a study employing conformational epitope mapping techniques, may 
demonstrate cross-reactivity. Moreover, the current computer databases are unlikely to represent 
all microbial proteins. 
Finally, since TH had multiple epitope regions and the antibody response provoked in 
vitiligo patients was heterogeneous, it is unlikely that a specific assay for measuring 
immunoreactivity to TH, limited to either of the epitopes identified here, would be of prognostic 
value for vitiligo.  
The in vitro translation system is a useful procedure for producing both intact and 
modified [
35
S]-methionine-labelled proteins, which can then be used for testing antibody 
reactivity and for epitope mapping (Wedlock et al. 1993; Daw et al. 1996; Volpato et al. 1998; 
Kemp et al. 2001). In this chapter, the technique was used to radiolabel deletion derivatives of 
TH, which were then used in RIAs to identify antigenic regions on the protein. A disadvantage of 
the use of deletion derivatives is in the inevitable loss of native conformation and, therefore, of 
 185 
 
epitope regions which are brought together by the secondary structure of the protein (Pettersson 
1992). In Graves’ disease, for example, it has been reported that the autoantibodies to the 
thyrotropin receptor, which are responsible for disease activity, recognise a number of different 
conformational epitopes (Morgenthaler et al. 1999). In so far as short linear sequences may 
contribute to conformational epitopes, it may be possible to identify at least part of some 
conformational epitopes using the methodology applied in this study. In addition, a previous 
study employing site-directed mutagenesis to dissect reactivity to a conformational autoepitope 
of steroid 21-hydroxylase in autoimmune endocrinological diseases, suggested that testing of 
radiolabelled antigens in liquid-phase immunoprecipitation assay can be conformation-sensitive 
(Nikoshkov et al. 1999). Nevertheless, it would be of interest to apply phage-display technology 
(Scott 1992; Williams et al. 2001) to future epitope mapping studies of TH. Phage-display is 
more suited to the study of conformational epitopes since expressed proteins are able to fold into 
their correct three-dimensional structures in the periplasmic space of the bacterial host, and can 
maintain a native arrangement once displayed on the surface of a phage particle (Wilson and 
Finlay 1998). Although potentially important TH epitopes which may be dependent upon protein 
conformation and so were not characterised in this part of the study, the significant absorption of 
TH antibodies by TH peptides 1-14 and 61-80, confirms that at least two widely recognised TH 
antibody binding sites are linear in nature. 
The use of human sera in the mapping of B cell epitopes can be problematic because sera 
contain multiple antibody species against a particular autoantigen and the immune response tends 
to diversify with duration. It is difficult therefore to examine the reactivity of a specific 
autoantibody in isolation and it is not possible to discriminate between a single autoantibody 
targeted at an epitope and a set of closely-related autoantibodies directed at the same epitope. In 
order to characterise the array of autoantibodies present in a particular serum and the epitope 
specificity of a particular autoantibody, the production of human monoclonal antibodies from the 
patient is usually required. Indeed, monoclonal antibodies isolated from individuals with type 1 
diabetes mellitus have been successfully employed to identify the antibody binding sites on 
glutamic acid decarboxylase, an autoantigen in this disease (Syren et al. 1996). Although the 
monoclonal antibody approach can allow the precise characterisation of epitopes recognised by a 
specific antibody, it is difficult to know the relative frequencies of the different monoclonal 
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antibodies in the patient under investigation. Despite this, the isolation of monoclonal antibodies 
from vitiligo patients will allow a more complete and detailed analysis of the epitopes recognised 
by TH antibodies. 
In summary, mapping of conformational epitopes and identifying TH antibodies with 
functional effects will give more information on the association of TH antibodies with vitiligo. 
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CHAPTER 5 
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5. Characterisation of IgG subclasses, avidities and titres of 
vitiligo patient TH antibodies  
 
5.1 Introduction 
 
5.1.1 Immunoglobulins  
The immunoglobulin G is a major effector molecule of the humoral immune response in man 
and accounts for about 75% of the total immunoglobulins in plasma of healthy individuals. The 
immunoglobulins of the other four classes, IgM, IgA, IgD and IgE, each of which has 
characteristic properties and functions, constitute the other 25% of the immunoglobulins 
(Spiegelberg 1974). Antibodies of the IgG class express their predominant activity during a 
secondary antibody response. Thus, the appearance of specific IgG antibodies generally 
corresponds with the 'maturation' of the antibody response, which is switched on upon repeated 
contact with an antigen. In comparison to antibodies of the IgM class, IgG antibodies have a 
relatively high affinity and persist in the circulation for a long time.  
 
5.1.2 IgG subclasses 
Four distinct subgroups of human IgG have been identified designated IgG1, IgG2, IgG3 and 
IgG4, respectively (Gergely 1967). Quantitatively, the relative serum concentrations of the 
human IgG subclasses are: IgG1>IgG2>IgG3=IgG4 (Table 5.1) (Shakib and Stanworth 1980; 
French 1986). The four subclasses have structural differences and, as a consequence, show 
differences in some of their biological properties which are summarised in Table 5.1. For 
example, the capacity of the four human IgGs to activate complement decreases in the order: 
IgG3>IgG1>IgG2, with IgG4 unable to activate complement (Flanagan and Rabbitts 1982; van 
Loghem 1986). The four human IgG subclasses also show differences in their interaction with Fc 
receptors for IgG (FcγR). The latter are expressed primarily on effector cells of the immune 
system, in particular macrophages, monocytes, myeloid cells and dendritic cells and binding of  
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Table 5.1: Properties of IgG subclasses
1
 
 
 
Property 
 
IgG1 IgG2 IgG3 IgG4 
Antibody concentrations     
Adult serum level range (g/l)  
(mean, g/l)  
4.9-11.4  
(6.98)  
1.5-6.4 
(3.8)  
0.20-1.10 
(0.51)  
0.08-1.40 
(0.56)  
Proportion of total IgG (%)  43-75  16-48  1.7-7.5  0.8-11.7  
Antibody response to          
Proteins  ++
3 
 +/- 
3
 ++  +/-  
Polysaccharides  +
3 
 ++  -
3
  -  
Allergens  +  -  -  ++  
Complement activation          
C1q binding  ++  +  +++
3
  -  
Binding to Fcγ receptors          
Fcγ RI2 (CD64:monocytes, 
macrophages, neutrophils, dendritic 
cells)  
++  -  +++  +  
Fcγ RII (CD32):monocytes, 
macrophages, neutrophils, eosinophils, 
platelets, B cells, dendritic cells, 
endothelial cells)  
++  - +++  -  
Fcγ RIIa-H131  ++  +++  +++  -  
Fcγ RIIa-R131  ++  -  ++  -  
Fcγ RIII (CD16:neutrophils, 
eosinophils, macrophages, NK cells, 
subsets of T cells)  
++  -  ++  -  
Fcγ RIIIb-NA1  +++  -  +++  -  
Fcγ RIIIb-NA2  ++  -  ++  -  
 
 
1
Information adapted from Roitt 1997. 
2FcγR, Fc receptors for IgG. 
3
-, negative; -/+, weakly positive; +, positive; ++, strongly positive; +++, very strongly positive.  
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the Fc part of IgG to a FcγR is instrumental in the induction of the effector cell’s function (van 
de Winkel and Capel 1993; van de Winkel and Capel 1996), which can comprise phagocytosis, 
endocytosis, antibody-mediated cellular cytotoxicity, release of a range of inflammatory 
mediators, antigen presentation and clearance of immune complexes. 
In autoimmune diseases, the levels of IgG subclasses mostly do not differ from those in 
healthy individuals, but specific antibodies show variable subclass restrictions. For example, in 
autoimmune Addison’s disease and autoimmune ovarian insufficiency, antibodies against 21-
hydroxylase, 17α-hydroxylase and cholesterol side-chain cleavage enzyme are predominantly of 
the IgG1 subtype (Boe et al. 2004; Brozzetti et al. 2010). This is also the case for antibody 
responses against protein tyrosine phosphatase IA-2 and glutamic acid decarboxylase in patients 
with type I diabetes mellitus (Bonifacio et al. 1999; Hawa et al. 2000). Comparisons of IgG 
subclass distributions of anti-thyroid peroxidase antibodies in patients with autoimmune 
hypothyroidism have indicated a predominance of IgG1 and IgG4 (Kohno et al. 1993; Silva et 
al. 2003; Xie et al. 2008). In the case of anti-thyroglobulin antibodies in Hashimoto’s thyroiditis 
and Graves’ disease, IgG2 and IgG4 were the dominant subtypes, respectively (Caturegli et al. 
1994). 
In autoimmune connective tissue diseases, the IgG subclass distribution of human 
autoantibodies to Sm-antigen, double-stranded DNA, ribonucleoprotein, SS-B-antigen (also 
called La), and IgG rheumatoid factor has been determined in patients with systemic lupus 
erythematosus, Sjögren's syndrome, and rheumatoid arthritis. For anti-Sm-antigen and anti- 
ribonucleoprotein antibodies, IgG1 was the predominant isotype. For anti-double-stranded DNA 
and anti-SS-B-antigen antibodies, IgG1 and a lesser contribution of IgG3 was found. In contrast, 
IgG1 and IgG4 were the predominant isotypes of human IgG rheumatoid factor (Gharavi et al. 
1988; Yount et al. 1988). 
Finally, patient antibodies to neutrophil cytoplasmic antigens (ANCA) are predominantly 
of the IgG1 and IgG4 subclass (Brouwer et al. 1991; Mellbye et al. 1994). However, in patients 
with renal involvement, ANCA antibodies of the IgG3 subclass can occur (Mellbye et al. 1994). 
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5.1.3 IgG avidity 
Antibody affinity refers to the strength of binding between a single antigenic determinant and an 
individual antibody combining site (Roitt and Delves 1997). In most practical circumstances, 
however, avidity (or functional affinity) is used to describe the overall strength of binding 
between multivalent antigens and antibodies, and this is most applicable to the measurement of 
the interaction of an antiserum or patient serum with its target antigen (Roitt and Delves 1997). 
In vivo, high avidity antibodies are superior to those of low avidity for a wide variety of immune 
functions (Roitt and Delves 1997). 
It has been suggested that antibody avidity could be an important feature of antibodies in 
autoimmune disease (Gharavi and Reiber 1996). However, the avidity of autoantibodies has not 
been sufficiently studied to give decisive answers of their clinical usefulness. In a few cases, 
high avidity antibodies have been shown to be associated with greater pathogenicity (Takeda et 
al. 2001; Cucnik et al. 2004; Cucnik et al. 2011). For example, high avidity anti-β2-glycoprotein 
I antibodies in patients with antiphospholipid syndrome have an increased pathological function 
compared with low avidity anti-β2-glycoprotein I antibodies (Cucnik et al. 2004; Cucnik et al. 
2011). Furthermore, in systemic lupus erythematosus patients, double-stranded DNA and 
ribosomal P antibodies which have lower binding avidities are considered less harmful and 
associated with a lower prevalence of nephropathy (Takeda et al. 2001). 
 
5.1.4 IgG titres 
An antibody titer is a measurement of how much antibody an organism has produced that 
recognises a particular epitope, expressed as the greatest dilution that still gives a positive result. 
Measurement of antibody titres can offer an easy and useful way for determination of disease 
progression, for example as in autoimmune thyroid disorders (Etienne-Decerf et al. 1987) 
 
5.1.5 TH antibodies in vitiligo 
Our previous work identified TH antibodies of the IgG class present in vitiligo patient sera. In 
addition, two main epitopes were determined for TH antibodies. The analysis of TH antibodies in 
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terms of their subclass, avidity and titres would be valuable characterisations of the humoral 
immune response against TH. 
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5.2 Aims 
The aims of this part of the study were: 
 
 
 
 To determine the titres of antibodies against TH epitopes 1-14 and 61-80 using 
TH peptide ELISAs. 
 
 
 To analyse the IgG subclasses of antibodies against TH epitopes 1-14 and 61-80 
using TH peptide ELISAs with IgG subtype-specific secondary antibodies. 
 
 
 To evaluate the avidities of antibodies against TH epitopes 1-14 and 61-80 using 
TH peptide ELISAs to measure antibody-binding in the presence of increasing 
NaCl concentrations. 
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5.3 Experiments and Results 
 
5.3.1 Determination of vitiligo patient antibody titres against TH epitopes 1-14 
and 61-80 
Patient antibody titres against TH peptides 1-14 and 61-80 (Table 2.9) were determined using 
TH peptide ELISAs as detailed in Section 2.26. In the TH peptide 1-14 ELISA, serum samples 
from 17 vitiligo and 10 healthy controls were analysed in duplicate at final dilutions ranging 
from 1:100 to 1:2000. In the TH peptide 61-80 ELISA, serum samples from 11 vitiligo and 10 
healthy controls were analysed in duplicate at final dilutions ranging from 1:100 to 1:2000. 
In each assay set, the binding reactivity of each patient and control sera to each TH peptide 
was expressed as an Ab index calculated as:  mean OD405 of tested serum/mean OD405 of a 
population of 10 healthy control sera. Each serum was tested in two experiments and the mean 
Ab index was calculated from the resulting Ab index values. Patient sera with an Ab index 
greater than the upper limit of normal were regarded as positive for binding to the TH peptide 
used in the ELISA: an Ab index of 1.69 for TH peptide 1-14, and 1.31 for TH peptide 61-80 
(Chapter 4). 
The results of the TH peptide ELISAs are shown in Figures 5.1a and b. In Table 5.2, the 
results are summarised showing the serum dilution in which antibody reactivity could still be 
detected at levels above the upper limit of normal for the TH peptide ELISA. In general, higher 
antibody titres were found against the TH peptide representing epitope 1-14. It is unclear why 
antibody titres against TH peptide 1-14 have a lower measurement at 1:200 dilution compared 
with 1:500 (Figure 5.1a), or why antibody titres against TH peptide 61-80 have a lower 
measurement at 1:100 dilution compared with 1:200 (Figure 5.1b). 
 
5.3.2 Analysis of IgG subclasses of vitiligo patient antibodies against TH 
epitopes 1-14 and 61-80 
To determine TH antibody IgG subclasses, sera from vitiligo patients and healthy controls were 
analysed in ELISAs with TH peptides 1-14 and 61-80 (Table 2.9) as detailed in Section 2.26. 
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IgG subclass-specific secondary antibodies were used to detect the binding of primary antibodies 
in the ELISAs (Section 2.26). In the TH peptide 1-14 ELISA, serum samples from 17 vitiligo 
and 10 healthy controls were analysed in duplicate at a final dilution of 1:100. In the TH peptide 
61-80 ELISA, serum samples from 11 vitiligo and 10 healthy controls were analysed in duplicate 
at a final dilution of 1:100. 
In each assay set, the binding reactivity of each patient and control sera to each TH peptide 
was expressed as an Ab index calculated as:  mean OD405 of tested serum/mean OD405 of a 
population of 10 healthy control sera. Each serum was tested in two experiments and the mean 
Ab index was calculated from the resulting Ab index values. The upper limit of normal for each 
TH peptide ELISA using different secondary antibodies was calculated using the mean Ab index 
+ 3SD of the population of healthy control sera. Patient sera with an Ab index greater than the 
upper limit of normal were regarded as positive for binding to the TH peptide used in the ELISA. 
The Ab indices of the patient and control sera and the upper limit of normal (mean Ab 
index + 3SD of 10 control sera) for each ELISA are shown in Figures 5.2a and b. The results, 
which are summarised in Table 5.3, indicated that antibodies against TH epitope 1-14 were 
exclusively of the IgG1 subclass in 17/17 (100%) vitiligo patients. Predominantly, antibody 
responses against TH epitope 61-80 were also of the IgG1 subclass and were detected in 9/11 
(82%) vitiligo patients. Two of 11 (18%) vitiligo patients had TH epitope 61-80 antibodies of 
subclass IgG3. 
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Figure 5.1a: Titres of vitiligo patient antibodies against TH epitope 1-14.  
 
The 17 TH antibody-positive vitiligo (V) sera and 10 healthy control (C) sera were analysed at dilutions 
of 1:100, 1:200, 1:500, 1:1000, and 1:2000 in TH peptide ELISAs with peptide 1-14. The Ab index (± 
SD) of each vitiligo patient serum at each dilution is shown and is the mean of two experiments. The 
results are also shown for 1 control. The upper limit of normal for the TH peptide 1-14 ELISA was an Ab 
index of 1.69 (Chapter 4).  
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Figure 5.1b: Titres of vitiligo patient antibodies against TH epitope 61-80. 
 
The 11 TH antibody-positive vitiligo (V) sera and 10 healthy control (C) sera were analysed at dilutions 
of 1:100, 1:200, 1:500, 1:1000, and 1:2000 in TH peptide ELISAs with peptide 61-80. The Ab index (± 
SD) of each vitiligo patient serum at each dilution is shown and is the mean of two experiments. The 
results are also shown for 1 control. The upper limit of normal for the TH peptide 61-80 ELISA was an 
Ab index of 1.31 (Chapter 4). 
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Table 5.2: Titres of vitiligo patient antibodies against TH epitopes 1-14 and 61-80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+, denotes positive for antibody reactivity; -, denotes negative for antibody reactivity. 
2
The antibody titre is given as the dilution at which immunoreactivity in the serum sample could still be 
detected at levels above the upper limit of normal in the TH peptide ELISA: An Ab index of 1.69 for TH 
peptide 1-14, and 1.31 for TH peptide 61-80 (Chapter 4). 
  
Vitiligo 
patient 
TH epitope 
1-14 antibodies 
TH epitope  
61-80 antibodies 
Antibody 
reactivity
1
 
Antibody 
titre
2
 
Antibody 
reactivity
1
 
Antibody 
titre
2
 
V4 +  1:500 +  1:200 
V8 +  1:1000 +  1:500 
V9 +  1:2000 +  1:200 
V10 +  1:1000 +  1:500 
V20 +  1:2000 +  1:200 
V25 +  1:1000 +  1:200 
V27 +  1:500 - - 
V30 - - +  1:1000 
V33 +  1:1000 +  1:200 
V39 +  1:2000 +  1:200 
V62 +  1:1000 +  1:200 
V63 +  1:500 - - 
V64 +  1:500 - - 
V69 +  1:500 - - 
V70 +  1:500 - - 
V82 +  1:500 - - 
V86 +  1:500 - - 
V87 +  1:2000 +  1:500 
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Figure 5.2a: IgG subclasses of vitiligo patient antibodies against TH epitope peptide 1-14. 
 
The 17 TH antibody-positive vitiligo (V) sera and 10 healthy control (C) sera at a dilution of 1:100 were 
analysed in TH peptide ELISAs with peptide 1-14 and IgG-specific subclass secondary antibodies. The 
Ab index is shown for each serum and is the mean of two experiments. The upper limits of normal for the 
TH peptide 1-14 ELISA were Ab indices of 1.41, 1.29, 1.63 and 1.63 for secondary antibodies IgG1, 
IgG2, IgG3 and IgG4, respectively. Taken with kind permission from John Wiley & Sons Ltd. (The 
Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012). 
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Figure 5.2b: IgG subclasses of vitiligo patient antibodies against TH epitope peptide 61-80. 
 
The 11 TH antibody-positive vitiligo (V) sera and 10 healthy control (C) sera at a dilution of 1:100 were 
analysed in TH peptide ELISAs with peptide 61-80 and IgG-specific subclass secondary antibodies. The 
Ab index is shown for each serum and is the mean of two experiments. The upper limits of normal for the 
TH peptide 61-80 ELISA were Ab indices of 1.27, 1.52, 1.56 and 1.46 for secondary antibodies IgG1, 
IgG2, IgG3 and IgG4, respectively. Taken with kind permission from John Wiley & Sons Ltd. (The 
Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012). 
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Table 5.3: IgG subclasses of vitiligo patient antibodies against TH epitopes 1-14 and 61-80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+, denotes positive for antibody reactivity; -, denotes negative for antibody reactivity. 
  
Vitiligo 
patient 
TH epitope 
1-14 antibodies 
TH epitope  
61-80 antibodies 
Antibody 
reactivity
1
 
IgG 
subclass 
Antibody 
reactivity
1
 
IgG 
subclass 
V4 +  IgG1 +  IgG1 
V8 +  IgG1 +  IgG1 
V9 +  IgG1 +  IgG1 
V10 +  IgG1 +  IgG1 
V20 +  IgG1 +  IgG1 
V25 +  IgG1 +  IgG1 
V27 +  IgG1 - - 
V30 - - +  IgG3 
V33 +  IgG1 +  IgG1 
V39 +  IgG1 +  IgG1 
V62 +  IgG1 +  IgG1 
V63 +  IgG1 - - 
V64 +  IgG1 - - 
V69 +  IgG1 - - 
V70 +  IgG1 - - 
V82 +  IgG1 - - 
V86 +  IgG1 - - 
V87 +  IgG1 +  IgG3 
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5.3.3 Evaluation of avidities of vitiligo patient antibodies against TH epitopes 
1-14 and 61-80 
To determine TH antibody avidity, sera from vitiligo patients, and healthy controls were 
incubated with NaCl at final concentrations of 0.15, 0.5, 1.5 and 3.0 M (with account taken of 
the concentration of NaCl in the PBS which was used as the diluent) to give chaotropic 
conditions (Takeda et al. 2001; Cucnik et al. 2004; Cucnik et al. 2011) prior to analysis in TH 
peptide ELISAs with peptides 1-14 and 61-80 (Table 2.9) as detailed in Section 2.26. 
In each assay set, the binding reactivity of each patient and control sera to each TH 
peptide was expressed as an Ab index calculated as:  mean OD405 of tested serum/mean OD405 of 
a population of 10 healthy control sera. Each serum was tested in two experiments and the mean 
Ab index was calculated from the resulting Ab index values. Patient sera with an Ab index 
greater than the upper limit of normal were regarded as positive for binding to the TH peptide 
used in the ELISA: An Ab index of 1.69 for TH peptide 1-14, and 1.31 for TH peptide 61-80 
(Chapter 4). 
The results of the TH peptide ELISAs are shown in Figures 5.3a and b. In Table 5.4, the 
results are summarised and show the molar NaCl concentration at which antibody reactivity 
could still be detected at levels above the upper limit of normal for the TH peptide ELISA. TH 
antibodies against TH epitope 1-14 in 15/17 (88%) vitiligo patients retained binding activity, as 
measured by a positive Ab index, at a NaCl concentration of 0.5 M. Loss of binding activity was 
evident in a further 8 vitiligo patient sera at 1.5 M NaCl, as indicated by a negative Ab index. At 
3.0 M NaCl, 7 vitiligo patient sera remained positive for TH antibodies in the TH peptide 1-14 
ELISA. For TH antibodies against epitope 61-80, immunoreactivity was still detected in 8/11 
(73%) vitiligo patients at a NaCl concentration of 0.5 M. Loss of binding activity was evident in 
a further 6 vitiligo patient sera at 1.5 M NaCl. Two vitiligo patient sera remained positive for TH 
antibodies against TH peptide 61-80 at 3.0 M NaCl. Overall, the results suggested that TH 
antibodies were of variable avidity towards their antigenic TH peptide target. 
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5.3.4 Comparison of patient details with TH antibody titres, IgG subclasses 
and avidities 
The demographic details, clinical features, MCHR1 and tyrosinase antibody reactivities, and TH 
antibody epitopes of the vitiligo patients are given in Table 5.5 along with TH antibody titres,  
  
 
Figure 5.3a: Avidities of vitiligo patient antibodies against TH epitope peptide 1-14. 
 
The 17 TH antibody-positive vitiligo (V) sera and 10 healthy control (C) sera were analysed at a dilution 
of 1:100 in TH peptide ELISAs with peptide 1-14 following incubation with NaCl at concentrations of 
0.15, 0.5, 1.5 and 3.0 M. The Ab index (± SD) is shown for 17 vitiligo patient sera and 1 control serum 
and is the mean of two experiments. The upper limit of normal for the TH peptide 1-14 ELISA was an Ab 
index of 1.69 (Chapter 4). Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, 
Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012). 
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Figure 5.3b: Avidities of vitiligo patient antibodies against TH epitope peptide 61-80. 
 
The 11 TH antibody-positive vitiligo (V) sera and 10 healthy control (C) sera were analysed at a dilution 
of 1:100 in TH peptide ELISAs with peptide 61-80 following incubation with NaCl at concentrations of 
0.15, 0.5, 1.5 and 3.0 M. The Ab index (± SD) is shown for 11 vitiligo patient sera and 1 control serum 
and is the mean of two experiments. The upper limit of normal for the TH peptide 61-80 ELISA was an 
Ab index of 1.31 (Chapter 4). Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, 
Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012). 
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Table 5.4: Avidities of vitiligo patient antibodies against TH epitopes 1-14 and 61-80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+, denotes positive for antibody reactivity; -, denotes negative for antibody reactivity. 
2
The antibody avidity is given as the highest molar (M) NaCl concentration at which immunoreactivity of 
the serum sample could still be detected at levels above the upper limit of normal in the TH peptide 
ELISAs; An Ab index of 1.69 for TH peptide 1-14, and 1.31 for TH peptide 61-80 (Chapter 4). 
 
 
Vitiligo 
patient 
TH epitope 
1-14 antibodies 
TH epitope  
61-80 antibodies 
Antibody 
reactivity
1
 
Antibody 
avidity
2
 
Antibody 
reactivity
1
 
Antibody 
avidity
2
 
V4 +  3.0 M +  0.15 M 
V8 +  3.0 M +  3.0 M 
V9 +  3.0 M +  0.15 M 
V10 +  3.0 M +  0.5 M 
V20 +  0.5 M +  0.5 M 
V25 +  3.0 M +  0.5 M 
V27 +  0.5 M - - 
V30 - - +  3.0 M 
V33 +  0.5 M +  0.5 M 
V39 +  0.5 M +  0.5 M 
V62 +  3.0 M +  0.15 M 
V63 +  0.5 M - - 
V64 +  0.15 M - - 
V69 +  0.5 M - - 
V70 +  0.15 M - - 
V82 +  3.0 M - - 
V86 +  0.5 M - - 
V87 +  0.5 M +  0.5 M 
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Table 5.5: Summary of TH antibody epitope reactivity, titres, IgG subclass and avidity with demographic details, clinical features 
and antibody responses of TH antibody-positive vitiligo patients 
 
1
AA, alopecia areata; ATD, autoimmune thyroid disease.
  
2
Tyrosinase (TYR) and MCHR1
 
antibody data are taken from Chapter 3. 
3
+, denotes positive for antibody reactivity; -, denotes negative for antibody reactivity. 
4
The antibody titre is given as the dilution at which immunoreactivity of the serum sample could still be detected at levels above the upper limit of normal in the TH 
peptide ELISA. 
5
The antibody avidity is given as the highest molar (M) NaCl concentration at which immunoreactivity of the serum sample could still be detected at levels above the 
upper limit of normal in the TH peptide ELISA. 
Taken with kind permission from John Wiley & Sons Ltd. (The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK) from (Rahoma et al. 2012). 
Vitiligo 
patient 
Sex Autoimmune 
disease1 
Onset 
age 
(years) 
Vitiligo 
duration 
(years) 
Antibodies2 TH epitope 
1-14 antibodies 
 
TH epitope  
61-80 antibodies 
MCHR1 TYR Antibody 
reactivity3 
Antibody 
titre4 
IgG 
subclass 
Antibody 
avidity5 
Antibody 
reactivity3 
Antibody 
titre4 
IgG 
subclass 
Antibody 
avidity5 
V4 M None 70 7 - - +  1:500 IgG1 3.0 M +  1:200 IgG1 0.15 M 
V8 F None 10 27 - - +  1:1000 IgG1 3.0 M +  1:500 IgG1 3.0 M 
V9 F None 40 36 + - +  1:2000 IgG1 3.0 M +  1:200 IgG1 0.15 M 
V10 M None 56 4 - + +  1:1000 IgG1 3.0 M +  1:500 IgG1 0.5 M 
V20 M AA 20 50 - - +  1:2000 IgG1 0.5 M +  1:200 IgG1 0.5 M 
V25 F None 6 13 - - +  1:1000 IgG1 3.0 M +  1:200 IgG1 0.5 M 
V27 F None 19 4 - + +  1:500 IgG1 0.5 M - - - - 
V30 F None 52 1 - - - - - - +  1:1000 IgG3 3.0 M 
V33 F None 51 3 - - +  1:1000 IgG1 0.5 M +  1:200 IgG1 0.5 M 
V39 M None 13 19 - - +  1:2000 IgG1 0.5 M +  1:200 IgG1 0.5 M 
V62 F ATD 7 20 + - +  1:1000 IgG1 3.0 M +  1:200 IgG1 0.15 M 
V63 M None 44 1 - + +  1:500 IgG1 0.5 M - - - - 
V64 M Psoriasis 5 42 - - +  1:500 IgG1 0.15 M - - - - 
V69 F None 39 31 - - +  1:500 IgG1 0.5 M - - - - 
V70 F ATD 20 28 - - +  1:500 IgG1 0.15 M - - - - 
V82 F None 6 1 - - +  1:500 IgG1 3.0 M - - - - 
V86 M None 35 41 + + +  1:500 IgG1 0.5 M - - - - 
V87 M None 19 4 - - +  1:2000 IgG1 0.5 M +  1:500 IgG3 0.5 M 
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IgG subclasses and avidities. There was no apparent association of patient gender, disease 
duration, age of disease onset, the presence of tyrosinase or MCHR1 antibodies or the presence 
of autoimmune disease with TH antibody titres, avidities or IgG subclasses. 
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5.4 Summary of Results 
The results indicated that: 
  
 
 In general, higher antibody titres were found against the TH peptide representing 
epitope 1-14. 
 
 
 Antibodies against TH epitope 1-14 were exclusively of the IgG1 subclass. 
 
 Antibody responses against TH epitope 61-80 were also predominantly of the IgG1 
subclass with IgG3 subtype antibodies in a minority of patients. 
 
 TH antibodies were of variable avidity towards their antigenic TH peptide target with 
antibody binding detected at 3 M NaCl in several patient sera. 
 
 
 There was no apparent association of patient gender, disease duration, age of disease 
onset, the presence of tyrosinase or MCHR1 antibodies or the presence of 
autoimmune disease with TH antibody titres, avidities or IgG subclasses. 
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5.5 Discussion 
In this part of the study, particular characteristics of TH antibodies in vitiligo patients were 
examined including titres, subclasses and avidities. Overall, the titres, subclasses and avidities of 
TH antibodies were not associated with the clinical features of the vitiligo patients.  
Like many reports on IgG subclass determination in autoimmune disease (Boe et al. 
2004; Brozzetti et al. 2010), TH antibodies against both identified epitopes were predominantly 
of the IgG1 subclass. Antibodies against epitope 61-80 were of the IgG3 subtype in a minority of 
patients. No TH antibodies representing subclasses IgG2 or IgG4 were detected. Previously, anti-
melanocyte antibodies have also been characterised as IgG (Naughton et al. 1983a; Naughton et 
al. 1983b; Cui et al. 1992; Cui et al. 1995; Hann et al. 1996a; Hann and Lee 1996; Rocha et al. 
2000; Farrokhi et al. 2005), and as belonging to subclasses IgG1, IgG2 and IgG3 (Xie et al. 
1991). Interestingly, IgG1 and IgG3 subclass antibodies have the capacity to activate 
complement and to induce cellular effector mechanisms (Flanagan and Rabbitts 1982; van 
Loghem 1986), both of which have been reported to damage melanocytes in vitiligo patients 
(Norris et al. 1988). Such possible functional effects of TH antibodies in vitiligo patients have 
yet to be studied. 
The profile of IgG isotypes is influenced by the T helper cell Th1/Th2 balance of the 
immune response (Snapper and Paul 1987; Finkelman et al. 1990). T helper cells differentiate 
into functionally distinct subsets termed Th1 and Th2 which produce distinct immune responses 
associated by distinct patterns of cytokine secretion (Romagnani 1995; Mosmann and Sad 1996). 
The Th1 subset is characterised by the production of IFN-γ, IL-2, and TNF-β, and Th1 responses 
induce macrophage and cytotoxic T lymphocyte activation and immunoglobulin IgG subclass 
switching to favor complement fixation and opsonisation (Romagnani 1995; Mosmann and Sad 
1996). Th1 responses favor effective clearance of intracellular pathogens and are likely to be 
important in organ-specific autoimmune diseases (Romagnani 1995; Mosmann and Sad 1996). In 
contrast, Th2 cells, defined by their propensity to secrete IL-4, IL-5, and IL-10, are important in 
allergy, mast cell/IgE-mediated immediate type hypersensitivity responses, and helminth 
infections, in which protective responses are mediated by eosinophils (Romagnani 1995; 
Mosmann and Sad 1996). In humans, the levels of IgG1 and IgG3 have been related to a Th1 
predominance of immune responses, whereas a Th2 dominant response promotes an antibody 
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selection of the IgG4 subclass (Snapper and Paul 1987; Finkelman et al. 1990). In vitiligo, there 
is an immunopolarisation of CD4+ and CD8+ T cells to a Th1-type cytokine profile associated 
with melanocyte loss, which would fit with the finding that TH antibodies are mainly of the IgG1 
subclass (Wankowicz-Kalinska et al. 2003). Interestingly, the SL chicken model of vitiligo also 
appears to be a Th1-polarised autoimmune disease (Section 1.3.9.3) (Shi and Erf 2012). 
More accurate identification of IgG subclasses of the TH antibodies could have been 
made by using affinity chromatography to purify the different IgG subtypes from vitiligo patient 
sera prior to using in the ELISA (Soundararajan et al. 2005). Furthermore, purified IgG subclass 
antibodies could have been used to immunoprecipitate TH in the TH antibody RIA. This might 
have enabled the identification of other IgG subclasses of TH antibodies that were not against the 
two dominant linear TH epitopes used as the antigen in the IgG subclass ELISA experiments.  
The avidities of the TH antibodies were found to vary between the vitiligo patient sera 
analysed. It has been suggested that antibody avidity could be an important feature of antibodies 
in autoimmune disease (Gharavi and Reiber 1996). High avidity antibodies have been shown to 
be associated with greater pathogenicity as in the case of anti-β2-GPI antibodies in patients with 
antiphospholipid syndrome (Cucnik et al. 2004; Cucnik et al. 2011). However, further studies 
will need to be undertaken with respect to TH antibodies in vitiligo to ascertain, in the first 
instance, if they have any pathogenic properties, and secondly to determine if any pathogenic 
properties are related to antibody avidity. 
The method used here to determine TH antibody avidity is relatively simple and 
measures the ionic interactions between the antibody and antigen, which can be disrupted by 
changing NaCl concentrations. A better measure of avidity could be gained from other solid 
phase assays including competitive inhibition assays, and elution assays (Pullen et al. 1986; 
Goldblatt et al. 1999; Zhang et al. 2010). In both of them the antigen is attached to a solid 
support. In the competitive inhibition assay, antibody is added in solution at a fixed 
concentration, together with free antigen in different concentrations, and the amount of antigen 
which inhibits solid phase binding in an ELISA by 50% is determined (Zhang et al. 2010). The 
less antigen needed, the stronger the avidity. 
In elution assays, the antibody is added in solution. After obtaining a state of equilibrium, 
a chaotrope or denaturant agent (e.g., isothiocyanate, urea, or diethylamine) is added in different 
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concentrations to disrupt antibody/antigen interactions. The amount of antibody resisting elution 
is determined thereafter with an ELISA. The higher the avidity, the more chaotropic agent is 
needed to elute a certain amount of antibody. The relative avidity of a heterogeneous mixture of 
antibodies can be expressed as the avidity index, equal to the concentration of eluting agent 
needed to elute 50% of the bound antibody. Refined analysis of data can be performed by 
determining percentages of eluted antibody at different concentrations of the eluting agent. 
However, the avidity index is not an absolute but only a relative measure, and for identical pairs 
of antibody/antigen, it strongly varies as a function of the precise conditions of the assay. 
Moreover, the coating antigen may be different from antigen found in physiological conditions 
with respect to density and conformation (Goldblatt et al. 1999). Information on low-avidity 
antibodies might be lost, as on reaching the equilibrium before addition of the eluting agent, 
lower proportions of low-avidity antibody are bound to the coating antigen than of higher-avidity 
antibody, which means that higher-avidity antibodies are preferentially detected and analysed 
(Butler 2000) 
The TH antibody titres varied between the different vitiligo patients. Further studies are 
required to determine if TH antibody titres alter during the course of the disease and whether or 
not they have any prognostic significance.  
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CHAPTER 6 
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6. General Discussion 
 
6.1 Discussion of the Results 
Various hypotheses have been suggested to explain the mechanisms involved in vitiligo 
pathogenesis such as genetic susceptibility, biochemical and neural abnormalities, melanocyte 
dysfunction and both the cellular and humoral immunity (Le Poole et al. 1993a; Schallreuter et 
al. 2008a; Boissy and Spritz 2009). There are several lines of evidence for the involvement of the 
immune system in the destruction of cutaneous melanocytes in vitiligo:  
 
 Vitiligo is frequently associated with a variety of autoimmune disorders such as 
autoimmune thyroiditis, Addison’s disease, pernicious anaemia and type 1 diabetes 
mellitus (Taïeb 2000; Alkhateeb et al. 2003). 
 Detection in vitiligo patients of autoreactive T lymphocytes and autoantibodies against 
melanocyte proteins (Kemp et al. 1997a; Kemp et al. 1997b; Kemp et al. 1998b; Kemp et 
al. 1998c; Lang et al. 2001; Palermo et al. 2001; Kemp et al. 2002; van den Boorn et al. 
2009). 
 Non-segmental vitiligo responds less well to autologous melanocyte grafting than 
segmental vitiligo (Gauthier and Surleve-Bazeille 1992; Taïeb 2000) and is responsive to 
treatment with immunosuppressive agents such as steroids and calcineurin inhibitors 
(Lepe et al. 2003). 
 The presence of allelic variations in genes that are involved in the regulation of the 
immune response (Spritz 2006; Spritz 2007; Spritz 2008; Spritz 2010b; Spritz 2011; 
Spritz 2012). For example, the association between certain allelic variations of HLA 
genes and vitiligo susceptibility (Metzker et al. 1980; Orecchia et al. 1992; Buc et al. 
1996; Yang et al. 2005; Singh et al. 2012).  
 
Characterisation of the immune response against melanocytes in vitiligo will help in designing 
therapeutic and diagnostic tools and in a better understanding of the aetiology of the disease. 
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 Tyrosine hydroxylase catalyses the initial step in catecholamine biosynthesis through 
conversion of L-tyrosine to L-dopa (Lewis et al. 1993; Nagatsu 1995). Previously, the enzyme 
was identified as a potential vitiligo-associated autoantigen after being enriched by vitiligo 
patient IgG from a melanocyte cDNA phage-display library in panning experiments (Kemp et al. 
2002; Waterman et al. 2010). Furthermore, antibodies directed against TH were identified in 
patients with APS1, including those patients where vitiligo was a part of their clinical 
manifestations (Hedstrand et al. 2000). The aims of my study were: (i) to investigate the 
frequency of TH antibodies in vitiligo patients using a RIA specific for TH antibodies; (ii) to 
determine if there are any associations between the presence of TH antibodies and the clinical 
features of vitiligo; (iii) to analyse the vitiligo patient TH antibody binding sites (epitopes) on 
TH using deletion derivatives of TH in RIAs; and (iv) to evaluate the characteristics of TH 
antibodies in terms of titres, subclasses and avidities.  
 Initially, the frequency of immunoreactivity against TH in vitiligo patient sera was 
investigated using a RIA specific for TH antibodies (Kemp et al. 2011). TH antibodies were 
detected in 23% of those patients with the non-segmental vitiligo. Although this frequency 
appears to be low, earlier studies have detected antibodies against several autoantigens in vitiligo 
patients at a similar prevalence. For example, antibodies against tyrosinase were present in 11% 
of tested patients (Kemp et al. 1997a), TYRP1 in 5% (Kemp et al. 1998c), DCT in 5% (Kemp et 
al. 1997b), PMEL in 5% (Kemp et al. 1998b), transcription factor SOX10 in 3% (Hedstrand et al. 
2000) and MCHR1 in 16% (Kemp et al. 2002). 
In contrast to non-segmental vitiligo, none of the segmental vitiligo patient sera showed 
immunoreactivity against TH (Kemp et al. 2011a). This supports the concept that segmental 
vitiligo has an aetiology that does not involve autoimmune processes (Taïeb 2000). However, 
serum samples from only eight segmental vitiligo patients were available for testing, so we 
cannot draw any firm conclusions as to the prevalence of TH antibodies in this disease sub-type 
and analysis of a larger number of segmental vitiligo patients would be required to confirm this 
finding. 
The results also demonstrated that the frequency of TH antibodies was significantly 
increased in the group of non-segmental vitiligo patients with active disease (Kemp et al. 2011a). 
Furthermore, the frequency of active vitiligo was elevated significantly in the group of patients 
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who were positive for TH antibody responses (Kemp et al. 2011a). However, only 15 patients 
with stable disease were available for study, so further verification of this result is also necessary 
in a larger series.  
Interestingly, TH was an antibody target in both patients with and without concomitant 
autoimmune disease (Kemp et al. 2011a). This finding contrasts to previous studies in which 
antibodies directed against melanocyte-specific proteins PMEL, TYRP1 and DCT were only 
detected in vitiligo patients who had other autoimmune diseases (Kemp et al. 1997b; Kemp et al. 
1998b; Kemp et al. 1998c). Tyrosinase and SOX10 antibodies were also predominantly detected 
in vitiligo patients with additional autoimmune disorders. Whether this reflects a distinct 
difference in the pattern of TH antibody production would require a very large series of patients 
tested for all autoantibodies. 
There are four isoforms of human TH (TH1-TH4), which differ in the regulatory N-
terminal region responsible for the enzyme activity (Lewis et al. 1993; Nakashima et al. 2009). 
In this study, immunoreactivity against TH enzyme was observed against the TH2 isoform 
(Kemp et al. 2011a). Nevertheless, it is possible that vitiligo patient TH antibodies react against 
other TH isoforms since they exhibit a high similarity of amino acid sequence (Hedstrand et al. 
2000). In APS1 patients, antibodies have also been demonstrated against two enzymes that have 
significant amino acid sequence homology with TH at the N-terminus, namely TPH and PAH 
(Ekwall et al. 1999; Ekwall et al. 2000). In the present study, antibodies against these two 
enzymes were not detected in vitiligo patients (Kemp et al. 2011a). Furthermore, TH antibodies 
were not cross-reactive with either PAH or TPH (Kemp et al. 2011a). 
Part of my study was concerned with the molecular analysis of the B cell epitopes on the 
TH autoantigen. The mapping of B cell epitopes can provide an understanding of the association 
of an autoantigen with a particular autoimmune disease (Morgenthaler et al. 1999; Gora et al. 
2004) and may give an insight into the mechanisms involved in the initiation and pathogenesis of 
the disease as well as it can be useful as diagnostic and therapeutic tool (Routsias et al. 2006; 
Mahler and Fritzler 2010). 
Molecular mapping of the B cell epitopes on TH protein was performed by using 
recombinant proteins in RIA coupled with absorption experiments (Rahoma et al. 2012). In 
RIAs, two regions of TH were found to be targets for vitiligo patient TH antibodies: between 
 216 
 
amino acid residues 1 and 14 and between amino acid residues 61 and 80 (Rahoma et al. 2012). 
Subsequently, the antibody-binding sites were confirmed in ELISAs with the relevant TH 
peptide representing the epitope (Rahoma et al. 2012). The immunoreactivity to both antibody-
binding sites was demonstrated in most of TH antibody-positive vitiligo patients (56%), 
indicating that the humoral response to TH in vitiligo is heterogeneous in nature (Rahoma et al. 
2012). Similar results have been obtained from characterisation of autoantigens in autoimmune 
thyroid disorders and in type 1 diabetes mellitus, where multiple epitopes have been detected on 
thyroid peroxidase (Zanelli et al. 1992) and tyrosine phosphatase-like IA-2 autoantigen 
(Lampasona et al. 1996), respectively. This has been explained in the case of in type 1 diabetes 
mellitus by expansion or ‘spreading’ of autoimmune reactivity against a single or a few epitopes 
from early childhood to multiple and different epitopes with the advancement of age (Naserke et 
al. 1998). In the current study, there was no follow-up sampling, so the possibility of epitope 
spreading could not be investigated.  
The TH epitopes identified in this study were linear in nature, so further studies need to 
be undertaken to characterise antibodies that may recognise conformational epitopes which 
depend on the native structure of the protein. Such antibodies are usually important in disease 
pathogenesis (Pettersson 1992; Morgenthaler et al. 1999). In Graves’ disease, for example, it has 
been reported that the autoantibodies to the thyrotropin receptor, which are responsible for 
disease activity, recognise a number of different conformational epitopes (Morgenthaler et al. 
1999).  
It has been speculated that the autoimmune responses may arise from cross-reactivity 
between self-proteins and those of infecting micro-organisms in so-called molecular mimicry 
(Wucherpfennig 2001). For example, bacterial and viral proteins have homology with 
endothelial cell components which can be damaged by cross-reacting antibodies resulting from 
infections (Luo et al. 2010; Liu et al. 2011). However, no similarity was apparent between the 
amino acid sequences of the identified epitope regions and those of microbial proteins and so no 
evidence for molecular mimicry in causing the humoral immune response to TH was apparent. 
Because of the presence of multiple TH epitope and the heterogeneity of the TH antibody 
response it is unlikely that TH antibody that a specific assay for measuring TH antibody 
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immunoreactivity for either of the epitopes demonstrated in this study would be of diagnostic 
usefulness in screening vitiligo patients.  
The IgG isotype of vitiligo patient TH antibodies was also determined in this study. The 
majority of TH antibodies against the two identified antibody-binding sites were of the IgG1 
subclass (Rahoma et al. 2012). Few vitiligo patient sera contained TH antibodies of the IgG3 
subtype and these were against the epitope between amino acids 61 and 80 (Rahoma et al. 2012). 
No TH antibodies representing subclasses IgG2 or IgG4 were detected (Rahoma et al. 2012). 
The IgG subclass distribution suggested a Th1 type of immune response in vitiligo. Indeed, in 
vitiligo, there is an polarisation of CD4+ and CD8+ T cells towards a Th1-type cytokine profile 
associated with melanocyte loss, which would fit with the finding that TH antibodies are mainly 
of the IgG1 subclass (Wankowicz-Kalinska et al. 2003). Interestingly, the SL chicken model of 
vitiligo also appears to be a Th1-polarised autoimmune disease (Shi and Erf 2012). In addition, it 
is well known that antibodies of the IgG1 and IgG3 subclasses are very effective in activating the 
complement system and inducing cellular effector mechanisms (Flanagan and Rabbitts 1982; van 
Loghem 1986; Bindon et al. 1988). Both of these pathogenic mechanisms, which can induce 
lysis of human melanocytes, have been demonstrated in the sera of vitiligo patients (Norris et al. 
1988). More studies are required to investigate the possible pathogenic effects of TH antibodies 
in vitiligo patients. 
 
6.2 TH Antibodies in Vitiligo: Possible Implications 
 
6.2.1 TH antibodies in diagnosis 
Although TH is an intracellular protein, serum antibodies against intracellularly located antigens 
can be of clinical importance with respect to diagnosis and prognosis. For example, the serum 
titre of antibodies can be correlated with disease activity as with anti-DNA antibodies in 
systemic lupus erythematosus (Riboldi et al. 2005). The presence of specific antibodies can also 
be of prognostic value as in the case of anti-Scl70 and anti-centromere protein B antibodies in 
systemic sclerosis  (Nihtyanova and Denton 2010). Particular antibodies or their higher incidence 
can also indicate different organ involvement in disease such as anti-Sm antigen antibodies in 
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systemic lupus erythematosus (Rahman and Isenberg 2008). With respect to TH antibodies, they 
appear to occur at a greater frequency in active vitiligo. However, larger numbers of patients 
would need to be tested to confirm these initial results. 
 
6.2.2 Possible origin of TH antibodies 
The origin of antibodies against intracellular antigens is not fully understood. It has been 
observed that apoptotic cells can release apoptotic blebs or microbodies that contain several 
intracellular antigens (Casciola-Rosen et al. 1999). With defective clearance reported in various 
autoimmune diseases, the subsequent accumulation of these microbodies, along with activation 
of dendritic cells and the triggering of the immune response, may result in the generation of 
antibodies to their content (Fehr et al. 2009; Fransen et al. 2009; Munoz et al. 2010). 
 In addition, increasing evidence indicates that alterations in epigenetic modification 
including DNA methylation, histone acetylation and microRNA expression can contribute to B 
cell autoreactivity and generation of antibodies to intracellular antigens (Renaudineau et al. 
2010). For example, it has been observed that a systemic lupus erythematosus-like syndrome 
develops in some patients treated with drugs such as hydralazine or procainamide. This was due 
to the reaction of these drugs with thymidine and deoxycytidine which prevented DNA 
methylation and thus initiated the disease (Dubroff and Reid 1980). Furthermore, in vasculitides 
patients with ANCA, epigenetic modifications due to gene silencing are responsible for improper 
intracellular expression of both of myeloperoxidase and proteinase-3, which are the main targets 
of ANCA in patients (Ciavatta et al. 2010). 
 Several studies have indicated that antibodies can be generated by molecular mimicry due 
to homology between the actual autoantigen and ‘foreign’ proteins (Routsias et al. 2006; 
Racanelli et al. 2011). In this context, viral, bacterial or fungal protein can induce antibodies that 
can cross-react with intracellular antigens. For example, a SSA-antigen epitope, targeted by 
antibodies in systemic lupus erythematosus, has a similar antigenic amino acid sequence to anti-
latent viral protein Epstein-Barr virus nuclear antigen-1. Mice immunised with Epstein-Barr 
virus nuclear antigen-1 produced antibodies that cross-reacted with multiple epitopes on Ro60 
antigen (McClain et al. 2005). The animals ultimately developed systemic lupus erythematosus-
like symptoms such as leucopenia and renal dysfunction (McClain et al. 2005), supporting the 
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hypothesis of molecular mimicry as one of the causes of the generation of antibodies against 
intracellular antigens.  
With respect to the development of TH antibodies, this is most likely a result of 
melanocyte destruction initiated primarily by non-antibody-dependent mechanisms such 
oxidative stress or cytotoxic T cells (Soubiran et al. 1985; D'Amelio et al. 1990; Abdel-Naser et 
al. 1992; Lang et al. 2001) (Ogg et al. 1998; Kroll et al. 2005; Schallreuter et al. 2005; 
Dell'Anna and Picardo 2006; Shalbaf et al. 2008). There have been several suggestions to 
account for immune responses against intracellular melanocyte proteins, including the formation 
of neo-antigens, the exposure of cryptic epitopes and the modification of proteins during 
apoptosis (Namazi 2007; Westerhof and d'Ischia 2007). Following processing by mature 
Langerhans cells, antigenic peptides could be presented to autoreactive T cells which have 
escaped clonal deletion or to naïve T lymphocytes which have not been tolerised against cryptic 
epitopes (Namazi 2007; Westerhof and d'Ischia 2007). Following stimulation of autoreactive B 
cells by activated autoreactive CD4
+
 T lymphocytes, antibodies could then be produced (Namazi 
2007).  
 
6.2.3 Possible pathogenic effects of TH antibodies 
Although TH is intracellularly located, there is evidence that antibodies can mediate their 
adverse effects inside the cell, for example, anti-SSA-antigen antibodies in systemic autoimmune 
disease (Mallery et al. 2010; Racanelli et al. 2011). Furthermore, TH antibodies that inhibit the 
function of the enzyme have been detected in patients with APS1 (Hedstrand et al. 2000). 
Expression of TH  has been detected in cutaneous melanocytes in association with tyrosinase on 
the membrane of the melanosome, where it has been suggested to play a direct role in 
melanogenesis by providing L-dopa to tyrosinase as its activating substrate (Marles et al. 2003). 
However, to date, the function of TH in melanogenesis is not clearly defined, so it is difficult to 
speculate on how antibodies that might affect TH function could affect melanin synthesis and 
ultimately melanocyte behaviour.  
 Other possible pathogenic effects of TH antibodies include complement binding and 
ADCC, but it is difficult to imagine how these would interact with their intracellular target 
antigen to cause melanocyte damage by a cytotoxic mechanism. It is also possible that TH 
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antibodies are an epiphenomenon and play no part in vitiligo aetiology, but rather indicate the 
presence of autoreactive anti-TH T lymphocytes that are cytotoxic to pigment cells.  
 
6.3 Future Work 
The study could be improved by the analysis of further vitiligo patient serum samples for TH 
antibodies. More non-segmental vitiligo patient sera are already being collected for testing in a 
replication study. In addition, more patients with stable vitiligo and also individuals with the 
segmental clinical subtype should be analysed for the presence of TH antibodies to extend the 
initial results. However, these categories of patients are less likely to be available in great enough 
numbers to make this possible in the short-term. Further future work that could be carried out 
also includes: 
 
6.3.1 Identification of TH antibodies which recognise conformation-dependent 
epitopes 
Antibodies that bind to conformational epitopes are usually important in autoimmune disease 
pathogenesis. In Graves’ disease, it is well-documented that the antibodies against the 
thyrotropin receptor, which are responsible for disease activity, recognise a number of different 
conformational epitopes (Morgenthaler et al. 1999). This is also the case for pathogenic 
antibodies against thyroid peroxidase in autoimmune hypothyroidism (Gora et al. 2004). The TH 
antibodies so far detected in vitiligo bind to linear determinants (Rahoma et al. 2012), and so it is 
possible that the prevalence of the humoral immune response against the enzyme has been 
underestimated (Kemp et al. 2011a; Kemp et al. 2011c). Future studies could identify antibodies 
that bind to conformational epitopes by employing mammalian expression systems to produce 
TH protein with native conformation which could be used in immunoprecipitation assays. This 
technique has been used in our laboratory to detect antibody binding to the calcium-sensing 
receptor (Gavalas et al. 2007).   
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6.3.2 Examination of the possible effects of TH antibodies on TH function 
Antibodies that affect TH function are more likely to have a role in disease pathogenesis than 
antibodies that simply bind TH. For example, thyroid-stimulating antibodies activate the 
thyrotropin receptor and elicit hyperthyroidism in Graves’ disease by mimicking the binding of 
thyroid-stimulating hormone (Weetman and McGregor 1994), and antibodies directed against the 
acetylcholine receptor block the acetylcholine-binding site and provoke accelerated receptor 
degradation causing myasthenia gravis (Hoedemaekers et al. 1997). Antibody-mediated 
deleterious effects on the function of TH could result in impaired melanocyte or keratinocyte 
behavior in vitiligo skin, a preliminary event in the development of disease. Although TH is 
located intracellularly, there is evidence that antibodies can mediate their adverse effects inside 
the cell, for example, anti-SSA-antigen antibodies in systemic autoimmune disease (Mallery et 
al. 2010; Racanelli et al. 2011). Furthermore, as a precedent, TH antibodies that inhibit the 
function of the enzyme have been detected in patients with APS1 (Hedstrand et al. 2000). 
Therefore, patient and control IgG samples should be tested for their effects upon TH function 
which can be done using an in vitro assay (Reinhard et al. 1986; Daubner and Fitzpatrick 1993; 
Lou et al. 2010).  
 
6.3.3 Examination of vitiligo patient lesions for TH antibodies  
The TH antibodies detected so far in vitiligo patients have been circulating serum antibodies 
(Kemp et al. 2011a; Kemp et al. 2011c). It would be of interest to determine if patient TH 
antibodies are also found in vitiligo lesions. Furthermore, the co-localisation within the same 
skin tissue sample of purified vitiligo patient TH antibodies and expressed TH could be 
evaluated using double indirect immunofluorescence.  
 
6.3.4 Investigation of cytotoxicity of TH antibodies  
It has been shown that vitiligo-associated antibodies have the ability to destroy melanocytes in 
vitro by complement-mediated damage and ADCC (Norris et al. 1988) and, in vivo, following 
passive immunisation of nude mice grafted with human skin (Gilhar et al. 1995). It would be 
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useful to investigate whether TH antibodies can have destructive effects on melanocytes by 
either of these mechanisms.  
 
6.3.5 Investigation of T cell responses against TH 
Several studies have detected the presence in vitiligo patients of circulating melanocyte-specific 
CD8+ cytotoxic T lymphocytes that target melanocyte differentiation antigens, including 
MelanA (MART-1), PMEL and tyrosinase (Ogg et al. 1998; Lang et al. 2001; Le Gal et al. 
2001; Palermo et al. 2001; Mandelcorn-Monson et al. 2003; Le Poole et al. 2004; Garbelli et al. 
2005; Le Poole and Luiten 2008; van den Boorn et al. 2009). Such cytotoxic T cells express high 
levels of the skin-homing receptor cutaneous lymphocyte-associated antigen and their frequency 
correlates with both the extent and activity of the disease supporting a crucial role of the cell-
mediated immune response in vitiligo (Lang et al. 2001). With regard to this, the investigation of 
T cell-mediated immune responses against the TH protein would be of importance, as TH 
antibodies may be markers of anti-TH T lymphocyte reactivity in vitiligo patients. 
 
6.4 Overall Conclusion 
This thesis has concentrated on characterising TH antibody reactivity in vitiligo patients. 
However, the relationship between TH antibodies, and indeed all vitiligo antibodies, and the 
pathogenesis of the disease has yet to be established. The possibility that TH antibodies play no 
part in vitiligo aetiology but rather indicate the presence of autoreactive anti-TH T lymphocytes 
that are cytotoxic to pigment cells should be investigated. Even if they prove not to be directly 
pathogenic, TH antibodies may serve as useful markers of cellular disruption in the epidermis of 
vitiligo patients so further characterisation of them will continue. 
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Appendix I: DNA sequence of TH cDNA and TH cDNA deletion derivatives 
 
pcDNA3-TH    ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH480       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH440       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH400       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH360       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH320       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH280       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH240       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH200       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH170       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH140       ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
pTH1-80      ATGCCCACCCCCGACGCCACCACGCCACAGGCCAAGGGCTTCCGCAGGGCCGTGTCTGAG  60 
 
pcDNA3-TH    CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH480       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH440       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH400       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH360       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH320       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH280       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH240       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH200       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH170       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH140       CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120 
pTH1-80      CTGGACGCCAAGCAGGCAGAGGCCATCATGTCCCCGCGGTTCATTGGGCGCAGGCAGAGC  120         
 
pcDNA3-TH    CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH480       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH440       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH400       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH360       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH320       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH280       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH240       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH200       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH170       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH140       CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
pTH1-80      CTCATCGAGGACGCCCGCAAGGAGCGGGAGGCGGCGGTGGCAGCAGCGGCCGCTGCAGTC  180 
 
pcDNA3-TH    CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH480       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH440       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH400       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH360       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH320       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH280       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH240       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH200       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH170       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH140       CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
pTH1-80      CCCTCGGAGCCCGGGGACCCCCTGGAGGCTGTGGCCTTTGAGGAGAAGGAGGGGAAGGCC  240 
 
pcDNA3-TH    GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
pTH480       GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
pTH440       GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
 296 
 
pTH400       GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
pTH360       GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
pTH320       GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
pTH280        GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG 300 
pTH240        GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
pTH200        GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
pTH170        GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
pTH140        GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
pTH81-140     GTGCTAAACCTGCTCTTCTCCCCGAGGGCCACCAAGCCCTCGGCGCTGTCCCGAGCTGTG  300 
 
 
pcDNA3-TH    AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH480       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH440       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH400       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH360       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH320       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH280       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH240       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH200       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH170       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH140       AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
pTH81-140    AAGGTGTTTGAGACGTTTGAAGCCAAAATCCACCATCTAGAGACCCGGCCCGCCCAGAGG  360 
 
pcDNA3-TH    CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH480       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH440       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH400       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH360       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH320       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH280       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH240       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH200       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH170       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH140       CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
pTH81-140    CCGCGAGCTGGGGGCCCCCACCTGGAGTACTTCGTGCGCCTCGAGGTGCGCCGAGGGGAC  420 
 
pcDNA3-TH    CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH480       CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH440       CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH400       CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH360       CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH320       CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH280       CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH240       CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH200       CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH170       CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
pTH141-497   CTGGCCGCCCTGCTCAGTGGTGTGCGCCAGGTGTCAGAGGACGTGCGCAGCCCCGCGGGG  480 
 
pcDNA3-TH    CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540 
pTH480       CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540 
pTH440       CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540 
pTH400       CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540 
pTH360       CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540 
pTH320       CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540 
pTH280       CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540 
pTH240       CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540 
pTH200       CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540 
pTH170       CCCAAGGTCCCCTGGTTCCCAAGAAAAGTG                                  540  
pTH141-497   CCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTCAGAGCTGGACAAGTGTCATCACCTGGTC  540          
 
pcDNA3-TH    ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
 297 
 
pTH480       ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
pTH440       ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
pTH400       ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
pTH360        ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
pTH320        ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
pTH280        ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
pTH240        ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
pTH200        ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
pTH141-497    ACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTACCGC  600 
 
pcDNA3-TH     CAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCC  660 
pTH480        CAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCC  660 
pTH440        CAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCC  660 
pTH400        CAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCC  660 
pTH360        CAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCC  660 
pTH320        CAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCC  660 
pTH280        CAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCC  660 
pTH240        CAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCC  660 
pTH141-497    CAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCC  660 
        
pcDNA3-TH     CGTGTGGAGTACACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAG  720 
pTH480        CGTGTGGAGTACACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAG  720 
pTH440        CGTGTGGAGTACACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAG  720 
pTH400        CGTGTGGAGTACACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAG  720 
pTH360        CGTGTGGAGTACACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAG  720 
pTH320        CGTGTGGAGTACACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAG  720 
pTH280        CGTGTGGAGTACACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAG  720 
pTH240        CGTGTGGAGTACACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAG  720 
pTH141-497    CGTGTGGAGTACACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAG  720 
         
pcDNA3-TH     GGCCTCTACGCCACGCACGCCTGCGGGGAGCACCTGGAGGCCTTTGCTTTGCTGGAGCGC   780 
pTH440        GGCCTCTACGCCACGCACGCCTGCGGGGAGCACCTGGAGGCCTTTGCTTTGCTGGAGCGC  780 
pTH400        GGCCTCTACGCCACGCACGCCTGCGGGGAGCACCTGGAGGCCTTTGCTTTGCTGGAGCGC  780 
pTH360        GGCCTCTACGCCACGCACGCCTGCGGGGAGCACCTGGAGGCCTTTGCTTTGCTGGAGCGC  780 
pTH320        GGCCTCTACGCCACGCACGCCTGCGGGGAGCACCTGGAGGCCTTTGCTTTGCTGGAGCGC  780 
pTH280        GGCCTCTACGCCACGCACGCCTGCGGGGAGCACCTGGAGGCCTTTGCTTTGCTGGAGCGC  780 
pTH141-497    GGCCTCTACGCCACGCACGCCTGCGGGGAGCACCTGGAGGCCTTTGCTTTGCTGGAGCGC  780 
 
pcDNA3-TH     TTCAGCGGCTACCGGGAAGACAATATCCCCCAGCTGGAGGACGTCTCCCGCTTCCTGAAG  840 
pTH480        TTCAGCGGCTACCGGGAAGACAATATCCCCCAGCTGGAGGACGTCTCCCGCTTCCTGAAG  840 
pTH440        TTCAGCGGCTACCGGGAAGACAATATCCCCCAGCTGGAGGACGTCTCCCGCTTCCTGAAG  840 
pTH400        TTCAGCGGCTACCGGGAAGACAATATCCCCCAGCTGGAGGACGTCTCCCGCTTCCTGAAG  840 
pTH360        TTCAGCGGCTACCGGGAAGACAATATCCCCCAGCTGGAGGACGTCTCCCGCTTCCTGAAG  840 
pTH320        TTCAGCGGCTACCGGGAAGACAATATCCCCCAGCTGGAGGACGTCTCCCGCTTCCTGAAG  840 
pTH320        TTCAGCGGCTACCGGGAAGACAATATCCCCCAGCTGGAGGACGTCTCCCGCTTCCTGAAG  840                 
pTH141-497    TTCAGCGGCTACCGGGAAGACAATATCCCCCAGCTGGAGGACGTCTCCCGCTTCCTGAAG  840 
 
pcDNA3-TH     GAGCGCACGGGCTTCCAGCTGCGGCCTGTGGCCGGCCTGCTGTCCGCCCGGGACTTCCTG 900 
pTH480        GAGCGCACGGGCTTCCAGCTGCGGCCTGTGGCCGGCCTGCTGTCCGCCCGGGACTTCCTG  900 
pTH440        GAGCGCACGGGCTTCCAGCTGCGGCCTGTGGCCGGCCTGCTGTCCGCCCGGGACTTCCTG  900 
pTH400        GAGCGCACGGGCTTCCAGCTGCGGCCTGTGGCCGGCCTGCTGTCCGCCCGGGACTTCCTG  900 
pTH360        GAGCGCACGGGCTTCCAGCTGCGGCCTGTGGCCGGCCTGCTGTCCGCCCGGGACTTCCTG  900 
pTH320        GAGCGCACGGGCTTCCAGCTGCGGCCTGTGGCCGGCCTGCTGTCCGCCCGGGACTTCCTG  900 
pTH141-497    GAGCGCACGGGCTTCCAGCTGCGGCCTGTGGCCGGCCTGCTGTCCGCCCGGGACTTCCTG  900 
 
pcDNA3-TH     GCCAGCCTGGCCTTCCGCGTGTTCCAGTGCACCCAGTATATCCGCCACGCGTCCTCGCCC  960 
pTH480        GCCAGCCTGGCCTTCCGCGTGTTCCAGTGCACCCAGTATATCCGCCACGCGTCCTCGCCC  960 
pTH440        GCCAGCCTGGCCTTCCGCGTGTTCCAGTGCACCCAGTATATCCGCCACGCGTCCTCGCCC  960 
pTH400        GCCAGCCTGGCCTTCCGCGTGTTCCAGTGCACCCAGTATATCCGCCACGCGTCCTCGCCC  960 
pTH360        GCCAGCCTGGCCTTCCGCGTGTTCCAGTGCACCCAGTATATCCGCCACGCGTCCTCGCCC  960 
pTH320        GCCAGCCTGGCCTTCCGCGTGTTCCAGTGCACCCAGTATATCCGCCACGCGTCCTCGCCC  960 
pTH141-497    GCCAGCCTGGCCTTCCGCGTGTTCCAGTGCACCCAGTATATCCGCCACGCGTCCTCGCCC  960                 
 298 
 
 
 
pcDNA3-TH    ATGCACTCCCCTGAGCCGGACTGCTGCCACGAGCTGCTGGGGCACGTGCCCATGCTGGCC 1020 
pTH480       ATGCACTCCCCTGAGCCGGACTGCTGCCACGAGCTGCTGGGGCACGTGCCCATGCTGGCC 1020 
pTH440       ATGCACTCCCCTGAGCCGGACTGCTGCCACGAGCTGCTGGGGCACGTGCCCATGCTGGCC 1020 
pTH400       ATGCACTCCCCTGAGCCGGACTGCTGCCACGAGCTGCTGGGGCACGTGCCCATGCTGGCC 1020 
pTH360       ATGCACTCCCCTGAGCCGGACTGCTGCCACGAGCTGCTGGGGCACGTGCCCATGCTGGCC 1020 
pTH1412-497  ATGCACTCCCCTGAGCCGGACTGCTGCCACGAGCTGCTGGGGCACGTGCCCATGCTGGCC 1020 
 
               
pcDNA3-TH    GACCGCACCTTCGCGCAGTTCTCGCAGGACATTGGCCTGGCGTCCCTGGGGGCCTCGGAT 1080 
pTH480       GACCGCACCTTCGCGCAGTTCTCGCAGGACATTGGCCTGGCGTCCCTGGGGGCCTCGGAT 1080 
pTH440       GACCGCACCTTCGCGCAGTTCTCGCAGGACATTGGCCTGGCGTCCCTGGGGGCCTCGGAT 1080 
pTH400       GACCGCACCTTCGCGCAGTTCTCGCAGGACATTGGCCTGGCGTCCCTGGGGGCCTCGGAT 1080 
pTH360       GACCGCACCTTCGCGCAGTTCTCGCAGGACATTGGCCTGGCGTCCCTGGGGGCCTCGGAT 1080 
pTH141-497   GACCGCACCTTCGCGCAGTTCTCGCAGGACATTGGCCTGGCGTCCCTGGGGGCCTCGGAT 1080 
 
pcDNA3-TH    GAGGAAATTGAGAAGCTGTCCACGCTGTCATGGTTCACGGTGGAGTTCGGGCTGTGTAAG 1140 
pTH480       GAGGAAATTGAGAAGCTGTCCACGCTGTCATGGTTCACGGTGGAGTTCGGGCTGTGTAAG 1140 
pTH440       GAGGAAATTGAGAAGCTGTCCACGCTGTCATGGTTCACGGTGGAGTTCGGGCTGTGTAAG 1140 
pTH400       GAGGAAATTGAGAAGCTGTCCACGCTGTCATGGTTCACGGTGGAGTTCGGGCTGTGTAAG 1140 
pTH141-497   GAGGAAATTGAGAAGCTGTCCACGCTGTCATGGTTCACGGTGGAGTTCGGGCTGTGTAAG 1140 
                
pcDNA3-TH    CAGAACGGGGAGGTGAAGGCCTATGGTGCCGGGCTGCTGTCCTCCTACGGGGAGCTCCTG 1200 
pTH480       CAGAACGGGGAGGTGAAGGCCTATGGTGCCGGGCTGCTGTCCTCCTACGGGGAGCTCCTG 1200 
pTH440       CAGAACGGGGAGGTGAAGGCCTATGGTGCCGGGCTGCTGTCCTCCTACGGGGAGCTCCTG 1200 
pTH400       CAGAACGGGGAGGTGAAGGCCTATGGTGCCGGGCTGCTGTCCTCCTACGGGGAGCTCCTG 1200 
pTH141-497   CAGAACGGGGAGGTGAAGGCCTATGGTGCCGGGCTGCTGTCCTCCTACGGGGAGCTCCTG 1200 
               
pcDNA3-TH    CACTGCCTGTCTGAGGAGCCTGAGATTCGGGCCTTCGACCCTGAGGCTGCGGCCGTGCAG 1260 
pTH480       CACTGCCTGTCTGAGGAGCCTGAGATTCGGGCCTTCGACCCTGAGGCTGCGGCCGTGCAG 1260 
pTH440       CACTGCCTGTCTGAGGAGCCTGAGATTCGGGCCTTCGACCCTGAGGCTGCGGCCGTGCAG 1260 
pTH141-497   CACTGCCTGTCTGAGGAGCCTGAGATTCGGGCCTTCGACCCTGAGGCTGCGGCCGTGCAG 1260 
 
pcDNA3-TH    CCCTACCAAGACCAGACGTACCAGTCAGTCTACTTCGTGTCTGAGAGCTTCAGTGACGCC 1320 
pTH480       CCCTACCAAGACCAGACGTACCAGTCAGTCTACTTCGTGTCTGAGAGCTTCAGTGACGCC 1320 
pTH440       CCCTACCAAGACCAGACGTACCAGTCAGTCTACTTCGTGTCTGAGAGCTTCAGTGACGCC 1320 
pTH141-497   CCCTACCAAGACCAGACGTACCAGTCAGTCTACTTCGTGTCTGAGAGCTTCAGTGACGCC 1320 
                 
pcDNA3-TH    AAGGACAAGCTCAGGAGCTATGCCTCACGCATCCAGCGCCCCTTCTCCGTGAAGTTCGAC 1380 
pTH480       AAGGACAAGCTCAGGAGCTATGCCTCACGCATCCAGCGCCCCTTCTCCGTGAAGTTCGAC 1380            
pTH141-497   AAGGACAAGCTCAGGAGCTATGCCTCACGCATCCAGCGCCCCTTCTCCGTGAAGTTCGAC 1380 
 
pcDNA3-TH    CCGTACACGCTGGCCATCGACGTGCTGGACAGCCCCCAGGCCGTGCGGCGCTCCCTGGAG 1440 
pTH480       CCGTACACGCTGGCCATCGACGTGCTGGACAGCCCCCAGGCCGTGCGGCGCTCCCTGGAG 1440 
pTH141-497   CCGTACACGCTGGCCATCGACGTGCTGGACAGCCCCCAGGCCGTGCGGCGCTCCCTGGAG 1440 
                 
pcDNA3-TH    GGTGTCCAGGATGAGCTGGACACCCTTGCCCATGCGCTGAGTGCCATTGGC 1491 
pTH141-497   GGTGTCCAGGATGAGCTGGACACCCTTGCCCATGCGCTGAGTGCCATTGGC 1491 
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Appendix II: Protein sequence of TH and TH deletion derivatives 
 
 
TH              MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH480           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH440           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH400           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH360           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH320           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH280           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH240           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH200           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH170           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH140           MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
TH1-80          MPTPDATTPQAKGFRRAVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREAAVAAAAAAV 60 
 
TH              PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH480           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH440           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH400           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH360           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH320           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH280           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH240           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH200           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH170           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH140           PSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
TH1-80          PSEPGDPLEAVAFEEKEGKA                                         120 
TH81-140                            VLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQR 120 
 
TH              PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
TH480           PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
TH440           PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
TH400           PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
TH360           PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
TH320           PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
TH280           PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
TH240           PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
TH200           PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
TH170           PRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKV           180 
TH140           PRAGGPHLEYFVRLEVRRGD                                         180             
TH81-140        PRAGGPHLEYFVRLEVRRGD                                         180 
TH141-497                           LAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLV 180 
 
TH              TKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLK 240 
TH480           TKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLK 240 
TH440           TKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLK 240 
TH400           TKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLK 240 
TH360           TKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLK 240 
TH320           TKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLK 240 
TH280           TKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLK 240 
TH240           TKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLK 240 
TH141-497       TKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLK 240 
               
TH              GLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFL 300 
TH480           GLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFL 300 
TH440           GLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFL 300 
TH400           GLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFL 300 
TH360           GLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFL 300 
TH320           GLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFL 300 
TH280           GLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLK                     300 
 300 
 
TH141-497       GLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFL 300 
 
TH              ASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASD 360 
TH480           ASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASD 360 
TH440           ASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASD 360 
TH400           ASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASD 360 
TH360           ASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASD 360 
TH320           ASLAFRVFQCTQYIRHASSP                                         360 
TH141-497       ASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASD 360 
 
TH              EEIEKLSTLSWFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQ 420 
TH480           EEIEKLSTLSWFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQ 420 
TH440           EEIEKLSTLSWFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQ 420 
TH400           EEIEKLSTLSWFTVEFGLCKQNGEVKAYGAGLLSSYGELL                     420 
TH141-497       EEIEKLSTLSWFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQ 420 
 
TH              PYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDVLDSPQAVRRSLE 480 
TH480           PYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDVLDSPQAVRRSLE 480 
TH440           PYQDQTYQSVYFVSESFSDA                                         480 
TH141-497       PYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDVLDSPQAVRRSLE 480 
 
TH              GVQDELDTLAHALSAIG 497 
TH141-497       GVQDELDTLAHALSAIG 497 
 
 
 
 
